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‘Of the heart… This moves of itself and does not stop unless forever.’ 
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3. ABSTRACT           
In cardiothoracic surgery, the use of the heart-lung machine for cardiopulmonary 
bypass (CPB) and induced cardiac arrest, cardioplegia, is required for performing the 
majority of the surgical procedures. Myocardial protection is essential during the 
ischemic period of cardioplegia. The aim of this project is to evaluate and verify if a 
recently developed routine for myocardial protection is feasible, safe and suited for use 
in clinical practice. This pre-clinical translational animal research project is designed 
to bridge the gap between basic research and new routines that may benefit the patient. 
In three different protocols, two groups of animals (10 in each group) are randomized 
to polarized or depolarized cardioplegic arrest. The novel and unexplored cardioplegic 
solution with esmolol, adenosine and magnesium; St Thomas’ Hospital polarizing 
cardioplegia (STH-POL) is compared with today’s gold standard; potassium-based St 
Thomas’ depolarizing solution (STH-2), both administered as repeated, cold, 
oxygenated blood. Left ventricular regional and global function in the early hours after 
weaning from CPB are evaluated together with myocardial ultrastructure and 
metabolism. Our hypothesis is that STH-POL improves myocardial protection 
demonstrated as better preserved postoperative cardiac function in a large animal 
translational model. This knowledge is essential before initiating clinical studies and 
implementation. An optimal myocardial protection is important when performing 
cardiac surgery in an ageing population with increased occurrence of more complex 
heart diseases and comorbidity. 
 
Paper I demonstrated improved regional and global contractility following 60 min of 
cardioplegic arrest with STH-POL compared to STH-2 blood cardioplegia. After 
weaning from CPB and following reperfusion, left ventricular dP/dtmax, Preload 
Recruitable Stroke Work and radial peak systolic strain rate were maintained 180 min 




Paper II focused on energy metabolism and ultrastructure with the STH-POL 
compared to the STH-2 cardioplegia during 60 min of cardiac arrest and at early 
reperfusion. The study demonstrated increased levels of creatine phosphate in left 
ventricular myocardial tissue samples at the end of the period of cardioplegic arrest 
and early after reperfusion in the STH-POL compared to the STH-2 group. 
Furthermore, the adenosine triphosphate content was increased and the mitochondrial 
surface-to-volume ratio decreased with polarizing compared to depolarizing 
cardioplegia 20 min after reperfusion. However, at 180 min after reperfusion these 
group differences were negligible. 
 
Paper III addressed myocardial function after prolonged cardioplegic arrest for 120 
min. A temporary increase in the load-independent contractility variable Preload 
Recruitable Stroke Work was seen in the STH-POL compared to the STH-2 group 150 
min after declamping. Neither regional nor global left ventricular function differed 
between groups up to 240 min after declamping. However, compared to the STH-2 
group, the left ventricular myocardial tissue blood flow rate decreased in the STH-
POL group at 150 and 240 min compared to 60 min after declamping. The relationship 
between the left ventricular total pressure-volume area and blood flow rate was 
maintained after declamping in the STH-POL group and decreased in the STH-2 
group. Thus, cardioplegic arrest with STH-POL alleviated the mismatch between 
myocardial function and perfusion after weaning from CPB compared to STH-2. 
 
Conclusion: In a porcine model, cardioplegic arrest with St. Thomas´ Hospital 
polarizing solution offered comparable myocardial protection and improved 
myocardial function (Paper I), preserved energy status (Paper II) and enhanced 
contractile efficiency (Paper III) in the early hours after weaning from 
cardiopulmonary bypass compared to St. Thomas´ Hospital No 2 blood cardioplegia.
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5. ABBREVIATIONS 
ATP/ADP/AMP Adenosine tri-, di- and monophosphate 
β The logarithmic regression coefficient of LV compliance 
cAMP Cyclic adenosine monophosphate 
CA Cardioplegic arrest 
CI Cardiac index (L/min/m2) 
CPB Cardiopulmonary bypass 
CPT-I/II Carnitine palmitoyltransferase-I/II 
CrP Creatine phosphate 
CVP Central venous pressure (mmHg) 
ECG Electrocardiography 
EDP End-diastolic pressure (mmHg) 
EDPVR End-diastolic pressure-volume relation (mmHg/mL) 
EDV End-diastolic volume (mL) 
EF Ejection fraction (%) 
ESPVR End-systolic pressure-volume relation (mmHg/mL) 
GRK2 G protein-coupled receptor kinases 2 
HLM  Heart-lung machine 
HPLC High-performance liquid chromatography 
HR Heart rate (beats/min) 
( i ) Value indexed for body surface area 
ICC Intraclass Correlation Coefficient 
J Joule, unit of energy 
LV Left ventricle 
LV-dP/dtmax Peak positive first derivate of LV pressure (mmHg/s) 
LV-dP/dtmin Peak negative first derivate of LV pressure (mmHg/s) 
MAP Mean arterial pressure (mmHg) 
MDA Malondialdehyde 
MVO2 Myocardial oxygen consumption (mL/min/g) 
PAP Pulmonary artery pressure (mmHg) 
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PE Potential energy 
PRSW Preload Recruitable Stroke Work (mmHg) 
PVA Pressure-volume area (mmHg*mL or Joule) 
RM-ANOVA Analysis of variance for repeated measurements 
ROI Region of interest 
RV Right ventricle 
SL Strain length (mm) 
STE Speckle Tracking Echocardiography 
STH-2 St. Thomas´ Hospital cardioplegic solution No 2 
STH-POL St. Thomas´ Hospital polarizing cardioplegic solution 
SV Stroke volume (mL) 
SVmit Mitochondrial surface density 
SVratiomit Mitochondrial surface-to-volume ratio 
SW Stroke work (mmHg*mL) 
t Tau, time constant of isovolumic relaxation (ms) 








In open heart surgery, the use of cardiopulmonary bypass (CPB) with a heart-lung 
machine (HLM) and cardioplegic arrest (CA) is required for the majority of the 
surgical procedures to be done in a motion- and bloodless field.1 In recent years, 
equipment and techniques have been developed to perform certain procedures without 
the use of CPB (off-pump surgery) together with less invasive catheter-based therapies 
for coronary artery disease, valve disorders and aortic diseases.2-5 Simultaneously, the 
need for support by heart-lung machine and cardiopulmonary bypass in modern 
cardiac and thoracic surgery has been further strengthened. Improved treatment 
routines and procedures for myocardial infarction and other cardiac life-threatening 
events have increased the chances of surviving the acute phase.6 This, together with 
increased life expectancy, has increased the age of the patient population that currently 
is offered cardiothoracic surgery.7,8 Furthermore, many of today’s patients present 
reduced cardiac function preoperatively and/or are in need for concomitant coronary 
artery bypass surgery (CABG) and valve surgery or other combined procedures which 
require prolonged cardioplegic arrest. At the same time, the proportion of patients with 
diabetes, lung- and kidney diseases and other co-morbidity has also increased.9 The 
importance of minimizing harmful effects from the use of HLM and optimal 
myocardial protection has therefore increased. 
 
6.2 Myocardial energy and oxygen consumption 
The heart is the most energy-consuming organ in the human body. About 6 kg of 
adenosine triphosphate (ATP) cycles every day, thus providing the biochemical energy 
allowing about 100.000 heartbeats following pumping of approximately 10 tons of 
blood through the body.10 Cardiac energy metabolism is complex and consists in 
principle of three main processes (Figure 1).11 The first is substrate utilization, the use 
of chemical energy stored fuel that originates from food. This process involves cellular 
uptake of mainly fatty acids and glucose. Beta-oxidation and glycolysis result in  
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intermediary metabolites that enter the Krebs cycle. The second component is the 
production of energy by oxidative phosphorylation by the mitochondrial respiratory 
chain. Phosphorylation of ADP produces the high-energy phosphate compound ATP, 
which is the direct source of energy for all energy-consuming reactions in the heart. 
The last component is ATP transfer and utilization. The energy-transfer mechanism to 
the myofibrils is also termed the creatine kinase energy shuttle.12 Failure to produce, 
transport or utilize an adequate amount of energy causes functional loss and failure of 




The energy production is in demand for oxygen due to the aerobic oxidative 
phosphorylation mechanism. The relation between myocardial oxygen consumption 
(MVO2) and the sum of potential energy (PE) and stroke work (SW) generated by one 
cardiac cycle, is schematically illustrated in Figure 2. The key element of myocardial 
protection during on-pump cardiac surgery, is to stop the contraction to reduce energy- 
Figure 1. Myocardial energy metabolism. Reproduced with permission from Neubauer S. The failing 
heart - an engine out of fuel. NEJM 2007;356:1140-51, Copyright Massachusetts Medical Society. 
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The most widely used and clearly dominant form of cardioplegia the last four decades 
is perfusion of the myocardium with hyperkalemic solutions that evoke myocyte 
membrane depolarization and cardiac arrest.1,14,15 Perfusion with cold solutions also 
improves protection and contributes to reducing myocardial damage.16,17 Repeated 
perfusion with oxygenated cold blood cardioplegia is considered by many to provide 
the best protection of the myocardium and is used as a routine at Haukeland University 
Hospital and numerous other cardiac surgical centers worldwide.18-20 In addition to 
cooling, blood cardioplegia also distributes oxygen to the myocardium in the 
cardioplegic phase. Upon reperfusion of the ischemic myocardium after CPB and CA, 
a transient decrease in heart function usually appears in the first hours after the 
procedure. This temporary decrease of function after reperfusion, may be due to 
myocardial stunning caused by reversible myocardial damage. Stunning, observed as a 
mismatch between myocardial function and blood flow rate, may last for hours and 
Figure 2. A schematic illustration of the relation between myocardial oxygen consumption (MVO2) 
and the pressure-volume area, the sum of potential energy (PE) and stroke work (SW), 
demonstrating MVO2 of the working heart (blue), the unloaded beating heart (dotted green) on CPB, 
the normothermic arrested heart (red) and the hypothermic arrested heart (dotted red). The 
pressure-volume area (PE + SW) is expressed in mmHg * mL or Joule on the x-axis (1 mmHg*mL is 
equal to 0.000133 Joule). On the y-axis oxygen consumption is expressed in mL O2 per heartbeat. 
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days, this in spite of optimal myocardial protection and preservation.21,22 Also 
irreversible tissue damage in these situations can appear as stunning if increased 
function and remodeling in the remaining myocardium compensate for the loss of 
contractile tissue.23,24 Extended time on CPB and CA are factors that increase or 
prolong this temporary dysfunction. In patients with impaired cardiac function before 
the surgical procedure, this can be critical in terms of survival, especially for high-risk 
patients with additional factors of comorbidity.25,26 The use of cold, potassium-based 
blood cardioplegia implicates coronary perfusion with hyperkalemic, oxygenated 
solution approximately every 20 min. This procedure thus provides cooling of the 
myocardium and the possibility for reoxygenation. However, it is well documented 
that reperfusion and reoxygenation paradoxically can cause tissue damage in the 
myocardium.27,28 This detrimental effect has been shown in various animal models of 
acute coronary occlusion and reperfusion, as well as in experimental models of heart 
surgery with cardiopulmonary bypass and reperfusion after cardioplegic arrest.29,30 
This tissue damage is called lethal reperfusion injury and can be prevented or limited 
by pharmacological interventions, such as beta-adrenergic blockers, oxygen-radical 
scavengers and anti-apoptotic interventions.21,31 
 
6.3 Cardioplegic mechanisms 
6.3.1 Depolarized cardioplegic arrest 
When the serum potassium concentration is ~10 mmol/L, the myocyte membrane 
potential will be about  – 65mV and the voltage-dependent fast Na+ ion channels will 
be inactivated.32,33 The action potential will not be elicited, myocardial contraction 
ceases in diastole, electromechanical arrest is induced and the resting membrane 
potential will be at equilibrium at approximately – 50 mV (Figure 3). At a higher 
concentration (~ 30 mmol/L) of extracellular potassium, the intended inactivation of 
the fast sodium channels will still be achieved, but also activate the voltage dependent 
slow calcium channels (threshold – 35 mV) which is disadvantageous.34,35 The 
window of the optimal amount of potassium is narrow with an ideal concentration 
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between the voltage thresholds of the sodium and calcium channels, like the classic St 
Thomas Hospital solution 2 (Plegisol®) with a K+ concentration of 16 mmol/L.36 A 
prolonged depolarization of the myocyte membrane can be harmful due to 
mechanisms like inhabitation of Na/K-ATPase caused by ischemia and hypothermia, 
Na+ window current and impaired Na+/H+ exchange. The net result is intracellular 
sodium loading. This effect pleads to a reversal of the sodium/calcium ion exchanger 
and the Ca2+ window current, with a resulting rise in intracellular calcium ions. The 
ion imbalance of Na+ and Ca2+ activates energy demanding processes to correct the 
disparity.37 If this alleviation fails, the result is aggravated reperfusion injury 















Figure 3. Excitation-contraction coupling and targets for depolarized arrest with potassium-based 
cardioplegic solution. The membrane potential of the resting myocyte is – 85 mV. At high 
concentration of extracellular K+, the membrane potential changes towards a more positive value, by 
definition depolarization. At – 65 mV, the voltage dependent fast sodium channels, which are 
responsible for the rapid, upstroke, phase zero towards action potential, are inactivated. The result is 
no action potential, no contraction and thereby diastolic arrest with myocyte membrane potential at – 
50 mV. Figure modified from Podesser BK, Chambers DJ; New Solutions for the Heart. An Update in 
Advanced Perioperative Protection, Springer Verlag/Wien;2001. 
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6.3.2 Polarized cardioplegic arrest  
The alternative concept, polarized arrest, is to achieve rapid cardiac arrest with 
cardioplegic solutions, also keeping the myocyte membrane potential at or near the 
cell membrane resting potential (Figure 4). Such polarized cardiac arrest results in less 
myocyte sodium and calcium loading and consequently reduced activation of cellular 
ion channels/pumps and hence reduced energy consumption.37,44-46 
A number of different routines for improving myocardial protection have been studied, 
both experimentally and clinically.47 Polarizing cardioplegic protocols using potassium 
channel openers (e.g. pinacidil, nicorandil, diazoxide, adenosine) or direct blockade of 
the fast sodium channel activation (e.g. tetrodotoxin, lidocaine, procaine, esmolol) 
have also been extensively studied.45,48-53 A combination of adenosine, lidocaine and 









Figure 4. Excitation-contraction coupling and targets for polarized arrest with our modified version 
of the normokalemic St. Thomas´ Hospital polarizing cardioplegic solution, STH-POL. The concept 
of polarized arrest is to maintain the membrane potential closer to the resting potential, which can 
be achieved in a number of ways. Relevant for this project is esmolol, adenosine, procaine and 
magnesium, which likely result in membrane potential at about – 70 mV, polarized arrest, compared 
to – 50 mV for the depolarized arrest (Figure 3). Figure modified from Podesser BK, Chambers DJ; 
New Solutions for the Heart. An Update in Advanced Perioperative Protection, Springer 
Verlag/Wien;2001. 
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A novel cardioplegia, the St. Thomas´ Hospital polarizing cardioplegic solution (STH-
POL), formulated with a mixture of esmolol, adenosine and Mg2+, has been suggested 
after experimental research in both ex-vivo and in-vivo models.54-56 The solution 
combines the inhibition of the fast Na+- and L-type Ca2+  channels by esmolol, the 
KATP channel opener effect of adenosine and the reduced myocardial Ca2+ load caused 
by magnesium.33,57 Before implementation of a new routine for myocardial protection 
in clinical studies and practice, this routine must be compared and found non-inferior 
or superior to the current routine in a translational large animal in-vivo model.  
 
6.4 Esmolol 
Esmolol has a rapid onset by blocking the fast Na+ channels, hence inhibiting the ion 
flux necessary to achieve the action potential.58 Furthermore, esmolol is a cardio-
selective direct β1 adrenergic receptor antagonist, which blocks the sarcolemmal L-
type Ca2+ channels and consequently inhibit calcium-activated mechanisms required 
for myocyte contraction.43 In isolated perfused hearts (Langendorff) and isolated 
myocytes without catecholamine stimulation, additional negative inotropic effects of 
esmolol has been demonstrated, likely to not be mediated via its antagonism at the β-
adrenoreceptors.57 The overall result is cardioplegic arrest with the membrane 
potential closer to the resting membrane potential (Em) compared to depolarized arrest 
(Figure 4).40,45 Esmolol has a short duration of effect (T ½ ~ 9 min) due to degradation 
by esterase activity in erythrocytes. As a consequence, bradycardia and negative 
inotropic effect can be avoided as a clinical problem when weaning from CPB.59-63 
Additionally, esmolol has antiarrhythmic properties and is protective in the vulnerable 
period of reperfusion.53,64,65 
 
6.5 Adenosine 
Adenosine is an endogenous purine nucleoside from the metabolism of the high-
energy phosphates. As a component in cardioplegic solutions, the foremost mechanism 
is binding to the A1-receptor which reduces cAMP by inhibiting adenylyl cyclase and 
 22 
thereby acts as a KATP channel opener.66 This effect causes outward K+ flux and 
induces hyperpolarized heart arrest. This hyperpolarization effect is especially seen on 
myocardial conductive tissue such as the sinoatrial (SA) and atrioventricular (AV) 
nodes.67 Additionally, adenosine may reduce K+ induced Ca2+ overload.68 Adenosine 
has a short half-life (T ½ < 10 s) in blood.69 However, the cardioprotective effect of 
adenosine is maintained, either by a prolonged activation of the A1-receptor or by the 
myocardial consequences of receptor activation similar to the mechanism of ischemic 
preconditioning.70 
 
The degradation of both adenosine and esmolol is independent from the liver- or 
kidney function, which improves clinical feasibility in patients with impaired organ 
function. These two cardiac arrest agents act synergistically resulting in a desired 




The effect of magnesium cations is antagonistic blockade of calcium channels in the 
myocyte membrane preventing Ca2+, which is required for myocardial contraction, 
from entering the cell.72 Mg2+ as an additive to cardioplegic solutions, also reduces 
myocardial metabolism during ischemia and optimizes the intracellular Ca2+/Mg2+ 
ionic hemostasis. Both mechanisms are important in preventing cell damage.73-75 
Additionally, Mg2+ acts like an antiarrhythmic agent.76,77 Magnesium is an additive to 
the standard potassium-based blood cardioplegia used in our institution. 
 
6.7 Procaine 
Procaine is a local anesthetic substrate and is widely used as a low concentration 
additive to cardioplegic solutions.1,78 The mechanism is direct blocking of the fast 
sodium channel activation leading to cell membrane stabilization, which is a class 1A 
antiarrhythmic effect.79 This is clinically relevant in the postischemic period of 
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reperfusion, especially after administration of hyperkalemic cardioplegic solutions.80 
In addition, procaine also prevents coronary artery constriction/spasm and has free 
radical scavenger properties.46,51 Procaine is included in the standard potassium-based 
blood cardioplegia used routinely in our institution and was therefore added in equal 
concentration to the St. Thomas´ polarizing solution in this research project. 
 
6.8 Blood 
Cardioplegic arrest can be achieved by using a crystalloid solution or mixed with 
blood as vehicle.18,81 In general, crystalloid solutions are composed of arresting- and 
occasionally buffering agents, administered as a cold (4°C) solution, but without 
oxygen delivery during the period of ischemic arrest.44,82 Blood cardioplegia is a 
composition of a cardioplegia concentrate mixed with the patient´s oxygenated blood 
derived from the HLM, thus oxygen can be provided to the ischemic myocardium 
during cardioplegic arrest.83 Furthermore, blood acts like a natural buffer, has 
antioxidant qualities and is a free-radical scavenger.20,84 The osmolality of blood may 
reduce cellular edema compared to crystalloids.85 Additionally, by using blood as a 
transport medium for the cardioplegic solution, hemodilution will be less compared to 
administration of crystalloid cardioplegia.86 A potential disadvantage of using blood as 
an additive to the cardioplegic solution is the increased viscosity of blood, especially 
at low temperatures. This may alter the distribution of the cardioplegic solution and be 
of clinical importance both in patients with native narrow coronary arteries (e.g. 
neonatal/pediatric patients) or in adult patients with acquired, obstructive coronary 
disease (e.g. atherosclerosis). 
 
6.9 Temperature 
Cardioplegia can be administrated as cold, tepid or normothermic infusate and will 
consequently influence the temperature of the myocardium after equilibration. 
Moderate topical and systemic cooling are also commonly used routines.44 General 
hypothermia adds another component of myocardial protection additional to the 
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diastolic arrest, by decreasing the basal metabolism and oxygen consumption.87 
Hypothermia may also have detrimental effect due to negative influence on enzymatic 
and cellular reparative processes and shift in the oxygen-hemoglobin dissociation 
curve interfering with delivery of oxygen at the cellular level.88 The optimal 
temperature, both during CPB and in the myocardium of the arrested heart, is still 
being questioned.47 
 
7. AIM OF THE PROJECT 
The main objective of this project was to evaluate if cardioplegic arrest with 
adenosine/esmolol/magnesium, STH-POL, offers myocardial protection comparable to 
a standard depolarizing potassium-based cardioplegic solution, STH-2, both delivered 
as antegrade, repeated, cold, oxygenated blood cardioplegia. We hypothesized that 
repeated perfusions of the myocardium with the novel STH-POL cardioplegic 
solution, provided an equal or better myocardial protection compared to the standard 
STH-2 cardioplegic solution in a clinically relevant and translational animal model.  
The specific aims of the three studies were to compare STH-POL and STH-2 
cardioplegic regimes with respect to:  
• Differences in regional and global cardiac function, β-adrenergic receptor 
desensitization and myocardial injury following weaning from CPB after 60 
min of cardioplegic arrest, thus simulating a standard, single procedure of open 
heart surgery (Paper I). 
• Differences in myocardial high-energy phosphate metabolism and myocardial 
ultrastructure following 60 min of cardioplegic arrest and after weaning from 
CPB (Paper II). 
• Differences in left ventricular function and contractile efficiency after weaning 
from CPB after an extended cardioplegic arrest of 120 min, simulating a more 




8.1 Animals and anesthesia 
All experiments were performed in Norwegian Landrace pigs of either gender. Results 
from 60 young animals weighting 42 ± 3 kg were included in Paper I - III. All animal 
experiments were done in accordance with the European Communities Council 
Directive of 2010 (63/EU). The animal handling and research protocols were approved 
by the Norwegian State Commission for Laboratory Animals (Project 20135835) and 
the responsible veterinarian at the Vivarium, University of Bergen. 
The pigs were brought to the animal facility at the Vivarium for acclimatization about 
one week before the experiments. Two ear veins were cannulated after premedication 
with intramuscular injection of a mixture of ketamine (20 mg/kg), diazepam (10 mg) 
and atropine (1 mg) and ventilation on mask with oxygen and 3% isoflurane (Rhodia, 
Bristol, UK). Loading doses of intravenous (IV) fentanyl (0.02 mg/kg), midazolam 
(0.3 mg/kg), pancuronium (0.063 mg/kg) and sodium pentobarbital (15 mg/kg) were 
given, followed by a continuous infusion of fentanyl (0.02 mg/kg/h), midazolam (0.3 
mg/kg/h) and pancuronium (0.2 mg/kg/h). A separate infusion (to prevent 
precipitation) with sodium pentobarbital (4 mg/kg/h) in Ringer´s acetate with 20 
mmol/L KCl added, was administrated. This pentobarbital infusion also constituted the 
basic fluid substitution of 15 mL/kg/h throughout the experiments. After tracheotomy 
for airway intubation, the animals were ventilated (Julian, Drägerwerk, Lübeck, 
Germany) with a mixture of nitrous oxide (56-58%) and oxygen. The tidal volume was 
set to 11 mL/kg and the frequency adjusted aiming at an end-tidal pCO2 of 5.0 to 5.6 
kPa. Prophylactic antibiotic therapy with Cefalotin 1g dissolved in saline, was given 
IV initially, followed by 0.5 g during CPB and 1.0 g after weaning (Paper I + III). In 
addition, intravenous Ringer’s acetate, 5 mL/kg/h, was provided after weaning from 
CPB. The anesthetic protocol has previously been evaluated by the research group 




8.2 Surgical protocol and instrumentation 
The right femoral artery and vein were cannulated for blood sampling and infusion by 
surgical cut-down in the groin. An early arterial blood gas analysis determined the 
need for ventilator adjustments. Rectal temperature was monitored and an open 
suprapubic cystotomy with insertion of a catheter measured diuresis. A midline 
sternotomy and pericardiotomy exposed the heart and heparin (125 IU/kg) was given 
IV to prevent catheter clotting. A continuous cardiac output catheter (CCO/EDV 
177HF 75, Edwards Lifesciences Inc, Irvine, CA) was advanced from the left internal 
mammary vein into the pulmonary artery for monitoring cardiac output, right 
ventricular end-diastolic volume (EDV), central venous pressure (CVP) and 
pulmonary artery pressure (PAP) (Vigilance II® and TruWave® transducers, Edwards 
Lifescience Inc) (Figure 5). A microtip pressure catheter (Millar MPC-500, Houston, 
TX) was inserted into the proximal aorta through the left internal mammary artery. An 
identical catheter through the apex of the heart monitored left ventricular pressure in 
Paper II. A dual-field pressure-conductance catheter (CA71083-PL, CDLeycom, 
Hengelo, the Netherlands) connected to a Sigma-M signal conditioner (CDLeycom) 
was inserted through the apex and into the left ventricle in Paper I + III. The distal part 
was positioned just above the aortic valve, verified by epicardial echocardiography 
(Vivid E9, GE Vingmed Ultrasound, Horten, Norway). An infant feeding tube 
allowing microsphere injections was inserted into the left atrium and a tourniquet was 
placed around the inferior vena cava (IVC) for short-term intermittent dynamic 
preload reductions (Paper I + III). After two-point sensor calibration on the day of the 
experiment, all hemodynamic parameters were sampled by a 16-channel Ponemah 
ACQ-7700 system (Data Sciences International, St. Paul, MN), and later analyzed 
















8.3 Cardiopulmonary bypass 
The heart-lung machine (Stöckert SIII, Munich, Germany) was primed with 1200 mL 
Ringer´s acetate in the circuit. Systemic heparinization (heparin 500 IU/kg) was 
followed by cannulation of the brachiocephalic artery (EOPA 18 Fr, Medtronic Inc., 
Minneapolis, MN) and right atrial appendage (MC2 28/36 Fr, Medtronic Inc.) (Figure 
6). CPB was established with a flow of 90 mL/min/kg and water temperature of 32°C 
in the heat exchanger. The time period of aortic cross-clamping was 60 min (Paper I + 
II) and 120 min (Paper III). A left heart vent catheter (DLP 13, Medtronic Inc.) was 
introduced in the left atrial appendix and advanced through the mitral valve into the 
left ventricle for passive drainage of the heart during cardioplegic arrest (Paper I). An 
alternative method for unloading the left ventricle, was a similar vent catheter 
Figure 5. Baseline instrumentation in Paper I + III. Millar pressure catheter (blue) through the left 
internal mammary artery for monitoring central aortic pressure. Edwards CCO-catheter/Swan Ganz 
(yellow) through the left internal mammary vein for monitoring CVP, PAP and CCO. Baby feeding 
tube (grey) into the left atrium for injection of fluorescent microspheres. CDLeycom dual-field 
pressure-conductance catheter (light blue) through the apex of the left ventricle for monitoring left 




temporarily placed through the apex into the ventricle (Paper II + III). The body 
temperature was allowed to drift towards 34°C and CPB flow was reduced to 72 
mL/min/kg when rectal temperature reached 35°C or after 20 min. After 40 min (Paper 
I + II) or 100 min (Paper III) of aortic cross-clamping, systemic rewarming was 
commenced with reset of CPB flow to 90 mL/min/kg and water temperature at 40°C. 
Arterial blood gases were acquired before cross-clamping, at half time during the 
cardioplegic period (Paper I + III) and prior to declamping. During CPB, the tidal 
volume of the ventilator was reduced to 50% to prevent atelectasis. Additional heparin 
(250 IU/kg) was given at half time during aortic cross-clamping. Defibrillation was the 
only allowed antiarrhythmic intervention in these research protocols and was used if 
ventricular fibrillation occurred after declamping. After 10 min of reperfusion, the 
animals were weaned from CPB. The residual blood in the HLM circuit was infused 
followed by decannulation. Protamine sulfate (1 mg/kg Paper I, 1,5 mg/kg Paper II, 2 
mg/kg Paper III) was slowly injected IV for heparin reversal.  
 
8.4 Cardioplegia 
Cardioplegia was given as either the normokalemic St. Thomas’ Hospital 
polarizing solution (STH-POL) formulated with a mixture of esmolol, 
adenosine and Mg2+, or the hyperkalemic St. Thomas’ Hospital cardioplegic 
solution 2 (STH-2). Both solutions were pre-prepared as concentrate, modified 
by adding procaine and administered as cold (120C), oxygenated, blood 
cardioplegia, freshly mixed by a dual-head pump and separate cooling on the 
HLM.  The cardioplegia was given into the aortic root with a flow set to 7% of 
CPB flow, following a standardized protocol with an initial ‘high-dose’ (1:4 
concentrate/blood) for 3 min and 2 min of ‘low-dose’ (1:8 concentrate/blood) 
given at 20 and 40 min after aortic cross-clamping (Paper I - III) and 
additionally at 60, 80 and 100 min in Paper III. The final molar concentrations 
























Figure 6. Instrumentation during CPB and CA in Paper III. Basic instrumentation as in Baseline 
situation (Figure 5). EOPA 18 Fr cannula (red) through the brachiocephalic artery and into to the 
ascending aorta for systemic return of oxygenated blood from the HLM. Two-stage 28/36 Fr venous 
cannula (blue) through the right atrial appendage for venous drainage into to the HLM from the right 
atrium and inferior vena cava. Cardioplegia needle in the proximal ascending aorta for antegrade 
delivery of STH-POL or STH-2 cold blood cardioplegic solution. Aortic cross-clamp in the distal 
ascending aorta. DLP 13 Fr left heart vent (grey) through the apex for unloading the left ventricle 





Table 1. Final molar concentrations in oxygenated blood cardioplegia. 
           STH-POL    STH-2 
          high-dose          low-dose         high-dose        low-dose 
              3 min               2 min                         3 min              2 min 
Esmolol (mM)  1.35  0.68     -    - 
Adenosine (mM)  0.50   0.25     -    - 
Mg2+ (mM)   20         10   16    9 
K+ (mM)   4.3  4.3   22  14 
Cl- (mM)   106  106   134  120 
Procaine-HCl (mM)   0.8  0.4    0.8  0.4 
STH-POL = Modified St. Thomas´ Hospital polarizing cardioplegic solution.                                                  
STH-2 = Modified St. Thomas´ Hospital cardioplegic solution No 2. 
 
8.5 Pressure-volume conductance catheter 
The systolic left ventricular performance is depending on three principle factors; 
preload, afterload and the contractile state of the myocardium. The contractile function 
can be evaluated by a pressure versus volume plot. Experimentally, several methods 
have been used to obtain this relation. Since the early 1980s, the use of conductance 
catheter and continuous ventricular volume estimations has been an established 
method.90 The principle of this method is a catheter with multiple electrodes 
generating an electrical field between the most distal and the most proximal electrode. 
Since the early 1990s, this method was improved by adding electrodes making two 
alternating electrical fields with opposite polarity (Figure 7) between the proximal and 
the distal pairs of electrodes.91 The result is a more homogeneous electric field and 
thereby a more linear relation between real volume in the heart chamber and estimated 
volume from the conductance signal. The dual-field conductance catheter is placed 
along the left ventricle (LV) long axis. Accessing the LV can either be through a 
retrograde approach from e.g. the right carotid artery or directly into the LV through 
the apex of the heart. The conductance catheter is designed with a soft pigtail for 








By using a dual-field conductance catheter with multiple electrodes and a full-bridge 
solid-state pressure sensor in the LV, a plot can be presented as real-time pressure-
volume loops (Figure 8). 
 
8.5.1 Pressure-volume loops 
Pressure-volume area (PVA) is a measure of total mechanical work, calculated as the 
sum of stroke work (SW) and potential energy (PE) (Figure 8). Other parameters, 
which can be calculated from a PV-loop, are e.g. stroke volume, end-systolic and end-
diastolic volumes, ejection fraction and cardiac output (stroke volume * heart rate). 
From the pressure signal, variables like dP/dtmin and dP/dtmax (peak negative/positive 
derivate of LV pressure) and Tau (time constant of isovolumic relaxation) can be 
calculated. The electrical field generated by the conductance catheter is not only 
limited to the LV blood volume. The dual electrical field also passes through the 
ventricular wall. Other conductive tissues (e.g. myocardium, lungs) and fluids 
surrounding the LV cavity, e.g. blood in the right ventricle (RV), affect the measured 
conductance and introduce an offset in the relation between true LV volume and the 
volume derived from the catheter. 
 
Figure 7. The two proximal and distal electrodes 
are driving electrodes for a dual electrical field 
along the ventricular axis. 7 segments are included 
for calculation of segmental volumes by measuring 
resistance between pairs of electrodes, cross 
sectional area and blood conductivity. The pressure 
sensor is located at segment 6. In addition, an 











This parallel conductance can be corrected for by injection of hypertonic saline into 
the pulmonary artery.92 Finally, the Baan equation is used for calculation of absolute 
volumes:    V(t)	=	1/α	*	ρ	*	L2	*	(G(t)	–	Gp)	                      
where V(t) is total intraventricular volume, α is alpha factor (derived from volume 
estimates from the Swan-Ganz catheter), ρ is blood resistance, L is distance between 
segmental electrodes, G(t) is total conductance and Gp is parallel conductance.93 
 
8.5.2 Acquisition 
In Paper I and III, a dual-field conductance-pressure catheter was inserted through the 
apex and into the left ventricle with the distal part including 2-3 electrodes in position 
just above the aortic valve (Figure 5). The remaining electrodes in the left ventricle 
allow assessments of conductance in up to 7 segmental electrical fields together with 
Figure 8. Real-time left ventricular pressure-volume loop (blue) from one single heart cycle. The loop 
turns counter-clockwise starting with mitral valve closure (MVC) at end-diastole, followed by 
isovolumic contraction before aortic valve opening (AVO) and start of the ejection of blood into the 
aorta. Aortic valve closing (AVC) defines end-systole followed by isovolumic relaxation, which ends in 
the mitral valve opening (MVO) initiating the passive filling phase. Stroke work (SW) is the area of the 
loop, stroke volume (SV) is EDV – ESV. Potential energy (PE) is the area (dotted red) defined by the 
end-systolic and the logarithmic end-diastolic pressure-volume relations together with descending 
part of the PV-loop. The total left ventricular mechanical work for one cardiac cycle is PE + SW. 
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pressure data. Following pre-oxygenation (short period of 100% O2 ventilation) and 
ventilator shut-off in end-expirium, five to 10 heartbeats with stable hemodynamics 
and six to 12 consecutive cardiac cycles during IVC occlusion using a tourniquet, were 
sampled as a dynamic run (Figure 9). Arrhythmia or other interferences were not 
accepted, and a new run was obtained when aortic pressure (AOP) was stabilized at 
pre-run level. A total of four valid run acquisitions were sampled in all experiments. In 
addition, at each of these situations three bolus injections of 5 mL hypertonic (10%) 
saline were rapidly injected into the pulmonary artery through the CCO-catheter, for 
estimation of parallel conductance.  
 
8.5.3 Load-independent indices of LV systolic and diastolic function 
Pressure-volume loops obtained during an acute preload reduction makes it possible to 
calculate variables describing volume-/load-independent systolic and diastolic 
function. The slope of the end-systolic pressure-volume relationship (ESPVR) derived 
from a regression line through the end-systolic points of the PV-loops is one variable 
describing left ventricular systolic function (Figure 9). The slope of the linear ESPVR 
relation can be described using the equation:94       
           ESP	=	Ees		(ESV	–	V0)               
where ESP is end-systolic pressure, Ees is the slope of the linear relationship, ESV is 
end-systolic volume and V0 is the x-axis intercept. The linear ESPVR and following 
calculation of ESPVRslope reflects the LV systolic function.95 However, the relation is 
often more of a logarithmic character and altering loading conditions may affect 
ESPVR. Consequently, this variable is considered not be accurate.96 Preload 
Recruitable Stroke Work (PRSW) is defined by the linear regression of stroke work 
(equivalent to the area of the PV-loop) on the y-axis, related to the end-diastolic 
volume (EDV) on the x-axis during a dynamic preload reduction (Figure 9). The 
relationship between stroke work and EDV is, for all practical purposes, linear and this 
load-independent index of myocardial contractility can be described using the 
equation:97            
          Mw	=	SW	/	(EDV	–	Vw)		                        
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where Mw is the slope of PRSW, SW is stroke work, EDV is end-diastolic volume and 
Vw is the x-axis intercept. 
The end-diastolic pressure-volume relationship (EDPVR) is derived from a regression 
line through the end-diastolic points of the PV-loop. As illustrated in Figure 9, this 
relationship is non-linear, hence the EDPVR is described as the slope (β) in a 
logarithmic equation:          
               EDP	=	a	*	e	(β	*	EDV)	                       
where EDP is end-diastolic pressure, a is the y-axis intercept and β is the slope. The 
slope of EDPVR is a measure of left ventricular compliance and describes its passive 
function in diastole.96 Peak negative first derivate of LV pressure (dP/dtmin) acquired 
from the pressure-conductance during stable preload conditions, describes the active 
relaxation of the left ventricle. Tau (t), which is the time constant of isovolumic 
relaxation, is an additional variable describing the active effectiveness of LV during 
diastole.98 Peak positive first derivative of intraventricular pressure (dP/dtmax) during 
isovolumic contraction (Figure 8) is a variable for LV contractility, but due to its pre- 












Figure 9. Pressure-volume loops at multiple time points during a sequence (= dynamic run) of 11 
heartbeats simultaneously with preload reduction by occlusion of the IVC. The slope of end-systolic 
(ESPVR) and end-diastolic (EDPVR) pressure-volume relations are marked as red interrupted or 
dotted line, respectively. The slope of the regression line defined by the end-systolic points in each 
loop, defines the ESPVR, one variable reflecting the load-independent contractility. Additional figure 
(right) is pressure-volume loop areas (blue dots) from the left figure, plotted against end-diastolic 
volumes (EDV) of the corresponding cardiac cycles. Preload Recruitable Stroke Work (PRSW) is the 
linear relation between stroke work and EDV while the slope is termed PRSWslope and represents the 





Associated data files (1 for evaluation of function, 3-4 for parallel conductance) 
obtained by the pressure-conductance catheter were coded and analyzed as 
independent entities with custom-made software (MATLAB, MathWorks Inc., Natick, 
MA). The mean of 5-8 cardiac cycles during stable situations together with load-
independent variables obtained during the dynamic preload reductions were 
calculated. Absolute volumes were estimated by correcting for parallel conductance 
and cardiac output. Volumes were indexed by body surface area (BSA) calculated as:                
                                BSA	(m2)	=	(BW2/3	*	k)	/	100               
where BW is body weight in kg and k for the pig is 9 m2/kg-2/3.99 
 
8.6 Epicardial echocardiography 
The use of two-dimensional transthoracic echocardiography is an established method 
for evaluation of morphology and function of the heart in both experimental settings 
and clinical practice.100 Echocardiography provides real-time imaging, is non-invasive, 
widely available and essential in the diagnosing and management of the majority of 
patients with cardiac conditions. New advances in echocardiographic technology 
incorporate three-dimensional techniques. Furthermore, a method for evaluation of 
cardiac function is the assessment of myocardial deformation either by Tissue Doppler 
Imaging (TDI) or Speckle Tracking Echocardiography (STE). Above all in an 
experimental laboratory setting, these two methods are essential for validation of 
minor, but significant changes of myocardial function. Epicardial echocardiography in 
an open chest model facilitates the use of ultrasound probes with higher frequency 
than in clinical practice. Consequently, the recordings enable data with high spatial 
and temporal resolution and thereby more reliable and reproducible measurements. 
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Figure 10. Strain assessment in three directions. Radial and 
circumferential deformation are evaluated using short-axis 
views. Longitudinal deformation is evaluated in the long-axis 
four-chamber direction from an apical view. 
 
8.6.1 Strain and strain rate 
Deformation in this context refers to the concept of strain. The definition is a fractional 
or percentage change in length compared to its original length. Additionally, positive 
strain is defined as lengthening or stretching, while negative strain is shortening.101 
If the strain is linear it can be defined by the Lagrangian formula:                                     
                                                 ε	=	C	DCE
CE
                
where ε = strain, L = length at a specific time during the cardiac cycle, usually the 
peak systolic value, and L0 the original length usually read at end-diastole giving peak 
systolic strain.102 The helical myocardial fiber orientation of the left ventricle is 
complex, and the motion and deformation following myocardial contraction can be 
measured in several directions during one heart cycle. The most commonly used 
arrangement for directional measurements is using the chamber axis, allowing 






Strain rate (SR) is the first derivate of strain with respect to time, describing the speed 
of deformation. Peak ejection strain rate is correlated to dP/dtmax derived from the 
pressure-conductance catheter (Ch. 8.5.3).103 Strain and strain rate can be measured 
both as a regional and a global variable. 
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8.6.2 Tissue Doppler Imaging 
Echocardiographic recordings using Tissue Velocity Imaging modality is the basis for 
subsequent processing and analyzing of Tissue Doppler Imaging strain (Figure 11A) 
and strain rate (Figure 11B).104 In TDI, the displacement towards the scanner probe is 
normally color-coded red while blue denotes displacement in the opposite direction. 
Myocardial velocities (displacement per unit time) for each sample volume can be 
displayed as time curves. The basis for strain rate measurements is the velocity 
differences. In a selected region of interest (ROI), velocities can be analyzed off-line 
on a workstation and the strain rate can be estimated and displayed as time curves. By 
measurement of two different velocities (V1 and V2) at two different positions by a 
predefined distance (strain length), myocardial velocity gradient can be calculated 
which is proportional to strain rate. Strain is calculated by temporal integration of SR, 
usually over one cardiac cycle. The method of TDI is restricted to measure the 
myocardial deformation component along the ultrasound beam and is consequently 
limited by angle dependency (Ch. 10.11.4). 
 
8.6.3 Speckle Tracking Echocardiography 
An alternative non-Doppler method for evaluation of myocardial deformation is the 
use of Speckle Tracking Echocardiography, which uses the Brightness mode (B-mode) 
images of a cine-loop (Figure 12).105 By speckles means acoustic markers produced at 
random by reflection, interference and scattering of the echo beam. Such speckles act 
as natural positional markers and is relatively stable during a part of the cardiac cycle 
(e.g. peak systole) and can be used for tracking the myocardial motion throughout a 
defined period of a heartbeat.106 The post-processing software defines a cluster of 
speckles (called ‘kernel’) and tracks the kernels displacement frame by frame based on 
the user-defined ROI using a sum-of-absolute differences algorithm. Ultimately, off-
line calculation of myocardial deformation parameters such as regional or global 
systolic strain (%) and strain rate (s-1) can be performed. In contrast to TDI, STE can 
quantify strain and strain rate in two directions within the imaging plane and is often 
called two-dimensional (2D) strain.104 
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Both TDI and STE have demonstrated to be reliable methods to measure left 
ventricular systolic function and are comparable to alternative techniques like 
sonomicrometry and MRI.107-109 
 
8.6.4 Acquisition  
In this project, regional myocardial function was evaluated in Paper I and III by 2D 
epicardial echocardiography (Vivid E9, GE Vingmed Ultrasound). Using a soft 
silicone pad (4 × 4 × 3 cm) as offset between the probe (6 MHz sector probe, GE 
Vingmed Ultrasound) and the epicardium, Pulsed Wave Doppler (PWD) spectral 
velocity traces with the sample volume in the aortic valve ostium obtained from the 
apex, was used to identify the aortic valve opening and the aortic valve closure for 
timing purposes. During B-mode recordings, the frequency was set to 6.5 MHz, and 
the anterior myocardial wall was focused by using a depth scale of 0-3 cm (Figure 
11A). In the TDI mode, color gain was adjusted and frame rate set to obtain a high 
frame rate by reducing the image sector width to avoid aliasing. Mean frame rates for 
the TDI recordings were 544 (range 249-696) and 619 (range 327-749) frames/s in 
Paper I and Paper III, respectively. Accurate position of the probe was essential for a 
perpendicular image view in relation to the anterior wall for measurement of radial 
strain. Mean frame rates for the STE recordings in Paper III were 74 (range 63-88) 
frames/s in the short-axis view (SAX) and 74 (range 63-93) frames/s in the four-
chamber apical view. 
To avoid hemodynamic variations due to airway pressure alterations, the ventilator 
was disconnected during echocardiographic recordings, and 3-5 stable cardiac cycles 
were recorded at each situation. TDI of the anterior left ventricular wall was recorded 
in SAX in Paper I and Paper III, while STE was recorded in SAX and four-chamber 
views in Paper III. End-diastole was defined as the first deflection in the QRS complex 
in the ECG, while start and end of ejection (end-systole) were defined as the aortic 
valve clicks in the PWD velocity spectrum. The size of the ROI in the TDI analysis 
was set to 6 × 6 mm and the strain length (SL) to 6 mm (Figure 11). Care was taken 
not to place the ROI within a distance of ½SL from the epicardium and ½SL from the 
endocardium since the TDI recording extends outside the ROI display.110 The initial 
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ROI for each recording in the STE analysis was selected by manually tracing the 
endocardium lining in the reference frame. Care was taken to include the full thickness 
of the left ventricular wall by optimizing the width of ROI, but without sampling 
outside the epicardium. Myocardial deformation was assessed throughout the cycle 
with the software dividing the ROI into 6 preset segments (Figure 12). Both visual and 
automatic validation of adequate tracking was performed before approval and 
subsequent final analysis. 
 
8.6.5 Analysis 
All analyses were performed by using commercial software (EchoPAC BT12, GE 
Vingmed Ultrasound). One cardiac cycle was selected without any prior arrhythmia 
causing hemodynamic variations and used for analysis. 
 
8.7 Myocardial tissue samples 
In Paper I – III, myocardial tissue samples were acquired ex-vivo when the final 
measurements were completed and after the heart was explanted. Samples were 
obtained from the right ventricle, endo-, mid- and epicardium of the septum, and the 
anterior- and the posterior wall of the left ventricle. Samples snap frozen in liquid 
nitrogen (– 196°C) were stored at – 80°C for later analysis of β-receptor activity, 
carnitine palmitoyl-transferases, apoptotic activity and oxidative stress. Furthermore, 
in Paper II samples from the LV epi- and midmyocardium of the anterior wall were 
acquired in-vivo, both from the working and the cardioplegic heart. At the time of 
sampling, a 6 mm biopsy was snap-frozen in liquid nitrogen within 5 s while a 4 mm 





Figure 11A. Baseline analysis of a single layer TDI radial strain of the LV anterior wall in an 
experiment in Paper III. Circular ROI = 6 mm radius (yellow circle) with SL = 6 mm is positioned in 
the mid-myocardium (left) and tracked through one heart cycle, visualized in both color map (upper) 
and B-mode (lower). Yellow curve (right) is the corresponding radial strain curve during the heart 
cycle. Peak systolic strain value (blue circle) at Baseline (38.4%) is representative for mean values in 
Paper III. AVO = aortic valve opening (green vertical dotted lines), AVC = aortic valve closure (end-
systole, red vertical line) from Pulsed Wave Doppler. 
Figure 11B. Baseline analysis of a single layer TDI radial strain rate of the LV anterior wall at 
Baseline in the same experiment as above (A). ROI (yellow circle) is equally positioned in the mid-
myocardium (left) and yellow curve (right) is the corresponding radial strain rate curve through one 
heart cycle. Peak ejection strain rate value (blue circle) at Baseline (2.11 s-1) is representative for 




























Figure 12A. Short-axis view of the LV, demonstrating Baseline analysis of STE radial strain in an 
experiment in Paper III. The left ventricle is divided into six preset segments (left). The 
corresponding colored curves of radial strain for each segment through one heart cycle are 
presented in the panel to the right. AVC = aortic valve closure (end-systole, green dotted vertical 
line) from Pulsed Wave Doppler. 
Figure 12B. Long-axis four-chamber view of the LV in STE mode. The standard six segments of the 
left ventricle are illustrated in the panel to the left. The corresponding colored curves for regional 
longitudinal strain in each segment during one heart cycle, are presented in the panel to the right. 
The peak systolic strain value (active contraction) is negative (i.e. shortening) in the longitudinal 




















In the pathway of apoptosis, sequential activation of cysteine-aspartic acid proteases 
(i.e. caspases) is essential in the execution-phase of the cell apoptosis. Caspase-3 is 
one of the pro-enzymes that are inactive under normal conditions, but in the apoptotic 
cell caspase-3 is activated following a complex intrinsic and extrinsic signaling 
pathway.111 In Paper I and III, caspase-3 activity was determined using the Caspase-3 




lysis performed according to the manufacturer’s instructions. Triplet samples 
containing 400 µg of total protein, measured by the Quick StartTM Bradford Protein 
Assay (Bio-Rad Laboratories, Inc., Hercules, CA), were incubated for 2h before 
fluorometric readings. 
 
8.7.2 ß-receptor activity 
Cardiopulmonary bypass and cardioplegic arrest cause adrenergic stress response.112  
A systemic inflammatory response syndrome is triggered by the surgical trauma and 
the contact of the blood components with the artificial surface of the bypass circuit 
during CPB. Leukocytes and endothelial cells are activated, and various pro- and anti-
inflammatory mediators are released. Among others, the consequence of this complex 
acute phase reaction is an increased level of circulating catecholamines.113 Myocardial 
catecholamine levels are also upregulated during the cardioplegic arrest. This local 
catecholamine release is independent of the central sympathetic activation. Modulating 
mechanisms are activation of presynaptic receptors (α2-adrenoreceptors, adenosine A1-
receptors), neuronal amine reuptake and metabolic alterations like hypoxia/anoxia, 
loss of high-energy phosphates, extracellular hyperkalemia and acidosis.114 
The adrenergic stress response may lead to some degree of desensitization of 
myocardial β-adrenergic receptors. Impaired signaling through this pathway may play 
a significant role in the etiology of postoperative myocardial dysfunction and also 
cause less response if inotropic support is needed.112 G protein-coupled receptor 
kinase-2 (GRK2) is a serine/threonine kinase, which is involved in this mechanism by 
phosphorylation and desensitization of agonist-occupied β-adrenergic receptors. In 
Paper I, the activation of GRK2 in the myocardium was assessed with immunoblotting 
using antibodies against phosphorylated GRK2 (LS-C199027, LifeSpan BioSciences 
Inc., Seattle, WA) and total GRK2 (CST3982, Cell Signaling, Boston, MA) according 




8.7.3 Oxidative stress 
Reperfusion of the ischemic myocardium after cardioplegic arrest can be detrimental 
to the myocardium due to oxidative stress induced by reactive oxygen species (ROS). 
Furthermore, cardiopulmonary bypass also affects neutrophil activation, which is pro-
inflammatory and essential in the mechanism of oxidative stress.115 Malondialdehyde 
(MDA) is a product formed from degrading polysaturated lipids by ROS. In Paper III, 
oxidative stress was evaluated by assessment of MDA by using a commercial 
fluorometric kit (K739-100, BioVision Inc., Milpitas, CA). Tissue samples obtained 
from the LV endo-, mid- and epicardium and the right ventricle were snap-frozen and 
stored in liquid nitrogen. Later the myocardial samples were homogenized, lyzed and 
analyzed according to the manufacturer’s instructions.  
 
8.7.4 Metabolism 
Fatty acids and glucose are the most important substrates for energy metabolism in the 
heart. Failure to produce, transport or utilize an adequate amount of energy causes 
functional loss and failure of the contractile work of the myocardium. Free fatty acids 
are transferred from the cytosol into the mitochondrion by the carnitine transport 
system. Carnitine palmitoyltransferase I and II (CPT-I, CPT-II) are enzymes essential 
for catalyzing the transport of carnitine from the cytosol through the outer– and inner 
membrane of the mitochondrion (Figure 1). The synthesis and catabolism of high-
energy phosphates is the final step in the process of transforming chemical energy into 
mechanical work. In Paper I, assessment of CPT-I and CPT-II activity in the outer and 
inner mitochondrial membranes were evaluated. Each sample was homogenized after 
adding 500 µl of ice-cold sucrose (0.25 M sucrose, 5 mM HEPES-buffer, 0.2 mM 
ethylene glycol tetraacetic acid, pH 7.4) and centrifuged at 4°C, 600 g for 12 min. The 
protein concentration in the supernatant (post-nuclear fraction) was measured (Bio-
Rad Protein Assay, Bio-Rad Laboratories, Inc., Hercules, CA). In 150 µg of protein, 
CPT-I and CPT-II were measured as described elsewhere.116 
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Figure 13. Explanted porcine heart with schematic 
illustration of multiple punch biopsies obtained from the 
left ventricular anterior wall at Baseline, during 
cardioplegic arrest and subsequent early and late during 
reperfusion in Paper II. In-vivo, the diagonal branches of 




In Paper II, frozen tissues samples (averaging 65 mg) from the epi-/midmyocardium of 
the anterior left ventricular wall were homogenized with a micro-dismembranator and 
deproteinized with 500 µL of 0.4 mol/L perchloric acid. After centrifugation (12000 g) 
200 µL of the acid extract was neutralized with 20-25 µL of 2 mol/L potassium 
carbonate (4°C). The supernatant (20 µL injection volume) obtained after 
centrifugation was used for high-performance liquid chromatography (HPLC) 
analysis. The pellets of the acid extract were dissolved in 1 mL of 0.1 mol/L sodium 
hydroxide and further diluted 1:10 with physiologic saline for protein determination 
(BCA Protein Assay, Pierce). High-energy phosphates (ATP, ADP, AMP and creatine 
phosphate), hypoxanthine and xanthine were measured by HPLC. Separation was 
performed on a Hypersil ODS column (5 µm, 250 mm x 4 mm I.D.) using a L-2200 
autosampler, two L-2130 HTA pumps and a L-2450 diode array detector (all: VWR 
Hitachi, Radnor, PA). Detector signals (absorbance at 214 nm and 254 nm) were 
recorded and the program EZchrom Elite (VWR Hitachi) was used for data acquisition 
and analyzes.  Energy charge (EC) was calculated as:117 









Morphological evaluation of the architecture of the myocyte in experimental models of 
myocardial ischemia has provided essential information on the pathogenesis of 
hypoxic heart injury.118 Transmission Electron Microscopy (TEM) produces a 2D 
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image with a maximum magnification of x 500.000. In heart muscle tissue, it 
visualizes cell structures like the nucleus, mitochondria, sarcoplasm system and the 
myofibrils.  
In Paper I and II, myocardial tissue samples from the anterior left ventricular wall, 
were fixed overnight in 0.1 mol/L Na-cacodylate buffer with 2.5% glutaraldehyde, 
washed, post-fixated with 1% OsO4, dehydrated and stored in 70% ethanol, sectioned 
and stained with uranyl acetate. Sections were visualized by TEM (JEM-1230, Jeol, 
Tokyo, Japan), and images acquired using a 1 MP Gatan camera. The scanning 
electron microscopy images (x15 000) were acquired with microscope (JSM-7400F, 
Jeol). By morphometry, the myocyte volume fraction of mitochondria (VVmit), 
myofibrils (VVmyo) and cytosol (VVcyt) were calculated as the number of overlaying 
points within the cellular structure related to the total number of points included in the 
extranuclear space on each micrograph with a grid of 81 points with random offset 
(Figure 14, left). With a random offset Merz grid (Figure 14, right) the mitochondrial 
surface-to-volume ratio was calculated as:  
                       SVratiomit	(µm2/µm3)	=	(2	*	Mx)	/	(Mp	*	l/p)             
where Mx = the total number of outer mitochondrial membrane line-crossings, Mp = 
total number of points encircled by outer mitochondrial membranes and l/p is a 
constant for the applied Merz grid. The mitochondrial surface density was calculated:
      SVmit	(µm2/µm3)	=	(2	*	Mx)	/	l         
where Mx = the total number of outer mitochondrial membrane line-crossings and l is 
the total length of lines in the Merz grid. In Paper I, a total number of 21813 
mitochondrial points and 16135 line-crossings were counted with the Merz grid, 
corresponding numbers for Paper II were 34629 and 44310. In Paper II, the six 
micrographs from 15 randomly selected biopsies were individually coded and 
reanalyzed by the first observer, then recoded and analyzed by a second observer. The 
intra- and interobserver Intraclass Correlation Coefficient and Coefficient of Variation 
for morphological variables in 15 biopsies were calculated. 
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Figure 14. Evaluation of myocardial volume fraction of mitochondria, myofibrils and cytosol by a 
grid of 81 points (left). Merz grid for evaluation of mitochondrial surface-to-volume ratio and surface 
density (right). Mitochondria crossing beyond the lower horizontal and the right vertical edges (red) 















8.7.6 Regional tissue blood flow and water content 
Fluorescent microspheres (15 µm), with four different colors administered in a 
randomized sequence, were used for evaluation of regional tissue blood flow in Paper 
I and III. At each time point, 6 million microspheres were injected into the left atrium 
for distribution in the systematic circulation. Simultaneously, an arterial blood sample 
was extracted for 2 min using a constant rate pump (Sage Instruments, Cambridge, 
MA) as an artificial reference organ. Tissue- and reference samples were weighed, 
hydrolyzed, microspheres isolated by filtration, colors dissolved and quantified by 
fluorospectrophotometry. Regional tissue blood flow was subsequently calculated 





where Q = flow and I = intensity measure from the fluorospectrophotometer. 
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For the evaluation of tissue water content, samples were dried for three weeks at 60°C 
before reweighting and water content calculated by the formula:                             




8.8 Left ventricular mechanical efficiency 
An indirect way of evaluating MVO2 is to use pressure-volume loops to define the 
pressure-volume area (PVA), which is the sum of stroke work and potential energy 
(Figure 8). PVA has been demonstrated to linearly correlate with LV oxygen 
consumption per beat independent of loading conditions, mode of contraction and 
contractile state.119 If myocardial blood flow is evaluated by the technique of 
fluorescent microspheres (Ch. 8.7.6), the relation between total mechanical work 
(PVA) and tissue blood flow rate in the left ventricle can be calculated as an index for 
mechanical efficiency.120 In Paper III, the mechanical efficiency (Joule/mL/g 
myocardium) was calculated as the sum of mechanical and potential energy performed 
by the left ventricle per min related to blood flow rate by the formula: 
                  Mechanical	Efficiency	=	(PE	+	SW)	*	HR	/	BFR                       
where PE and SW are pressure-volume areas for the left ventricular potential energy 
and stroke work in Joule, HR is heart rate and BFR is left ventricular blood flow rate 
per g myocardium. 
 
8.9 Blood chemistry 
Blood samples were obtained from the arterial line in the groin, serum prepared and 
analyses of serum troponin-T (Troponin-T hs®, Roche Diagnostics, GmbH, 
Mannheim, Germany) were subsequently performed at the Laboratory for Clinical 
Biochemistry, Haukeland University Hospital. Blood for measuring arterial blood 
gases were sampled from the arterial line in the groin or directly from the heart-lung 
machine during CPB and momentarily analyzed at the Vivarium (ABL80 FLEX 
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COOX, Radiometer Medical ApS, Brønshøj, Denmark or OPTI CCA-TS2, OPTI 
Medical Systems, Atlanta, GA). 
 
8.10 Experimental protocols 
8.10.1 Paper I 
Animal preparation and surgical instrumentation were performed as previously 
described (Ch. 8.2). Following baseline assessments, tepid (34°C) CPB was initiated 
before 60 min of CA with STH-POL or STH-2 administered every 20 min. Cardiac 
and hemodynamic variables were continuously recorded. Global and regional cardiac 
function and tissue blood flow rate at Baseline and 60, 120 and 180 min after 
declamping and weaning from CPB, were evaluated with pressure–conductance 
catheter, epicardial echocardiography and microsphere injections. After the final 
registration, the animal was euthanized with intracardiac injection of high-dose 
potassium chloride, the heart was explanted and myocardial samples were obtained for 
later analysis. 
 
8.10.2 Paper II 
Left ventricular and general hemodynamic variables were continuously recorded in 
Paper II. At Baseline, myocardial biopsies from the anterior left ventricular wall were 
sampled. CPB was established followed by 60 min of CA as described in Paper I. 
After 58 min of arrest, myocardial biopsies were repeated. The animals were weaned 
from CPB after 10 min of myocardial reperfusion. At 20 and 180 min after 
declamping, myocardial biopsies were repeated (Figure 13). Finally, the animal was 
euthanized with intracardiac injection of high-dose potassium chloride, the heart was 




8.10.3 Paper III 
The protocol in Paper III was a modification of the protocol in Paper I. Following 
Baseline assessments using pressure–conductance catheter, epicardial 
echocardiography and microspheres, tepid CPB was initiated before 120 min of CA 
with STH-POL or STH-2 administered every 20 min. Ten min after declamping, the 
animals were weaned from CPB. Corresponding measurements as for Baseline were 
performed at 60, 150 and 240 min after myocardial reperfusion. After the final 
registration, the animal was euthanized with intracardiac injection of high-dose 
potassium chloride, the heart was explanted and myocardial samples were obtained for 
later analysis. 
 
8.11 Statistical analysis 
Data were analyzed by using the commercial software Statistical Package for Social 
Science (IBM Corp., Armonk, NY) with SPSS version 22 (Paper I) and SPSS version 
23 (Paper II + III). Values were given as mean ± SEM or median (25% quartile; 75% 
quartile) unless otherwise notified. In all studies, P < 0.05 was considered statistically 
significant except for the interaction effect in the two-way analysis of variance for 
repeated measurements, RM-ANOVA (Pi < 0.10 = significant). Baseline variables 
were analyzed for normal distribution and equal variance using the Kolmogorov-
Smirnov and Levene tests. After testing for normality, the baseline data were 
compared by two-sample Student’s t-test or Wilcoxon–Mann–Whitney U-test on 
ranks. Both hemodynamic variables obtained during and after CPB and tissue contents 
of high-energy phosphates (Paper II) were analyzed by RM-ANOVA with time as 
within factor (Pw) and cardioplegia with STH-POL or STH-2 as grouping factor (Pg) 
and post hoc Bonferroni contrasts between individual group means.121 The 
Greenhouse-Geisser adjustment of the degrees of freedom was used for the evaluation 
of main effects when Mauchly´s test of sphericity was significant (P < 0.05). If a 
significant interaction (Pi < 0.10) was found between the within and the grouping 
factor, new ANOVAs for simple main effect were performed with adjustment of the 
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degrees of freedom. Cell means were finally compared with Neumann-Keuls multiple 
contrast tests when justified by the preceding ANOVA. For estimation of caspase-3 
activity (Paper I + III), GRK2 (Paper I) and MDA (Paper III), myocardial wall layers 
were set as related variables. The morphometric variables in Paper II were analyzed 
with a nested RM-ANOVA using 6 micrographs from each biopsy and 4 different 
biopsies (time) from each animal. Additionally, in Paper II the Intraclass Correlation 
Coefficient (ICC) and Coefficient of Variation (CV%) for inter- and intraobserver 
variability were calculated for morphometric data. In Paper III, the interobserver ICC 
for 20 randomly TDI and STE recordings were calculated. The Chi-square test was 
used for calculating group differences for nominal data.  
 
9. SUMMARY OF RESULTS 
9.1 Paper I 
In the first paper, 20 animals were assigned for 60 min of cardioplegic arrest followed 
by 180 min of reperfusion after weaning from CPB. Asystole was rapidly induced and 
maintained throughout the ischemic period. During reperfusion, the heart rate was 
increased and left ventricular end-systolic and end-diastolic pressures decreased in 
both groups compared to Baseline. Cardiac index (CI), systolic pressure and radial 
peak systolic strain did not differ between groups. Contractility, evaluated as dP/dtmax 
gradually increased from 120 to 180 min after declamping in the STH-POL group, and 
was significantly higher compared to the STH-2 group after 180 min of reperfusion 
(1871 ± 160 (SEM) mmHg/s vs. 1351 ± 70 mmHg/s, P = 0.008). Furthermore, the 
load-independent contractility variable Preload Recruitable Stroke Work was 
increased with polarizing cardioplegia (64 ± 3 vs. 54 ± 2 mmHg, P = 0.018) 180 min 
after declamping and weaning. Likewise, radial peak ejection strain rate decreased in 
the STH-2 group at 180 min only, indicating better preserved left ventricular 
contractility with polarizing cardioplegia. At 180 min after aortic declamping, 
phosphorylation of GRK2 in myocardial tissue did not differ between groups. 
Fractional cytoplasmic volume in myocytes was reduced in hearts following polarizing 
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cardioplegia, indicating reduction of cytoplasmic edema. However, myocardial tissue 
water content did not differ between treatment groups. 
In summary: In this study of myocardial function, polarizing oxygenated blood 
cardioplegia with esmolol, adenosine and Mg2+, offered comparable myocardial 
protection and improved contractility compared to the standard potassium-based 
depolarizing blood cardioplegia. Contractility was increased three hours after 
reperfusion following polarizing cardioplegia. 
 
9.2 Paper II 
In Paper II, results were presented for 10 animals in each group. The protocol was 60 
min of cardioplegic arrest followed by 180 min of observation after weaning from 
CPB. With STH-POL cardioplegia, myocardial creatine phosphate was increased 
compared to STH-2 at 58 min of aortic cross-clamping (59.9 ± 6.4 (SEM) vs. 44.5 ± 
7.4 nmol/mg protein; P < 0.025), and at 20 min after reperfusion (61.0 ± 6.7 vs. 49.0 ± 
5.5 nmol/mg protein; P < 0.05), ATP levels were increased at 20 min of reperfusion 
with STH-POL (35.4 ± 1.1 vs. 32.4 ± 1.2 nmol/mg protein; P < 0.05). Mitochondrial 
surface-to-volume ratio was decreased with polarizing compared to depolarizing 
cardioplegia 20 min after reperfusion (6.74 ± 0.14 vs. 7.46 ± 0.13 µm2/µm3; P = 
0.047). None of these differences were present at 180 min of reperfusion. From 150 
min of reperfusion and onwards, cardiac index was increased with STH-POL; 4.8 ± 
0.2 compared to 4.0 ± 0.2 L/min/m2 (P = 0.011) for STH-2 at 180 min. 
In summary: In this study of myocardial energy metabolism and ultrastructure, 
polarizing cardioplegia (STH-POL) improved energy status compared to standard 




9.3 Paper III 
In Paper III, 20 animals (10 in each group) were randomized to cardioplegic arrest for 
120 min followed by 240 min of reperfusion after weaning from CPB. Mean arterial 
pressure (MAP) was significantly decreased in the STH-POL compared to the STH-2 
group at 60, 80 and 100 min of aortic cross-clamping, but equal at declamping after 
120 min. Serum potassium gradually increased over time in both groups during CPB 
but more pronounced with STH-2 cardioplegia. At declamping, serum potassium 
averaged 4.4 ± 0.1 mmol/L in the STH-POL vs. 5.5 ± 0.2 mmol/L in the STH-2 group 
(P < 0.001). Electrical cardioversion of ventricular fibrillation before weaning from 
CPB was required in 2 out of 10 animals in the STH-POL vs. 8 out of 10 in the STH-2 
group (P = 0.025). Preload Recruitable Stroke Work was significantly increased in the 
STH-POL compared to the STH-2 group 150 min after declamping (73.0 ± 3.2 vs. 
64.3 ± 2.4 mmHg, P = 0.047), but did not differ after 240 min. Radial peak ejection 
strain rate decreased during reperfusion in both STH-POL and STH-2 with no 
significant differences between groups. Left ventricular wall blood flow rate decreased 
in the STH-POL group only (P < 0.005) from 60 min to 150 min after declamping and 
was essentially unchanged in the STH-2 group. At 240 min after declamping, left 
ventricular blood flow rate was significantly reduced in the STH-POL compared to the 
STH-2 group (P < 0.05). The left ventricular mechanical energy gain related to blood 
flow rate, was reduced by approximately 50% 60 min after aortic declamping 
compared to Baseline. Mechanical efficiency gradually decreased in the STH-2 group 
only and was significantly lower than in the STH-POL group at 150 and 240 min after 
declamping. 
In summary: In this study of myocardial function following prolonged cardioplegic 
arrest, STH-POL in oxygenated blood alleviated the mismatch between myocardial 
function and perfusion after weaning from CPB compared to STH-2 blood 
cardioplegia. Left ventricular mechanical efficiency was better preserved after 




10.1 Polarizing cardioplegia 
The mechanism of polarized cardioplegic arrest is previously described (Ch. 6.3.2). 
However, there is no clear definition of the concept of polarizing cardioplegia. The 
terminology is used to distinguish it from what was originally described by Cohen and 
colleagues in 1995, suggesting that the use of a Na+ channel blocker would induce 
hyperpolarized arrest.122 The initial studies of Chambers and Hearst measuring the 
resting membrane potential during arrest with tetrodotoxin (TTX), demonstrated that 
cardioplegic arrest was obtained with a membrane potential around – 70 mV, which is 
clearly not a hyperpolarized state.56,123 Others, such as Cohen and Dobson, used the 
Nernst equation to calculate what would occur with the myocyte membrane potential, 
but when actually measuring it with sharp electrodes it does not occur as 
calculated.45,46,122 There is, in fact, a depolarization but it is less than what occurs with 
potassium arrest (classically defined as depolarized arrest). The use of the phrase STH-
polarized arrest is to distinguish the new solution from the original STH-2 
cardioplegia. However, it cannot be stated that the resting membrane potential is – 70 
mV during esmolol/adenosine/Mg2+ arrest. It is only assumed that there is a polarized 
arrest by the fact that esmolol also acts to inhibit the Na+ channel in the same way as 
TTX.124 
 
10.2 Esmolol and adenosine for myocardial protection 
10.2.1 Esmolol 
The short acting β1-blocker esmolol is the main component in the St. Thomas Hospital 
polarizing cardioplegic solution. The use of continuous infusion of esmolol solely to 
obtain cardiac arrest or minimal myocardial contraction, have previously been studied 
in translational large animal models and in clinical studies.125-127 Continuous coronary 
perfusion with normothermic esmolol-enriched blood without aortic cross-clamping 
avoids myocardial ischemia and minimize myocardial edema, thus completely 
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preserving cardiac performance in dogs.128 In patients, a similar cardioplegic protocol 
with aortic cross-clamping during elective CABG is associated with slightly better 
functional recovery and less structural myocardial alterations compared to intermittent 
cold blood cardioplegia.129 However, improved clinical outcome has not been 
reported.130,131  
Esmolol given prior to 80 min of cardioplegic arrest with cold oxygenated blood 
cardioplegia, alleviates left ventricular dysfunction in the early hours after weaning 
from CPB in a porcine model.132 Esmolol given immediately before CPB  and as an 
additive in Custodiol® crystalloid cardioplegia in elective patients, reduced peak 
postoperative troponin levels but without differences in clinical outcome.133 Esmolol 
supplementation in cardioplegia administered to patients with unstable angina operated 
with urgent CABG, did not increase the efficacy of cardioprotection.134 In a porcine 
model, esmolol as additive in STH-2 cold blood cardioplegia preserved left ventricular 
systolic function during the first 3 hours after reperfusion following 100 min of 
cardioplegic arrest.53 If esmolol was added to STH-2 crystalloid cardioplegia 
administered as a single-dose in pediatric patients operated for congenital heart 
defects, less inotropic support was required postoperatively with increased ejection 
fraction and cardiac output one week postoperatively.135 In general, β-blockers 
significantly reduced the incidence of postoperative supraventricular and ventricular 
arrhythmias and the length of hospital stay, but with no reduction of all-cause 
mortality, acute myocardial ischaemia/infarction and cerebrovascular events.136  
The studies sited above are not contradictory to the results in Paper I - III, but 
somewhat confirm and support the main findings (Ch. 9) in this thesis. A potential 
protective mechanism of esmolol during and after cardioplegic arrest, is the inhibition 
of desensitization of β-adrenergic receptors (β-AR). Impaired signaling and 
desensitization of β-AR contribute to myocardial dysfunction and is demonstrated in 
both chronic heart failure as well as in patients undergoing cardiac surgery due to the 
acutely increased catecholamine and norepinephrine release following CPB and CA.112 
Furthermore, β-AR desensitization is associated with increased GRK2 activity (Ch. 
8.7.2). Paper I demonstrated no differences in myocardial levels of phosphorylated 
GRK2 activity after STH-POL compared to STH-2 cardioplegia. However, neither 
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adenylate cyclase activity nor GRK2 activity were measured directly, thus the 
inhibition of β-AR desensitization cannot be entirely excluded as an explanation for 
the improved contractile function observed in animals with polarizing cardioplegia. 
Whether the time of CPB and CA in Paper I were too limited for detecting potential 
group differences of β-AR desensitization, remains unclear. 
 
10.2.2 Adenosine 
Adenosine administrated before onset of ischemia (pharmacological preconditioning), 
during ischemia or at reperfusion (postconditioning), has been extensively investigated 
with clear evidence of protection of the myocardium through activation of various 
adenosine receptor subtypes (A1, A2a, A2b, A3).137-140 Adenosine as a sole cardioplegic 
agent has been investigated in isolated rat hearts and induces rapid cardiac arrest and 
improved postischemic recovery compared to potassium cardioplegia.141 Also, 
adenosine as an adjunct to hyperkalemic cardioplegia has been investigated with 
similar results regarding arresting time and myocardial recovery.55,142 Adenosine 
instead of hyperkalemic cold crystalloid cardioplegia, has demonstrated improved 
postcardioplegic left ventricular systolic function and efficiency in addition to less 
myocardial cell damage in an in-vivo large animal model.50 Also, adenosine as key 
agent in cold crystalloid cardioplegia increases postcardioplegic myocardial blood 
flow and preserves the endothelium-derived hyperpolarization dependent 
vasodilatation, compared to high potassium cardioplegia.143 Other experimental studies 
have investigated adenosine as an adjunct to standard cardioplegia and demonstrate 
adenosine-supplemented cardioplegia to attenuate postoperative dysfunction in 
severely injured hearts.144,145 Adenosine in combination with lidocaine, has 
demonstrated better functional recovery compared to hyperkalemic cardioplegia both 
experimentally and clinically.46, 52,146  
Other clinical studies with adenosine instead of hyperkalemic cardioplegia, 
demonstrated a more rapid CA and lower incidence of postoperative atrial fibrillation, 
but without proof of differences regarding cardioprotection or preservation of 
hemodynamic parameters.147  Moreover, treatment benefits from adenosine 
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supplementation have not been demonstrated regarding risk of myocardial infarction, 
low output syndrome, inotropic support, intra-aortic balloon pump (IABP) requirement 
or postoperative mortality.148  
Pharmacological preconditioning with adenosine has been investigated in patients with 
reduced left ventricular function (EF < 30%) undergoing CABG, demonstrating better 
preserved CI and less creatine phosphokinase release in the adenosine group.149 
Adenosine pretreatment has also been investigated in pediatric patients undergoing 
congenital heart surgery. Main findings in this study were postoperative increased 
levels of serum troponin I and more use of inotropic agents in the control group, with 
the conclusion that adenosine pretreatment protects the myocardium during open heart 
surgery in pediatric patients.150 During heart valve replacement in adults, the effect of 
adenosine given as a bolus injection immediately after aortic declamping, 
demonstrated less troponin I release, less inotropic drug use, and shorter stay in the 
intensive care unit.151 
 
10.3 Polarized vs. depolarized cardioplegic arrest 
In this clinically relevant porcine model, both STH-POL and STH-2 cardioplegic 
solutions trigger and maintain cardiac arrest when administered as repeated, cold, 
oxygenated blood. The STH-POL cardioplegia must be freshly mixed with the blood 
by a dual-head HLM pump at the time of infusion to prevent rapid degradation of both 
the esmolol and adenosine components. 
The time from aortic cross-clamping to left ventricular mechanical arrest was 
comparable between groups in Paper I. However, the time to isoelectric ECG was 
significantly prolonged with STH-POL compared to STH-2 cardioplegia (Table 2). 
This was also confirmed in Paper III, demonstrating a similar difference, 121 s (105; 
150) for STH-POL vs. 47 s (30; 61) for STH-2 (P = 0.001) until isoelectric ECG. 
During the 60 min period of cardioplegic arrest, there were no differences between 
treatment groups regarding MAP during CPB in Paper I and II. This was also observed 
for the first 40 min of CA in Paper III. However, STH-POL cardioplegia significantly 
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reduced MAP at 60, 80 and 100 min after aortic cross-clamping. The increased 
amounts of esmolol and adenosine administered in Paper III compared to Paper I and 
II together with prolonged general hypothermia, may have resulted in accumulation of 
both esmolol and adenosine, due to prolonged half-lives at 34°C compared to 37°C. 
After rewarming and at the time of declamping, there were no differences between 
groups regarding MAP in Paper III (Figure 15). At this point of time, MAP was 
comparable to the levels observed in Paper I and II. 
Table 2. Effects of polarizing (STH-POL) and depolarizing (STH-2) cardioplegia 
delivered as repeated oxygenated blood in pigs from Paper I. Mean ± SEM or Median 
(25%; 75%). 
    STH-POL  STH-2   Statistics 
     (n = 10)  (n = 10)    
X-clamp: 
Time to LV asystole (s): 28 (11; 43)  22 (18; 27)  P = 0.79 
Time to isoelectric ECG (s): 86 (80; 134)  41 (32; 43)  P = 0.002 
Declamp: 
Time to first LVP (s):  81 ± 19  129 ± 32  P = 0.22 
Time to regular LVP (s): 108 (87; 122)  138 (112; 286) P = 0.13 
X-clamp = aortic cross-clamping; LV = left ventricle; LVP = left ventricular pressure, registered by 
the pressure-conductance catheter; s = time in seconds. 
 
10.4 Energy metabolism 
In Paper II, a transient improvement in energy status with STH-POL cardioplegia was 
demonstrated as an increase in the myocardial tissue content of creatine phosphate 
(CrP) after 58 min of CA and at 20 min after reperfusion and weaning from CPB 
compared to STH-2 cardioplegia. In addition, tissue ATP content was increased in the 
early period of reperfusion. In the metabolic pathway of high-energy phosphate 
degradation and synthesis, creatine kinases present in the mitochondrial inner 
membrane space and in cytosol, regenerates CrP from creatine imported from the 
cytosol and surplus mitochondrial ATP. 
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Cytosolic CrP serves as an energy reservoir for the rapid buffering and regeneration of 
ATP in situ. Myocardial creatine kinase thus facilitates intracellular energy transport 
by the phosphocreatine shuttle or circuit (Figure 1). 
The reduced consumption of CrP demonstrated in Paper II during the 60 min of 
cardioplegic arrest and early after reperfusion in the STH-POL group, can be 
interpreted as a result of a reduced energy consumption with polarizing cardioplegia 












Also, the resulting abundance of CrP facilitates stabilizing of the myocyte membrane 
phospholipid bilayer by binding to the polar heads and decreasing membrane fluidity. 
As a consequence, this attenuates some of the damage caused by the transient ischemia 
and hypoxia and thus alleviates cytoplasmic leakage.124,152 Following 180 min of 
reperfusion, the levels of high-energy phosphates and degradation products regained 
baseline levels and did not differ between the treatment groups. 
Figure 15. Mean aortic pressure (MAP) in Paper I and III during the period of aortic cross-clamping 
(X-clamp) and administration of cardioplegia, repeated every 20 min. Assessment of MAP was just 
before and one min after cardioplegic administrations. Pre = point in time just before X-clamp (0); # 






The adenosine component of STH-POL cardioplegia resulted in high tissue levels of 
the degradation product hypoxanthine both during the period of arrest and early after 
declamping (Paper II). This increase could represent a potential disadvantage due to 
further degradation to xanthine and uric acid by xanthine oxidase and subsequent 
production of detrimental reactive oxygen species in the endothelial cells.152 However, 
the levels of xanthine oxidase has been demonstrated to be low in the porcine heart 
and therefore the surplus myocardial hypoxanthine in the STH-POL group is more 
likely to be washed out during reperfusion.153 This feasible explanation is further 
strengthened in Paper III where oxidative stress was evaluated by assessment of levels 
of MDA (Ch. 8.7.3), which did not differ between the two cardioplegic solutions in 
different regions of the left and in the right ventricle 240 min after aortic declamping.  
 
10.5 Ultrastructure 
Following 60 min of cardiac arrest with STH-POL cardioplegia and 180 min of 
reperfusion, a decrease in myocyte cytosolic volume fraction and mitochondrial 
surface-to-volume ratio was demonstrated compared to STH-2 arrested hearts (Paper 
I). This could be explained by a shift of intracellular volume from cytosol to 
mitochondria. Reduced tissue edema and improved left ventricular function after 
declamping have been linked to continuous esmolol perfusion compared to warm 
blood cardioplegia.128 However, except for a temporary mitochondrial swelling with 
STH-POL cardioplegia 20 min after reperfusion, no ultrastructural differences were 
demonstrated between polarizing and depolarizing cardioplegia 180 min after 
declamping in Paper II. 
 
10.6 Weaning from cardiopulmonary bypass 
Following aortic declamping and reperfusion, ventricular fibrillation was a regular 
event in relation to declamping. In a total of 40 animals with 60 min of cardioplegic 
arrest (Paper I and II), electrical cardioversion was needed in eight out of 20 animals 
with STH-POL cardioplegia compared to 12 out of 20 animals with STH-2 
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cardioplegia (P = 0.34). The time to the first left ventricular contraction and the time 
needed to establish a regular ventricular rhythm did not differ between hearts arrested 
with STH-POL or STH-2 cardioplegia (Table 2). 
The frequency of necessary electrical cardioversion is likely related to serum 
potassium levels at the time of reperfusion.154 After 60 min of cardiac arrest, s-K+ 
averaged 4.3 ± 0.1 mmol/L for STH-POL and 4.8 ± 0.1 mmol/L for STH-2 
cardioplegia at aortic declamping. Following 120 min of cardioplegic arrest, 
corresponding potassium levels were 4.4 ± 0.1 mmol/L in the STH-POL vs. 5.5 ± 0.2 
mmol/L in the STH-2 group. Two out of 10 animals in the STH-POL and eight out of 
10 in the STH-2 group needed electrical cardioversion following declamping (Paper 
III). 
 
10.7 General hemodynamics 
In all three studies, heart rate gradually increased following CPB and CA in both 
experimental groups over time. The left ventricular systolic pressure (LVSP) 
decreased in Paper I and III whereas was essentially unchanged in Paper II. End-
diastolic pressure (LVEDP) decreased gradually in both groups in Paper I and II and 
was unchanged in Paper III after weaning from CPB. Venous filling, evaluated by 
central venous pressure (CVP), increased over time in Paper I and II but was 
unchanged in Paper III. These hemodynamic changes are not fully consistent, probably 
reflecting the experimental protocol differences between the studies. An increase in 
heart rate result in less left ventricular filling with reduced contribution of the Frank-
Starling effect and reduction of LVSP after weaning from CPB. These changes are 
comparable between the different studies. 
Cardiac index (CI) was increased in the period of reperfusion in the STH-POL 
compared to the STH-2 group in Paper II, whereas no differences between groups 
were observed in Paper I and III.  
In Paper I – III, the mean pulmonary artery pressure (PAPmean) had the similar 
tendency of increasing in the early period after CPB and CA but without significant 
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differences between groups. In Paper III, PAPmean tended to decrease in the late period 
of observation. The duration of CPB has been identified as a factor of postoperative 
pulmonary hypertension, but this effect was not observed in our studies when the time 
of aortic cross-clamping was increased from 60 min (Paper I + II) to 120 min (Paper 
III).155 
In general, within each study, variables describing the pre- and afterload conditions 
after aortic declamping were comparable between treatment groups. Furthermore, 
variables like heart rate, mean aortic pressure, left ventricular end-diastolic pressures 
and volumes after declamping were reproducible between studies. 
 
10.8 Systolic and diastolic function 
Both left (LV-EF) and right (RV-EF) ventricular ejection fraction remained normal in 
all protocols and did not differ between groups. In Paper I, LV-dP/dtmax was 
significantly higher compared to the STH-2 group after 165 and 180 min of 
reperfusion. A similar, but not significant difference was also observed in Paper II. In 
Paper III, LV-dP/dtmax decreased from 90 min and onwards but without differences 
between treatment groups. Indexed stroke work (SWi) was better maintained in the 
STH-POL group at 180 min after declamping in Paper I while this difference was not 
observed in Paper III. 
The load-independent contractility variable PRSW was better maintained at 180 min 
of reperfusion in the STH-POL compared to the STH-2 group in Paper I. In Paper III, 
PRSW was significantly increased in the STH-POL compared to the STH-2 group 150 
min after declamping but did not differ after 240 min. At the end of the experiment, 
peak ejection strain rate was significantly increased in the STH-POL compared to the 
STH-POL group in Paper I. As for PRSW, this difference was not observed after the 
prolonged cardioplegic arrest and observation period after aortic declamping in Paper 
III.  
The left ventricular relaxation properties in diastole (lusitropy) were evaluated by the 
isovolumic relaxation time constant Tau (τ) and end-diastolic pressure-volume relation 
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β, which did not differ over time between groups or protocol (Paper I and III). 
Furthermore, LV-dP/dtmin was more negative in the STH-POL compared to the STH-2 
group at the end of reperfusion in Paper I. 
With comparable loading conditions, the load-dependent systolic variables SWi and 
dP/dtmax and the load-independent PRSW were better preserved at the end of 
reperfusion after STH-POL compared to STH-2 cardioplegia following 60 min of 
cardioplegic arrest (Paper I and II). These differences were not observed in Paper III 
when the time of CPB and CA were extended to 120 min following 240 min of 
reperfusion.  
Data of general hemodynamics and functional variables, both from PV-loops and 
TDI/STE, have previously been reported from studies conducted in our laboratory 
using a similar porcine model with 60, 80 or 100 min of STH-2 cardioplegic arrest as 
control groups.52, 128, 151-153 Overall, data from these studies supports and verifies the 
results from the different STH-2 control groups in this thesis. 
Despite strict standardized protocols where only time of CPB, CA and postoperative 
observation were different (Paper I and III), there will always be variations and 
compensatory mechanisms that will influence the complex hemodynamic interactions. 
However, our hemodynamic and functional data indicates that normokalemic 
polarized cardioplegic arrest is non-inferior to hyperkalemic depolarized arrest. 
 
10.9 Myocardial injury 
In this model of cardioplegic arrest, evaluation of myocardial injury due to the 
mechanism of ischemia/reperfusion (I/R) was implemented in Paper I and III. In both 
studies, serum troponin-T accumulated over time but did not differ between groups. At 
180 min (Paper I), median values were 504 (328; 886) vs. 580 (401; 717) ng/L, 
compared to 802 ± 114 vs. 907 ± 169 ng/L at 240 min in Paper III. It is not clear if the 
observed higher level of troponin-T in Paper III was caused by the extended time of 
CA or longer time of observation compared to Paper I. In theory, a potential difference 
between groups was not revealed since myocardial troponins peaks later in the 
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postoperative period. Increased troponin levels following CA is set and ascribed to a 
number of causes, but in the context of this model, may be due to cell death from 
insufficient myocardial protection during the ischemic period. The serum levels of 
postoperative myocardial enzymes are independently associated with both increased 
intermediate- and long-term risk of mortality.156 
Myocardial apoptotic activation evaluated by caspase-3 activity, did not differ between 
groups neither in Paper I nor in Paper III. In both studies, cleaved caspase-3 activity 
was increased in the subepicardial layer compared to the mid- and subendocardial wall 
layers. This observation is contradictory if cardioplegia delivery and protection is 
favorable in the outer epicardium compared to the inner endocardium layer due to low 
coronary perfusion.157 However, additional topical cooling of the heart was not 
integrated in either of the experimental protocols. Consequently, a gradual rewarming 
of the outer surface of the heart will occur between the administrations of cold 
cardioplegia and is likely to impair the subepicardial protection in this open chest 
model. Furthermore, in Paper III apoptotic activation was more pronounced in the 
right ventricular wall. Non-uniform distribution of the cardioplegic solution in hearts 
even without the presence of coronary artery disease, is acknowledged when using 
retrograde administration.158 This is also reported during antegrade cardioplegia 
delivery and thus the right ventricle is especially vulnerable.159 Also, in our porcine 
model, atrial P-waves at the ECG were observed frequently during cardioplegic arrest 
and were sometimes associated with right ventricular mechanical activity. 
Oxidative stress was evaluated in Paper III only, where the assessment of MDA did 
not indicate any differences between treatment groups. To our knowledge, esmolol has 
no antioxidative effect, dissimilar from the combined α- and β-adrenergic blocker 
carvedilol.160 Adenosine has antioxidative properties during reperfusion in both animal 
models and in clinical trials (Ch. 10.2.2). In our model, the final dose of adenosine was 
administered 20 min prior to reperfusion. Due to the dosage and short half-time in 
blood (T ½ < 10 s), we did not expect to observe less oxidative stress in the STH-POL 
group caused by the effect of adenosine. In this thesis, there were no evidence for a 
relationship between loss of function and verified myocardial injury. Increased 
apoptotic activation during prolonged ischemia in Paper III compared to Paper I, could 
 64 
be expected but was not demonstrated in our studies. This observation could be a 
consequence of adequate myocardial protection in both protocols. As a summary, there 
were no indications of better protection from I/R-injury in the esmolol/adenosine 
treated group, evaluated by the markers of apoptosis or oxidative stress used in this 
thesis. 
Ischemia/reperfusion due to cardioplegic arrest may lead to injury demonstrated as 
myocardial inflammation and apoptosis, which clinically can be presented as 
arrhythmias, transient contractile dysfunction (stunning) or irreversible myocardial 
infarction.161 The pathophysiology and mediators of I/R-injury in correlation to 
hyperkalemic cardioplegic solutions, have been extensively investigated for over four 
decades.33,47,70 Prolonged depolarized myocyte membrane (Ch. 6.3.1) results in 
increased intracellular Na+ and Ca2+ due to ion current across inactivated Na+ and Ca2+ 
channels.162 The global ischemia results in compromised ATP production following 
ineffective ATP dependent pumps (sarcolemmal Na+/K+ ATPase, Ca2+ ATPase, 
sarcoplasmatic reticulum Ca2+ ATPase), which also increases intracellular Na+ and 
Ca2+ concentrations. Because of increased intracellular sodium, the reversal of the 
Na+/Ca2+ exchanger causes a net influx of Ca2+ (1 Na+ out, 3 Ca2+ in) into to the 
myocardial cell.163 Furthermore, metabolic acidosis due to proton accumulation 
activates the compensating Na+/H+ exchanger with the effect of additional augmented 
Na+ concentrations. In addition, hypothermia has been demonstrated to exacerbate the 
adverse effect of Ca2+ loading during ischemia.164 
 
10.10 Myocardial dysfunction 
Hyperkalemic depolarizing cardioplegic solutions have been demonstrated to both 
contribute and aggravate myocardial stunning/dysfunction due to continual metabolic 
requirements and detrimental transmembrane ionic fluxes as previously described (Ch. 
10.9). The term stunning in this context is reversible postcardioplegic contractile 
dysfunction, which may last for hours or days. Myocardial stunning can also be 
defined as a temporary mismatch between myocardial function and oxygen 
consumption, hence also myocardial blood flow.165,166 With 120 min of cardioplegic 
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arrest (Paper III), the relationship between pressure-volume loop area of the left 
ventricle and blood flow rate in the left ventricular myocardium was clearly reduced 
60 min after aortic declamping compared to Baseline. The mismatch between function 
and blood flow deteriorated further in the STH-2 group, only. However, the 
observation time of 240 min after declamping is too short to interpret this finding as 
alleviated stunning in the STH-POL group. 
 
10.11 Methodological considerations 
10.11.1 Animal model 
The use of domestic pigs in in-vivo cardiovascular experiments is common.167 The 
intact porcine model allows analysis of interventions on the heart, with the humoral, 
neural, adrenergic and anesthetic influence also seen in clinical practice. In general, 
the anatomy and physiology resemble human conditions and the porcine heart is 
applicable due to its similarity to the human heart regarding hemodynamic function 
and coronary circulation.168 By operating on young pigs, advanced instrumentation is 
technically achievable, and medical devices and equipment developed for human 
healthcare can be used. Still, the possibility of species differences is a limitation. 
Furthermore, the use of healthy young hearts does not represent the common clinical 
practice.  
The porcine heart is particularly predisposed for various tachyarrhythmias.169 
Additionally, patent foramen ovale (PFO) or other atrial septal defects (ASD) are often 
present.170 Ventricular septal defect (VSD) and patent ductus arteriosus (PDA) are also 
more common compared to the human heart.171 After weaning from cardiopulmonary 
bypass, pulmonary arterial hypertension (PAH) is a frequent and a major problem in 
the porcine model. PAH followed by acute right heart failure in combination with PFO 
or ASD, result in right-to-left atrial shunting. This leads to a severe arterial hypoxia 
and may terminate in left ventricular failure. In general, porcine blood vessels are 
more fragile than in humans, hence with occasionally intimal dissection or other 
technical difficulties causing failure during instrumentation and cannulations.  
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Table 3. Baseline variables before cardioplegic arrest in three experimental studies. 
Values are mean (95% confidence interval). 
Variable   Paper I   Paper II  Paper III 
    (n = 20)   (n = 20)  (n = 20) 
BW    42 (1)    42 (1)   42 (1)  
HR (beats/min)  87 (3)    96 (7)   91 (5)  
LV-SPmax (mmHg)  111 (6)   95 (5)   114 (7)  
LV-EDP (mmHg)  11.2 (1.4)   7.5 (1.3)  9.3 (1.2)  
LV-dP/dtmax (mmHg/s) 1577 (124)   1303 (128)  1506 (133)  
LV-dP/dtmin (mmHg/s) -2625 (216)   -1782 (116)  -2248 (280)  
LV-Tau (ms)   32.1 (1.8)   31.6 (1.7)  36.6 (2.9)  
LV-EDVi (mL/m2)  81 (7)         -   80 (5) 
LV-ESVi (mL/m2)  38 (6)        -   36 (4)  
LV-SVi (mL/m2)  50 (4)        -   44 (3)  
LV-EF (%)   58 (4)        -   54 (2)  
LV-SWi (mmHg*mL/m2) 4060 (354)       -   4310 (539)  
CI (L/min/m2)   4.0 (0.3)   3.8 (0.2)  4.0 (0.2)  
RV-EDVi (mL/m2)  142 (9)   132# (8)  135 (11)  
RV-EF (%)   25 (2)    33# (2)   26 (3)  
AOPmean (mmHg)  96 (5)    84 (7)   97 (7)  
CVPmean (mmHg)  6.0 (0.7)   7.0 (1.0)  7.0 (1.0)  
PAPmean (mmHg)  20 (2)    17 (1)   19 (2)   
Tissue blood flow (mL/min per g) 
LV-Epi   0.98 (0.08)       -   0.84 (0.07)  
LV-Mid   0.94 (0.09)       -   0.97 (0.07)  
LV-Endo   1.02 (0.11)       -   1.02 (0.08)  
RV    0.75 (0.11)       -   0.65 (0.08)  
___________________________________________________________________________ 
BW = bodyweight; HR = heart rate; LV and RV = left and right ventricle; i = value indexed for body 
surface area; SP = systolic pressure; EDP = end-diastolic pressure; dP/dt = pressure-volume 
relationship; EDV = end-diastolic volume; ESV = end-systolic volume; SV = stroke volume; EF = 
ejection fraction; SW = stroke work; CI = cardiac index; AOP = aortic pressure; CVP = central 
venous pressure; PAP = pulmonary artery pressure; Epi-, Mid- and Endo- = Subepi-, midmyo- and 
subendocardium; # = n = 19. 
 
Our porcine model of cardiopulmonary bypass and cardioplegic arrest, requires open 
chest access in order to achieve an extensive preparation and instrumentation. The 
time from start of anesthesia to Baseline ranges from two to three hours in all studies 
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included in this project. After a period of stabilization, baseline variables were 
obtained. The stability and reproducibility of the model at Baseline is illustrated in 
Table 3. The experiments lasted up to 10 hours. The anesthetic protocol has been 
evaluated to be reliable and demonstrated to be hemodynamic consistent.89 
In Paper I - III, 60 animals (42 kg ± SD 3) were included. In addition, a total of 14 
animals were excluded due to non-technical failure. The causes were various situations 
of tachyarrhythmia, pulmonary arterial hypertension, acute right heart failure, arterial 
hypoxia, systemic hypotension and myocardial ischemia. The majority of these events 
occurred shortly after weaning from CPB, especially after prolonged cardioplegic 
arrest in Paper III. 
 
10.11.2 Study design 
This project is designed as an intervention study with comparison of a novel method to 
an established routine as control group. Acute experiments were performed using a 
translation large animal model. By using a strict protocol together with especially 
sensitive and reproducible methods for evaluation, minor, yet significant differences 
can be identified even if the sample size is relatively small. Furthermore, by using 
repeated measurements analyzes as a statistical tool, the probability of type II error is 
reduced. Thus, the sample size of 20 animals in each study is reasonable to satisfy 
statistical, ethical and economic considerations. Block randomization (four animals in 
five blocks) is used to achieve balance between the intervention and control groups by 
equally distribution with time. In complex experimental protocols with extensive 
surgery and instrumentation, the learning curve of the research team may influence the 
results. An unintended, but skewed distribution in time between intervention groups is 
avoided by using block randomization. 
The time of cardioplegic arrest was 60 min in Paper I and II, which is an ischemic time 
typical for a single procedure in heart surgery like aortic valve replacement (AVR) or 
multiple coronary artery bypass grafting (CABG). The study protocol in Paper III was 
120 min of cardioplegic arrest, simulating a combined procedure like AVR and 
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concomitant CABG, or other more complex and time-consuming procedures. In this 
study, also the observation period was extended from 180 to 240 min of reperfusion 
with the aim of further verifying and clarifying results from the previous studies.  
 
The rate of unsuccessful weaning from CPB was high in Paper III (8 animals vs. 4 and 
2 in Paper I and II), which is a limitation for the experimental study design. 
Furthermore, no additional surgery or intervention except for CPB and CA were 
implemented, and the period of postoperative observation was relatively short. 
Consequently, the relevance of this model for clinical cardiac surgery may be limited. 
In our experience, 120 min of aortic cross-clamping following weaning from the heart-
lung machine and 240 min of reperfusion, is close to the limit of what is feasible and 
reproducible for a translational animal study design in pigs. 
 
10.11.3 Conductance catheter 
Pressure-volume loops acquired from the conductance catheter method is considered 
the be  the gold standard in evaluating cardiac performance in translational animal 
models.172 The use of a correct catheter is essential due to the importance of 
appropriate electrode spacing to get a substantial number of segments into the 
ventricle for covering the entire ventricular long axis. Furthermore, the catheter must 
be placed as straight as possible and stabilized with the pigtail just above the aortic 
valve when the apical approach is used. While measuring real time pressure is straight 
forward after calibration of the catheter, calculation of exact volumes is more 
demanding. Several factors may influence the accuracy and hypothetically represents a 
limitation of the method, as demonstrated in the Baan equation:                                              
             V(t)	=	1/α	*	ρ	*	L2	*	(G(t)	-	Gp)                               
as previously described (Ch. 8.5.1). 
The acquired total conductance (G(t)) also includes conductance of the surrounding 
cardiac tissue. Because of dissimilarity of electrical resistivity of the intraventricular 
blood (~140 Ω*cm) and adjacent myocardium (~750 Ω*cm), estimation of this 
parallel conductance (Gp) can be used to derive the actual intraventricular volume.173  
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By rapid bolus injection of 5 mL hypertonic (10%) saline in the pulmonary artery 
during registration of the PV-loops, the conductivity (ρ) of blood in the left ventricle 
will increase temporarily, while both the volume and parallel conductance can be 
considered unaffected. The minimum (Gmin) and maximum (Gmax) conductance are 
plotted in a x-y diagram from the consecutive cardiac cycles during the saline bolus 
injection. By extrapolating the linear regression line for these points to the crossing for 
the line of unity, parallel conductance is found, where Gmax = Gmin. Both assessments 
of the conductance and the estimation by extrapolation are factors in the equation that 
may represent some degree of inaccuracy. For this reason, hypertonic saline injections 
were repeated three times at each occasion, averaged and used in the equation. The 
saline method has been used in Paper I and III. This routine is an indirect method that 
provides reliable estimates of parallel conductance.92,174 However, other studies have 
questioned whether Gp remains constant during preload reduction by IVC 
occlusion.175,176 
The alpha factor (α) in the Baan equation represents another variable that may 
represent an inaccuracy. This calibration factor adjusts for actual ventricular volumes 
(i.e. near apex and distal outflow tract) not assessed by the conductance catheter. 
Consequently, the estimated stroke volume by conductance is calibrated against a 
reference stroke volume. The alpha factor is calculated as the ratio between stroke 
volume from the conductance catheter and the actual stroke volume estimated by 
thermodilution. Stroke volume derived from thermodilution has also some limitations 
due to a potential ± 15% margin of error for absolute values.177 Some of these 
inaccuracies, related to catheter placement and injection technique, are reduced by 
using the continuous cardiac output technique (Figure 5). 
In addition to the challenges in the acquisition from the conductance catheter, 
evaluation and interpretation of the results derived from the PV-loops may also have 
some limitations. In Paper I and III, left ventricular systolic- and diastolic function are 
evaluated by the PV-loops and are founded on the slope of end-systolic (ESPVR) and 
end-diastolic (EDPVR) pressure-volume relations as previously illustrated (Figure 9). 
The calculation of ESPVR is based on a presumption of a linear relationship between  
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the end-systolic volume and pressure during preload reductions. However, increased 
contractility enhances a convex tendency of curvilinearity, whereas a decrease in 
contractility changes the pressure-volume relationship to a more concave shape.96 The 
linear relationship represents an empirical and not a mathematical model, purposed to 
fit the actual variance that occurs secondary to load alteration. Likewise, this is 
applicable to the linear model of PRSW (Figure 9 right). Preload Recruitable Stroke 
Work is considered the most reliable load-independent variable describing 
contractility. The slope of the end-diastolic pressure-volume relationship is curvilinear 
(Figure 9). Therefore, the logarithmic end-diastolic pressure-volume relationship (β) is 
presented in Paper I and III. 
The acquired data from the pressure-volume catheter, electron microscopy (Ch. 8.7.5) 
and epicardial echocardiography (Ch. 8.6.5) necessitate post-processing by the 
investigator to calculate the relevant variables, which involves a possibility for 
observer bias. Thus, randomly selected situations/images were grouped, coded, post-
processed and analyzed as independent entities by two independent observers (Table 
4). Evaluations of the reliability of these analyses were done by using both the inter- 
and intraobserver Intraclass Correlation Coefficient (ICC). According to Altman, an 
ICC below 0.2 demonstrates poor agreement, 0.21 - 0.40 fair agreement, 0.41 - 0.60 
moderate agreement, 0.61 - 0.80 good agreement, and 0.81 - 1.00 a very good 
agreement.178 
The ICC for interobserver variance demonstrated a high intertester reliability for both 
values from selected cardiac cycles obtained from the dynamic runs (Figure 9) and 
volume estimates. Also, values obtained from the morphometric evaluation and TDI 
recordings demonstrated good or very good reproducibility. The interobserver 
variance of the STE short-axis values were defined as moderate, while ICC for the 
long-axis recordings were good (Ch. 10.11.4). 
It should be emphasized that the use of ICC in this thesis is not an evaluation of the 
quality of the methods and the data collected, but a validation of the post-processing 
complementary analyses for various variables used in Paper I – III. The ICC values for 
interobserver variability are presented in Table 4.  
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Table 4. Interobserver variability between two independent observers evaluated by the 
intraclass correlation coefficient (ICC) for key variables requiring post-analysis of 
data acquired during experiments from Paper I - III. 
 
Study Variable  ICC 
 
Paper I (n = 34) ESPVR (mmHg/mL) 0.951 
 PRSW (mmHg) 0.734 
 β (unitless) 0.621 
 SW (mmHg*mL) 0.997 
 EDV (mL) 0.786 
 ESV (mL) 0.657 
 SV (mL) 0.999 
 EF (%) 0.743 
 τ 0.990 
   
Paper II (n = 15 x 6) VVmit (%) 0.897 
 VVmyo (%) 0.741 
 VVcyt (%) 0.780 
 SVratiomit 0.790 
 SVmit 0.871 
   
Paper III (n = 20) TDIRad Strain (%) 0.783 
 TDIRad Strain Rate (s-1) 0.874 
 STECirc Strain AntSept (%) 0.486 
 STERad Strain AntSept (%) 0.512 
 STELong Strain AntSept (%) 0.794 
 
 
ESPVR = End-systolic pressure-volume relation; PRSW = Preload Recruitable Stroke Work; β = the 
logarithmic regression coefficient of LV compliance; SW = Stroke Work; EDV = end-diastolic 
volume; ESV = end-systolic volume; SV = stroke volume; EF = ejection fraction; t = Tau, time 
constant of isovolumic relaxation; VVmit = myocyte volume fraction of mitochondria; VVmyo = myocyte 
volume fraction of myofibrils; VVcyt = myocyte volume fraction of cytosol; SVratiomit = mitochondrial 
surface-to-volume ratio; SVmit = mitochondrial surface density; TDI = Tissue Doppler Imaging; STE = 
Speckle Tracking Echocardiography; Rad, Circ, Long = radial, circumferential or longitudinal 
direction; AntSept = antero-septal segment of the left ventricle. 
 
10.11.4 Epicardial echocardiography 
An important advantage of using echocardiography in an open chest model, is the use 
of a high frequency transducer directly on the epicardium. By using a soft silicon pad 
as offset for optimal sector and acoustic transmission, image acquisition at high 
frequency (6.5 MHz in this project) produces B-mode images with high spatial 
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resolution. In theory, epicardial echocardiography may affect the assessed regional 
function if the probe influences the deformation of the myocardium. By applying 
pressure with the probe, alterations in ventricular configuration may occur, especially 
in the diastolic phase with low interventricular pressure. However, in the present 
model of continuously monitoring of hemodynamic variables (e.g. HR, MAP), a 
distortion will be noticed immediately and a new assessment performed after a short 
period of stabilization. In the systolic phase, this potential error is less relevant because 
of high intraventricular pressures. In addition, the soft silicon pad used as offset 
reduces the applied pressure on the epicardium. Using a conductance-catheter through 
the LV apex (Figure 5) may interfere with the correct position of the probe for 
obtaining longitudinal strain recordings from the apical long-axis four-chamber view. 
In an open chest model, both sternotomy and pericardiotomy influence on 
hemodynamic and respiratory variables, but a significant effect on strain 
measurements has not been demonstrated.179,180 
The angular dependency of TDI is a limitation due to the principle of decreased 
Doppler shift as the angle of the ultrasound beam increases.100 However, in this open 
chest porcine model, obtaining TDI SAX recordings perpendicular to the anterior wall 
of the left ventricle is feasible due to a rotation of the pig heart to the right side 
compared to the human heart. Conversely, simultaneous SAX assessment of the 
posterior wall is less accurate, since radial deformation of the myocardial wall will not 
be perpendicular to the ultrasound beam due to the asymmetrical geometry of the 
porcine heart. Therefore, TDI strain and strain rate are reported in the radial directions 
of the left ventricular anterior wall, only (Paper I and Paper III). Moreover, one-layer 
analysis of deformation was performed since healthy hearts without coronary 
pathology have an almost uniform myocardial blood flow distribution. Likewise, the 
induced ischemia (cardioplegic arrest) was global, and one-layer analysis in this 
setting has shown to be reliable compared to multi-layer analysis.181  
Another potential inaccuracy of TDI is the influence of deformation by adjacent  
myocardium (tethering effect) or cardiac translation.104 The TDI strain curves obtained 
from epicardial echocardiography will not necessarily return to baseline because of the 
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beat to beat variation. This was taken into consideration by the default software setting 
of drift compensation.  
For reliable measurement of the ejection strain rate, a clear definition of the ejection 
phase is mandatory. For this reason, timing from the PWD recordings in the aortic 
orifice were used and ejection phase was defined as aortic valve opening (AVO) to 
closure (AVC) in addition to the definition of end-diastole by ECG.  
The algorithm for deformation calculation used in STE is different compared to 
TDI.182 Angle dependency is not a limitation and quantification of strain and strain rate 
in two directions within 2D imaging is feasible. Furthermore, STE derived 
deformation parameters only reflects active contraction and is not influenced by 
tethering effects.102 Despite the accuracy, validity and clinical applications of STE, 
image quality is still a limitation, especially for recordings obtained at high heart 
rates.109 Occasionally, some of the six myocardial segments cannot be analyzed and 
result in an inaccurate estimation of global deformation parameters. For this reason, 
global STE strain was not evaluated in Paper III.  
Both TDI and B-mode recordings by epicardial echocardiography generate images of 
high quality. Nevertheless, there is always a tradeoff between the spatial and the 
temporal resolution in echocardiography. This is especially challenging in this project 
due to the variable heart rates, especially at the end of the experiments. The mean 
frame rate for the TDI recordings in Paper I and Paper III were 544 (range 249-696) 
and 619 (range 327-749) frames/s, respectively. The mean frame rate for the STE 
recordings in Paper III was 74 (range 63-88) in the short-axis view and 74 (range 63-
93) frames/s in the four-chamber view. Likewise, the averaged heart rates in these two 
studies were 115 beats/min. Adequate myocardial tracking is demanding and may be 
unreliable if the ratio frame rate (fps) to heart rate (bpm) is too low. This is not a 
problem in TDI due to the high frame rate but represents a limitation in STE where the 
frame rates are substantially lower. As a rule of thumb, this ratio should be more than 
0.7 fps/bpm if acceptable tracking for both strain and strain rate should be achieved.183 
In Paper III, frame rate to heart rate ratio was approximately 0.64 fps/bpm. 
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The methodologies of TDI and STE are fundamentally different, therefore direct 
comparison is difficult to interpret.104 Factors like different image resolution, frame 
rate, TDI parameters (ROI size, SL) and STE parameters (ROI width, default spatial 
and temporal smoothing) make the results intricate to interpret. Occasionally, 
inadequate tracking occurred, and consequently, data were not accepted by the 
software algorithm during the blinded analyzes. These recordings were discussed by 
the two investigators performing the analyses together with a third impartial 
investigator, and consensus was made within the group. The same examiner performed 
all echocardiographic recordings in this thesis, while two investigators performed all 
analyses. The interobserver variability using epicardial echocardiography in Paper I 
and Paper III, are previously presented (Ch. 10.11.3). As Table 4 illustrates, the 
interobserver variability diverge from good to very good for the TDI and STE for 
longitudinal strain, in the same order of range as the variables from the conductance 
catheter. However, the interobserver agreement for the STE short-axis measurements 
in Paper III are moderate. This is caused by in and out of plane motion in the short-
axis recordings, which depends on the especially high frame rate for STE. The 
increased variability in short-axis parameters with STE has previously been 
demonstrated by others.184,185 Also, the geometry of the recorded images tends to 
produce ultrasound artifacts (reverberations) in epicardial echocardiography. 
 
10.11.5 Myocardial oxygen consumption and mechanical efficiency 
In principle, there are three energy-consuming processes in the myocardium; basal 
metabolism, excitation-contraction coupling and generation of mechanical work 
(Figure 2). Due to the aerobic cardiac metabolism, myocardial oxygen consumption 
(MVO2) is an index of total energy consumption. The reference method for assessment 
of MVO2 is the use of coronary flow probes and measurement of arteriovenous pO2 
difference, simultaneously obtained from coronary sinus and the proximal aorta. 
Cardiac output can be obtained by flow probe to the main pulmonary artery, Swan 
Ganz catheter or by conductance catheter.  
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In Paper III, an alternative method has been used for evaluation of mechanical 
efficiency based on the concept previously described by others.120 There is a strong 
correlation between the total left ventricular work (PVA) defined the from pressure-
volume loops and myocardial blood flow rate. Furthermore, there is a strong 
correlation between the pressure-volume area and MVO2 in the left ventricle.119 It 
must be emphasized that PVA is not an indirect estimate of MVO2. Neither oxygen 
consumption due to mechanical work in the atria, the right ventricle nor oxygen used 
for sustaining basic metabolism and the excitation-contraction coupling are included. 
The total pressure-volume loop area of the left ventricle included in the formula (Ch. 
8.8) defines only the potential (PE) and the mechanical energy (SW) generated by the 
left ventricle. If the arterial and coronary sinus oxygen saturations are not altered, 
tissue blood flow rate in the left ventricular myocardium is an indirect estimate of 
oxygen consumption in the left ventricle. Coronary sinus pO2 was not measured in 
Paper III. Hemoglobin levels and the arterial pO2 values did not differ significantly 
between groups (Supplemental Material, Paper III). 
 
10.11.6 Metabolism 
Evaluation of myocardial metabolism became relevant and of interest when the 
linkage between chemical cardioplegic arrest, bioenergetics and contractile 
consequences were revealed in the early 1970s.16,186 The awareness of the rare but 
fatal ischemic contracture of the left ventricle (“stone heart”) following cardiac 
surgery, initiated a focus on pathophysiologic research and new methods for 
myocardial protection.187 Shortage of ATP energy reserves was an essential ethology 
and these findings resulted in a focus on optimizing cardioplegic arrest and 
hypothermia, hence to delay ATP depletion and to provide anaerobic production of a 
minor but essential amount of ATP.188 In isolated working rat hearts, an almost linear 
correlation between myocardial ATP levels and function was demonstrated.189 A 
corresponding relationship between energy status and functional recovery is predicted 





Myocyte alterations during ischemia following different methods of cardioplegic 
arrest, can be evaluated by various morphological or morphometrical parameters.190,191 
Evaluation of myocyte volume is a morphometric quantification of myocyte swelling. 
In the context of ischemic injury caused by calcium entering the mitochondria, water 
will follow and lead to mitochondrial swelling.192 The myofibril is the organelle most 
resistant to hypoxia, while the mitochondrion is the most susceptible.193 Furthermore, 
the surface-to-volume ratio of mitochondria (SVratiomit) has been demonstrated to be 
an independent parameter of mitochondrial swelling, serving as an indicator of the 
state of structural preservation of mitochondria during ischemia. Increasing volume of 
the myocyte (swelling) also increases the reference space, and with simultaneously 
ischemic swelling of the mitochondria, the consequence will be a relative decrease of 
the free sarcoplasm. For this reason, volume densities of mitochondria (VVmit) and 
sarcoplasm (VVsarc) are not considered as reliable indicators of the degree of edema.191  
 
Myocardial tissue requires extensive preparation prior to TEM, including chemical 
fixation, cryofixation, dehydration, embedding, sectioning, staining, freeze fracturing 
and finally mounting. The structure of the sample can be altered in all these steps of 
preparation. The electron beam can also damage biological material. Another possible 
limitation is that the region being analyzed is not representative for the whole sample 
due to the extensive magnification. 
 
In Paper I and II, a total of six randomly selected micrographs from each biopsy were 
coded and independently evaluated with random offset of the grids. The mean values 
for the six micrographs represent the result from one single animal at one point in 
time. Both the inter- and the intraobserver Intraclass Correlation Coefficients were 
high. It should be emphasized that ICC in Paper II is calculated based on the mean 
values for a given biopsy. When using the recommended random offset for grids, an 
ICC based on a number of single micrographs is futile. To increase reliability, the 
number of micrographs analyzed from each biopsy and several biopsies from each 
heart at the same point in time, should be sampled. 
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11. FUTURE PERSPECTIVES 
This translational experimental porcine model of cardiopulmonary bypass and 
cardioplegic arrest simulates a clinical setting involving myocardial ischemia and 
reperfusion. The results demonstrate that the polarizing cardioplegia with esmolol, 
adenosine and magnesium, has several advantages compared to standard depolarizing, 
potassium-based repeated, oxygenated blood cardioplegia. Based on the results 
presented in this PhD-thesis, clinical research protocols may safely be initiated. 
Validation of adverse effects and comparable results should be obtained in clinical 
trials before implementation into a new clinical routine. Due to the increasing life 
expectancy of the population in general, together with a considerable number of 
patients with previous cardiac surgery and interventional cardiology, future patients in 
need of CPB and CA are likely to be increasing in numbers.194,195 The use of STH-
POL could be beneficial especially in patients with enhanced co-morbidity and/or in 
patients requiring a prolonged period of cardioplegic arrest due to complex 
procedures. Furthermore, modifications of the current procedure in term of increasing 
time intervals between cardioplegic administrations may be a forthcoming advantage 
with non-depolarizing cardioplegic solutions.196-198 Optimal protection of the arrested 
heart during cardiac surgery is essential, not only regarding the choice of cardioplegic 
solution but also in terms of administration strategies.199 Furthermore, the translation 
of knowledge from animal experiments into new clinical routines and subsequently 
patient outcome studies is challenging.200 In this perspective, the results from the 
experimental studies presented in this thesis, may contribute to establishing improved 
myocardial protection routines in future cardiac surgery. 
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12. CONCLUSION 
From the results of the experimental studies presented in this thesis, the following 
conclusions are: 
 
• The administration of STH-POL blood cardioplegia is feasible, induces rapid 
diastolic arrest and the heart remains quiescent during the ischemic period.  
 
• STH-POL minimizes potassium accumulation compared to STH-2 blood 
cardioplegia. 
 
• STH-POL protects against ventricular fibrillation at onset of reperfusion. 
 
• STH-POL offers comparable myocardial protection and improves contractility 
compared to STH-2 blood cardioplegia. 
 
• STH-POL blood cardioplegia results in advantageous energy status during 
cardioplegic arrest and early after reperfusion. 
 
• STH-POL blood cardioplegia alleviates mismatch between myocardial function 





In Paper I, s-troponin-T is given in μmol/L, which should be read ng/L. 
In Paper II (Table 5), VVsarc should be read VVcyt. 
In Figure 9 (right) X-axis, spelling error is corrected to Left ventricular EDV (mL). 
Some minor typing errors are corrected. 
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Abstract
OBJECTIVES: Potassium-based depolarizing St Thomas’ Hospital cardioplegic solution No 2 administered as intermittent, oxygenated blood
is considered as a gold standard for myocardial protection during cardiac surgery. However, the alternative concept of polarizing arrest may
have beneficial protective effects. We hypothesize that polarized arrest with esmolol/adenosine/magnesium (St Thomas’ Hospital Polarizing
cardioplegic solution) in cold, intermittent oxygenated blood offers comparable myocardial protection in a clinically relevant animal model.
METHODS: Twenty anaesthetized young pigs, 42 ± 2 (standard deviation) kg on standardized tepid cardiopulmonary bypass (CPB) were ran-
domized (10 per group) to depolarizing or polarizing cardiac arrest for 60 min with cardioplegia administered in the aortic root every 20 min
as freshly mixed cold, intermittent, oxygenated blood. Global and local baseline and postoperative cardiac function 60, 120 and 180 min after
myocardial reperfusion was evaluated with pressure–conductance catheter and strain by Tissue Doppler Imaging. Regional tissue blood flow,
cleaved caspase-3 activity, GRK2 phosphorylation and mitochondrial function and ultrastructure were evaluated in myocardial tissue samples.
RESULTS: Left ventricular function and general haemodynamics did not differ between groups before CPB. Cardiac asystole was obtained and
maintained during aortic cross-clamping. Compared with baseline, heart rate was increased and left ventricular end-systolic and end-diastolic
pressures decreased in both groups after weaning. Cardiac index, systolic pressure and radial peak systolic strain did not differ between groups.
Contractility, evaluated as dP/dtmax, gradually increased from 120 to 180 min after declamping in animals with polarizing cardioplegia and was
significantly higher, 1871 ± 160 (standard error) mmHg/s, compared with standard potassium-based cardioplegic arrest, 1351 ± 70 mmHg/s,
after 180 min of reperfusion (P = 0.008). Radial peak ejection strain rate increased and the load-independent variable preload recruitable
stroke work was increased with polarizing cardioplegia after 180 min, 64 ± 3 vs 54 ± 2 mmHg (P = 0.018), indicating better preserved left
ventricular contractility with polarizing cardioplegia. Phosphorylation of GRK2 in myocardial tissue did not differ between groups. Fractional
cytoplasmic volume in myocytes was reduced in hearts arrested with polarizing cardioplegia, indicating reduction of cytoplasmic oedema.
CONCLUSIONS: Polarizing oxygenated blood cardioplegia with esmolol/adenosine/magnesium offers comparable myocardial protection and
improves contractility compared with the standard potassium-based depolarizing blood cardioplegia.
Keywords: Cardioplegia •Myocardial protection • Cardiac function • Animal model
INTRODUCTION
Over the past two decades, surgical treatment for cardiac disease
has occurred in patients that are more elderly and have more
complex disease. As a consequence, there is an increasing demand
for new perfusion strategies associated with prolonged duration of
cardiopulmonary bypass (CPB) and cardiac arrest that will provide
improved myocardial protection. Potassium-based depolarizing
cardioplegia, delivered as oxygenated cold blood, is a dominant
routine used worldwide [1]. A number of different techniques
for optimizing myocardial protection have been studied, both
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experimentally and clinically. Polarizing cardioplegic protocols have
also been extensively studied [2]; the concept of polarized arrest has
shown that enhanced protection can be achieved [3]. A new
polarizing cardioplegic solution, the St Thomas’ Hospital Polarizing
cardioplegic solution (STH-POL), containing a mixture of the short-
acting β-adrenergic receptor blocker esmolol, adenosine and Mg2+,
has recently been suggested. The solution combines the inhibition
of fast Na+- and L-type Ca2+-channels of esmolol, the KATP-channel
opener effect of adenosine and the reduced myocardial Ca2+ load
caused by magnesium [3, 4]. Before implementation of a new tech-
nique for myocardial protection in clinical studies and practice, it
must be compared and found to be non-inferior or superior to the
current technique in a translational large animal in vivomodel.
In a standardized clinically relevant porcine model involving CPB,
we have investigated whether cardioplegic arrest with STH-POL offers
myocardial protection comparable with a standard depolarizing
potassium-based cardioplegic solution; both delivered as repeated,
cold, oxygenated blood cardioplegia. The main focus for the evalu-
ation was to compare the left ventricular global and local function up
to 3 h after aortic declamping, weaning and decannulation.
MATERIALS ANDMETHODS
Animals and anaesthesia
The experimental protocol was approved by the Norwegian State
Commission for Laboratory Animals (Project 20135835), and con-
ducted in accordance with the European Communities Council
Directive of 2010 (63/EU). The animals were brought to the animal
facility about 1 week in advance for acclimatization. Twenty-four
young pigs (Norwegian land race) of either gender, weighing 42 ± 2
[standard deviation (SD)] kg were used. After premedication with
intramuscular injection of a mixture of ketamine (20 mg/kg), diaze-
pam (10 mg) and atropine (1 mg), the pigs were ventilated spontan-
eously on mask for a short period with oxygen and 3% isoflurane
(Rhodia, Bristol, UK) allowing intravenous access through two ear
veins. Before tracheotomy and intubation, loading doses of intra-
venous fentanyl (0.02 mg/kg), midazolam (0.3 mg/kg), pancuro-
nium (0.063 mg/kg) and pentobarbital (15 mg/kg) were given, and
continuous infusions of fentanyl (0.02 mg/kg per h), midazolam
(0.3 mg/kg per h), pancuronium (0.2 mg/kg per h) and pentobar-
bital (4 mg/kg per h) were initialized. The animals were ventilated
( Julian, Drägerwerk, Lübeck, Germany) with a mixture of nitrous
oxide (56–58%) and oxygen. Prophylactic antibiotic therapy with
cefalotin 1 g (in 50 ml 0.9% NaCl) was given IV initially, followed by
0.5 g during CPB and 1.0 g after weaning. Fluid substitution,
Ringer’s acetate 15 ml/kg per h with 20 mmol/l KCl added, was
given throughout the experiment. In addition, Ringer’s acetate 5
ml/kg per h was provided after weaning from CPB. The anaesthetic
protocol has been thoroughly evaluated, allowing the use of neuro-
muscular blocking agents in young pigs [5].
Surgical protocol and instrumentation
The right femoral artery and vein were cannulated for blood sam-
pling and infusion by surgical cut-down in the groin. An early arterial
blood gas analysis determined the need for ventilator adjustments.
An open suprapubic cystotomy with insertion of a catheter drained
the urine bladder. Rectal temperature was monitored. Midline ster-
notomy and pericardiotomy was performed and heparin (125 IU/
kg) given IV to prevent clotting of catheters. A continuous cardiac
output catheter (CCO/EDV 177HF 75, Edwards Lifesciences, Inc.,
Irvine, CA, USA) was advanced from the left internal mammary vein
into the pulmonary artery for monitoring cardiac output, right
ventricular end-diastolic volume, central venous pressure (CVP) and
pulmonary artery pressure (PAP) (Vigilance II® and TruWave® trans-
ducers, Edwards Lifescience, Inc.). The aorta was cannulated proxim-
ally with a Millar microtip pressure catheter (Millar MPC-500,
Houston, TX, USA) through the left internal mammary artery. The
haemodynamic parameters were sampled in real time by a
16-channel Ponemah (ACQ-7700; Data Sciences International, St
Paul, MN, USA), digitized and later analysed (Ponemah Physiology
Platform v. 5.2, Data Sciences International). A dual-field conduct-
ance-pressure catheter (CA71083-PL, CDLeycom, Hengelo,
Netherlands) was inserted through the apex and into the left ven-
tricle with the distal part in position just above the aortic valve, veri-
fied by epicardial echocardiography (Vivid E9, GE Vingmed
Ultrasound, Horten, Norway). The catheter was connected to a
Sigma-M signal conditioner (CDLeycom). The left atrium was cannu-
lated by an infant feeding tube for microsphere injections and a
tape placed around the inferior vena cava for brief intermittent
dynamic preload reductions.
Cardiopulmonary bypass
CPB (Stöckert SIII, Munich, Germany) was set up with 1200 ml
Ringer’s acetate as prime in the circuit. After anticoagulation
with heparin 500 IU/kg, the brachiocephalic artery (EOPA 18 Fr,
Medtronic, Inc., Minneapolis, MN, USA) and right atrial appendage
(MC2 28/36 Fr, Medtronic Inc.) were cannulated, and CPB was estab-
lished with a flow of 90 ml/min per kg and water temperature of 32°
C in the heat exchanger. Aortic cross-clamp time was 60 min and a
left heart vent catheter (E061 17 Fr, Edwards Lifesciences, Inc.) was
placed through the left atrial appendage into the ventricle. The body
temperature was allowed to drift towards 34°C and the CPB flow was
reduced to 72 ml/min per kg when the rectal temperature reached
35°C or after 20 min. Rewarming was commenced after 40 min of
cross-clamping with reset of CPB flow to 90 ml/min per kg and
water temperature at 40°C. Arterial blood gases were obtained
before cross-clamping, after 30 min and just before declamping after
60 min. If ventricular fibrillation occurred after declamping, defibril-
lation was the only allowed antiarrhythmic intervention. All animals
were weaned from CPB at 10 min after declamping followed by
decannulation. The residual blood in the circuit was returned and
protamine sulphate 1 mg/kg was given for heparin reversal.
Cardioplegia
The animals were block-randomized to receive either hyperkalae-
mic cardioplegia based on a modification of St Thomas’ Hospital
cardioplegic solution No. 2 (STH-2), or cardioplegia containing the
short-acting β-adrenergic blocking agent esmolol, adenosine and
magnesium; St Thomas’ Hospital polarizing solution (STH-POL)
(Table 1). Both solutions were pre-prepared as concentrate and
administered as cold (12°C), oxygenated, blood cardioplegia,
freshly mixed and delivered by a dual-pump with separate cooling.
The cardioplegia was delivered into the aortic root with a flow set
to 7% of CPB flow, following a standardized protocol with an
initial ‘high-dose’ (1:4 concentrate/blood) for 3 min and 2 min of
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cross-clamping. The final concentrations of key components in the
two cardioplegic solutions are presented in Table 1.
Experimental protocol
After 10 min of stabilization, baseline variables were obtained;
arterial blood gases (ABL80 FLEX COOX, Radiometer Medical
ApS, Brønshøj, Denmark), s-troponin-T (Troponin-T hs®, Roche
Diagnostics, GmbH, Mannheim, Germany), haemodynamic vari-
ables and the first injection of 15-µm microspheres (Dye-Trak ‘F’;
Triton Technology, Inc., San Diego, CA, USA). After a short period
of ventilation with 100% oxygen, left ventricular pressure–volume
loops were registered with respirator shut-off in end-expirium
before and during a brief period of inferior vena cava occlusion. A
bolus of 5 ml hypertonic saline (10%) was injected into the pul-
monary artery and pressure volume loops were recorded in a
stable situation three times for estimation of parallel conductance
[6, 7]. Epicardial echocardiography was performed with a soft sili-
cone pad placed between the probe (6 MHz sector probe, GE
Vingmed Ultrasound) and the epicardium. During brief periods of
respiratory shut-off, pulsed wave Doppler (PWD) velocity spec-
trum recordings in the left aortic outflow tract were noted for
timing of end-systole and end-diastole. Tissue Doppler images
(TDIs) of the anterior left ventricular wall in short axis view were
recorded for radial strain and strain rate measurements.
At full CPB flow, an arterial blood gas was sampled followed by
aortic cross-clamping and cardioplegic arrest with STH-POL or
STH-2 given as cold blood cardioplegia. During CPB, the ventilator
volume was reduced to 50% and with passive drainage of the heart.
Additional heparin (250 IU/kg) was given at 30 min of cross-
clamping. After 60 min of cardioplegic arrest, the aortic clamp was
removed. The animals were weaned from CPB after 10 min of myo-
cardial reperfusion. General haemodynamics were continuously
recorded for 180 min. As for baseline, measurements of left ven-
tricular pressures, volumes, contractility, systolic and diastolic func-
tion, regional tissue blood flow and echocardiographic recordings
were repeated at 60, 120 and 180 min after aortic declamping.
Finally, the animal was euthanized with intracardiac injection of
high-dose potassium chloride, the heart removed and samples
were obtained for regional tissue blood flow measurements, ana-
lysis of mitochondrial ultrastructure and mitochondrial fatty acid
oxidation capacity, phosphorylated GRK2, Caspase-3 activity and
tissue water content.
Pressure–conductance catheter
Data from the pressure-conductance catheter were analysed with a
custom-made programme. The mean of 5–8 cardiac cycles during
the stable condition and load-independent variables obtained
during the dynamic preload reduction were calculated. Absolute
volumes were estimated by correcting for parallel conductance and
cardiac output. Volumes were indexed by body surface area (BSA)
calculated as BSA (m2) = (BW2/3 × k)/100 where BW is body weight
in kg and k for pigs is 9 m2/kg−2/3 [8].
Epicardial echocardiography
Local myocardial function (TDI strain and strain rate) in the anter-
ior wall was recorded. Peak systolic strain and peak ejection strain
rate were measured with commercial software (EchoPack BT12,
GE Vingmed Ultrasound). The size of the region of interest (ROI)
was set to 6 × 6 mm and the strain length (SL) to 6 mm. Care was
taken not to place the ROIs within a distance of ½SL from the
epicardium and ½SL from the endocardium [9]. End-diastole was
defined as the first deflection in the QRS complex in the ECG, and
start of ejection was defined at the aortic valve opening and end-
systole was defined as the time of aortic valve closure from the
PWD recording. The mean frame rate for the TDI recordings was
544 ± 78 (SD) frames/s (range 249–696).
Myocardial tissue samples and analyses
Multiple biopsies were obtained from the LV endo-, mid- and
epicardium, snap-frozen in liquid nitrogen and stored at −80°C for
later analysis. Caspase-3 activity was determined using the
Caspase-3 Colorimetric Assay Kit (BioVision, Inc., Milpitas, CA,
USA). Tissue was homogenized and lysis performed according to
the manufacturer’s instructions, and triplet samples containing 400
µg total protein, measured by the Quick Start™ Bradford Protein
Assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA), were incu-
bated for 2 h before fluorometric readings. The activation of
G-protein-coupled receptor kinase 2 (GRK2) in the myocardium
was assessed with immunoblotting using antibodies against phos-
phorylated GRK2 (LS-C199027, LifeSpan BioSciences Inc., Seattle,
WA, USA) and total GRK2 (CST3982, Cell Signaling, Boston, MA,
USA) according to manufacturer’s instructions. The blots were
quantified using scanning densitometry. Mitochondrial carnitine
palmitoyltransferase I and II (CPT-I, CPT-II) activity in the outer and
inner mitochondrial membranes were measured in frozen myocar-
dial tissue samples. Each sample was homogenized after adding
500 µl of ice-cold sucrose (0.25 M sucrose, 5 mM HEPES-buffer,
0.2 mM ethylene glycol tetraacetic acid, pH 7.4) and centrifuged at
4°C, 600 g for 12 min. The protein concentration in the supernatant
(post-nuclear fraction) was measured (Bio-Rad Protein Assay,
Bio-Rad Laboratories, Inc.). In 150 µg of protein, CPT-I and CPT-II
were measured as earlier described [10]. In addition, corresponding
biopsies were obtained and fixed overnight in 0.1 M Na-cacodylate
buffer with 2.5% glutaraldehyde, washed, post-fixated with 1%
OsO4, dehydrated and stored in 70% ethanol, sectioned and
stained with uranyl acetate for the analysis of myocardial ultrastruc-
ture with electron microscopy. From six randomly selected sections,
images (×15 000) were obtained from the mid-myocardium,
myocyte volume fractions of mitochondria, myofibrils and sarco-
plasma were calculated by point counting. The mitochondrial











Esmolol (mM) 1.35 0.68 – –
Adenosine (mM) 0.50 0.25 – –
Mg2+ (mM) 20 10 16 9
K+ (mM) 4.3 4.3 22 14
Cl− (mM) 106 106 134 120
Procaine HCl (mM) 0.8 0.4 0.8 0.4
STH-POL: St Thomas’ Hospital Polarizing cardioplegic solution;
STH-2: Modified St Thomas’ Hospital cardioplegic solution No. 2.
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surface density and surface-to-volume ratio were calculated by a
Merz grid using the ImageJ freeware [11, 12]. Tissues obtained from
the left and the right ventricle were weighed, hydrolysed, micro-
spheres isolated by filtration, colours dissolved and quantified by
fluorospectrophotometry together with the reference blood
samples. Blood flow rate was calculated as earlier described [13].
Myocardial tissue water content was calculated as a fraction of wet
weight after drying samples for 3 weeks at 60°C.
Statistical analysis
Data were analysed by using SPSS v. 22 (SPSS, Inc., Chicago, IL, USA)
and values given as mean ± (SE) or median (25% quartile; 75% quar-
tile) unless otherwise noted. Baseline variables were compared by
two-sample Student’s t-test on data with normal distribution and
with Wilcoxon–Mann–Whitney U-test on ranks if the Kolmogorov–
Smirnov test or the Levene equal variance tests were significant.
Variables obtained during and after CPB were analysed separately
by two-way analysis of variance (ANOVA) for repeated measure-
ment (RM-ANOVA) with time as within factor (Pw) and cardioplegia
with STH-POL or STH-2 as grouping factor (Pg) and post hoc
Bonferroni contrasts between individual group means. If Mauchly’s
test of sphericity was significant (P < 0.05), the Greenhouse–Geisser
adjustment of degrees of freedom was selected for the evaluation
of main effects. For Caspase-3 activity and estimation of GRK2, wall
layers were set as related variables. If a significant interaction
(Pi < 0.10) effect was found, new ANOVAs for simple main effect
were performed with adjustment of degrees of freedom. Cell
means were finally compared with Neumann–Keuls multiple con-
trast tests when justified by the preceding ANOVA. The morpho-
logical variables were analysed with a nested ANOVA. P < 0.05 was
considered statistically significant.
RESULTS
Group characteristics at baseline and during
cardiopulmonary bypass
Four animals were excluded due to reasons other than technical
failure: two in the STH-POL group developed severe pulmonary
hypertension and arterial hypoxia with heart failure during baseline
measurements before allocation to treatment groups; two in the
STH-2 group, one due to severe pulmonary hypertension during
instrumentation before CPB and one due to persistent ventricular
fibrillation after declamping. Excluded animals were replaced by
consecutive experiments and the results are given for 10 animals in
each group. Baseline variables describing left and right ventricular
function, general haemodynamics, tissue blood flow rate, arterial
blood gases and serum troponin-T did not differ between groups
(Table 2, Figs 1–3).
The myocardial contraction rapidly ceased after aortic cross-
clamping and start of the cardioplegic infusion, with the median
time being 28 (11; 43) s for STH-POL and 22 (18; 27) s for STH-2
group (P = 0.79). During CPB, haemoglobin levels and serum-
potassium were moderately, but significantly increased in the
STH-2 group compared with the STH-POL group at 30 and 60 min
(see Supplementary Material). There were no differences between
the groups regarding mean arterial pressure, temperature and
arterial blood gases during CPB.
Cardiac and haemodynamic variables after
declamping
Heart rate was increased and left ventricular systolic (LVSP) and dia-
stolic (LVEDP) pressures decreased with time in both groups after
weaning from CPB (Fig. 1). Cardiac index (CI) increased during the
first hour after declamping in both groups, but then decreased slight-
ly but staying above baseline levels during the remaining 120 min of
reperfusion (Pw = 0.024). There were no significant differences
between the groups. In the STH-POL group, the first derivative of the
left ventricular pressure (LV-dP/dtmax) increased from 120 to 180
min of reperfusion, reaching values significantly higher than the
STH-2 group after 165 and 180 min of reperfusion. LV-dP/dtmin was
more negative in the STH-POL group after 180 min. There was a sig-
nificant difference between groups for indexed stroke work (SWi)
and for the load-independent contractility variable preload recruit-
able stroke work (PRSW) at 180 min after declamping (Fig. 2).
Ejection fraction and the slope of the end-systolic pressure–volume
relationship (ESPVRslope) did not differ between groups, neither did
the isovolumic relaxation constant Tau nor the left ventricular
compliance β. Whereas radial peak systolic strain in the anterior left
ventricular wall decreased significantly over time in both groups
(Pw = 0.004), radial peak ejection strain rate decreased in the STH-2
group to values significantly lower than in the STH-POL group at
180 min (Fig. 3). There was a significant decrease over time in
indexed left ventricular stroke volume (LV-SVi) and a decrease in
Table 2: Baseline variables before cardiac arrest with
polarizing (STH-POL) and depolarizing (STH-2) cardioplegia
Variable STH-POL STH-2 Statistics
LV-EDVi (ml/m
2) 83 ± 5 78 ± 4 P = 0.50
LV-ESVi (ml/m
2) 41 ± 4 35 ± 4 P = 0.28
LV-SVi (ml/m
2) 50 ± 3 51 ± 2 P = 0.72
RV-EDVi (ml/m
2) 136 ± 4 148 ± 7 P = 0.16
RV-EF (%) 24 ± 1 26 ± 1 P = 0.28
MAP (mmHg) 95 ± 4 96 ± 3 P = 0.77
CVPmean (mmHg) 5.8 ± 0.5 6.2 ± 0.5 P = 0.58
PAPmean (mmHg) 18.8 (15.5; 21.8) 19.6 (18.3; 20.4) P = 0.47
LV blood flow
(ml/min per g)
0.92 ± 0.05 1.04 ± 0.06 P = 0.16
RV blood flow
(ml/min per g)
0.68 ± 0.07 0.83 ± 0.05 P = 0.14
Arterial blood gases
pH 7.51 (7.49; 7.52) 7.52 (7.51; 7.53) P = 0.25
pCO2 (kPa) 5.2 ± 0.1 5.02 ± 0.1 P = 0.24
HCO3
− (mmol/l) 31.2 ± 0.2 31.2 ± 0.4 P = 0.95
BE (mmol/l) 7.3 ± 0.2 7.2 ± 0.4 P = 0.89
pO2 (kPa) 25.8 ± 0.8 25.6 ± 0.5 P = 0.88
Hb (g/dl) 8.2 ± 0.2 8.1 ± 0.2 P = 0.64
Hct (%) 25.6 ± 0.5 25.2 ± 0.6 P = 0.64
s-Na+ (mmol/l) 142 (140; 143) 142 (141; 143) P = 0.94
s-K+ (mmol/l) 3.7 ± 0.1 3.7 ± 0.1 P = 0.59
s-Cl− (mmol/l) 103.1 ± 0.9 103.4 ± 0.6 P = 0.78
s-Troponin-T
(µmol/l)
47.6 ± 4.7 53.4 ± 6.5 P = 0.48
Values are mean ± SE or median (25-percentile; 75-percentile), n = 10.
LV and RV: left and right ventricle; i: value indexed for body surface
area; EDV: end-diastolic volume; ESV: end-systolic volume; SV: stroke
volume; MAP: mean arterial pressure; CVPmean: mean central venous
pressure; PAPmean: mean pulmonary artery pressure; STH-POL: St
Thomas’ Hospital Polarizing cardioplegic solution; STH-2: St Thomas’
Hospital cardioplegic solution No. 2; SE: standard error.
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right ventricular end-diastolic volume (RV-EDVi) for both groups
(Table 3). The mean aortic blood pressure (MAP) was unchanged in
the STH-POL group and decreased over time in the STH-2 group
with a significant difference between groups at 180 min of reperfu-
sion. The mean PAP was unchanged and CVP slightly increased over
time in both groups (Pw = 0.003). Regional tissue blood flow rate in
the left and the right ventricular wall was unchanged from 60 to 180
min of reperfusion. Left ventricular tissue water content averaged
80.1 ± 0.1% (n = 20), with no group difference. Serum troponin-T
levels did not differ between groups at 180 min after declamping;
median values were 504 (328; 886) µmol/l in the STH-POL group
and 580 (401; 717) µmol/l in the STH-2 group (P = 0.73).
Myocardial apoptosis and β-receptor activity
There was no difference between groups in myocardial apoptotic
activation evaluated as cleaved caspase-3 activity (Pg = 0.84) (Fig. 4).
In the subepicardium, cleaved caspase-3 activity was increased
in both groups compared with that in the mid-myocardial and
subendocardial wall layers (Player = 0.024). Phosphorylation of GRK2
(relative to tissue from control heart) in the mid-myocardial wall
layers was increased in both groups compared with levels in the
subendo- and subepicardial wall layers (Player = 0.001). The total
GRK2 content did not differ between wall layers or between
groups.
Figure 1: Baseline left ventricular haemodynamic variables mean (SE) or median (25%; 75%), and values obtained after CPB and 60 min of cardiac arrest with polariz-
ing (STH-POL) and depolarizing (STH-2) cardioplegia. Bars represent SE. Pw, Pg and Pi: P-values for within subjects, between groups and interaction from two-way
RM-ANOVA, respectively; #Significantly different from STH-POL at 180 min of reperfusion with Bonferroni post hoc test. SE: standard error of the mean; CPB: cardio-
pulmonary bypass; RM-ANOVA: analysis of variance for repeated measurement; CI: Cardiac Index; LVSP: left ventricular peak systolic pressure; LVEDP: left ventricular
peak end-diastolic pressures; dP/dtmax and dP/dtmin: peak positive and peak negative of the first derivative of left ventricular pressure.
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Mitochondrial ultrastructure and metabolism
In the mid-myocardium, there was a significant increase in the
volume fraction of the sarcoplasma resulting in a concomitant de-
crease in the volume fraction of myofibrils in the STH-2 group
(Fig. 5). The volume fraction of mitochondria did not differ signifi-
cantly. Furthermore, the surface density of the mitochondria did
not differ between groups. The surface-to-volume ratio was slight-
ly decreased for the STH-POL group, indicating mitochondrial
swelling. The carnitine transport systems for long chain fatty acids,
evaluated as CPT-I and CPT-II activity, were not affected by the
selection of the cardioplegic protocol.
DISCUSSION
This study provides evidence that ‘polarised’ arrest with a solution
containing a mixture of esmolol, adenosine and magnesium in
oxygenated blood offers myocardial protection that is comparable
with standard potassium-based (depolarised) cold, intermittent
Figure 2: Left ventricle functional variables at baseline and 60, 120 and 180 min after CPB and aortic declamping following cardiac arrest with polarizing (STH-POL)
and depolarizing (STH-2) cardioplegia. Mean or median values, bars are SE or 25 and 75 percentiles. Statistics as in Fig. 1. #Significantly different from STH-POL at 180
min of reperfusion, *Significantly different from 60 min of reperfusion within STH-2 group. EF: ejection fraction; SWi: indexed stroke work; PRSW: slope of preload re-
cruitable stroke work; ESPVRslope: slope of the end-systolic pressure volume relationship; Tau: isovolumic relaxation constant; β: the logarithmic end-diastolic pressure
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oxygenated blood cardioplegia in a clinically relevant porcine
model. At 180 min after aortic declamping, left ventricular con-
tractile function evaluated as LV-dP/dtmax, PRSW and peak ejec-
tion strain rate was better maintained in animals with polarizing
compared with depolarizing cardioplegic arrest for 60 min.
Furthermore, the hearts arrested with polarizing cardioplegia gen-
erate an increased systemic blood pressure (MAP) 180 min after
declamping. This could be a result of reduced development of left
ventricular myocardial stunning in the STH-POL group 3 h after
declamping. Troponin-T release and the degree of apoptosis did
not differ and contradict differences in irreversible myocardial
damage between groups. The increase in variables describing
contractility such as PRSW, LV-dP/dtmax and strain rate in the
STH-POL group 180 min after declamping is not a result of activa-
tion of the Frank–Starling mechanism in the left ventricle. The left
ventricular end-diastolic volume was unchanged and did not
differ between groups (Table 3). Similarly, the load-dependent
variables of left ventricular EF (Fig. 2) and radial TDI strain (Fig. 3)
were not different between groups during the 180 min of obser-
vation after declamping. Group differences in LV-dP/dtmax and
strain rate could be affected by the differences in heart rate.
However, heart rate did not differ between groups after declamp-
ing (Fig. 1). The increased contractility did not improve cardiac
function evaluated by LV-EF and Cardiac Index. The increased
indexed stroke works at 180 min in the STH-POL group, potential-
ly resulting from slight, but non-significant increases in LVSP and
CI, indicate that left ventricle performance was improved follow-
ing polarizing cardioplegic arrest in the present study. This in-
crease in left ventricular workload was not reflected in a
substantial increase in left ventricular tissue blood flow rate. We
interpret these results due to an improvement in myocardial pro-
tective efficacy with polarised cardioplegic arrest, possibly due to
a reduced ionic inhomogeneity and consequently reduced energy
utilization [3].
In chronic heart failure, increased catecholamine release with
impaired signalling and desensitization of β-adrenergic receptors
(β-AR) contributes to myocardial dysfunction [14]. During CPB and
cardioplegic arrest, serum catecholamines increase and norepin-
ephrine is released locally from the hypothermic and anoxic myo-
cardium [15, 16]. This can lead to β-AR desensitization and is
associated with increased GRK2 activity. Hence, β-AR desensitiza-
tion and increased GRK2 activity may explain several aspects of
the myocardial stunning observed after cardiac surgery [17]. The
addition of esmolol systemically during CPB in dog hearts subse-
quently arrested with potassium-based crystalloid cardioplegia
demonstrated enhanced β-adrenergic receptor signalling with
improved postischaemic function [18]. Similarly, the addition of
esmolol before CPB in pigs arrested with cold potassium-based
blood cardioplegia improved late contractile function [19].
Interestingly, the addition of esmolol to cold potassium-based
blood cardioplegia was also able to enhance late myocardial re-
covery of function in pigs subjected to CPB and 100 min of ischae-
mic arrest [20]. As indicated by the tissue levels of phosphorylated
GRK2 in the present study, there is no evidence for altered GRK2
activity in either group (Fig. 4). Since neither adenylate cyclase ac-
tivity nor GRK2 activity was measured directly, the prevention of
β-receptor desensitization could not be completely ruled out as
an explanation for the improved contractile function observed in
animals with polarizing cardioplegia (Figs 1–3).
The administration of repeated oxygenated blood cardioplegia
during cardiac surgery implies multiple episodes of ischaemia and
re-oxygenation before the final declamping and reperfusion.
Beta-receptor blockade during cardioplegic arrest is of potential
interest for reducing both ischaemic- and lethal reperfusion injury.
However, the unwanted negative inotropic effect during reperfu-
sion and weaning could be potentially harmful, especially if the
β-blocking agent has a prolonged half-life. Esmolol is rapidly meta-
bolized by blood esterase and has a half-life of !9 min [21].
Esmolol has been found beneficial as an alternative to cardioplegia
by inducing ‘minimal myocardial contraction’ [22], or as a supple-
ment to standard cardioplegic regimes [19, 20]. In the present study,
there was a trend towards an early but transient reduction in heart
rate as well as a significantly higher LVEDP at 20 min after declamp-
ing (Fig. 1), indicating a residual negative chronotropic and inotrop-
ic effect of esmolol early after declamping. However, by 30 min
after declamping, these negative effects were abolished.
Myocardial ischaemic injury and lethal reperfusion injury are
reduced by β-adrenergic blockers and the modulation of apoptot-
ic cell death is also linked to β-receptor adrenergic signalling and
GRK2 activation [23]. In the present study, neither release of
troponin-T at 180 min after aortic declamping nor activation of
apoptotic activity ( judged by tissue cleaved caspase-3 activity) dif-
fered between treatment groups.
In research and in clinical practice, different forms of cardioplegic
solutions delivered as crystalloid or as blood-based cardioplegia
Figure 3: (A) Radial peak systolic TDI strain and (B) peak ejection strain rate at
baseline and 60, 120 and 180 min after CPB and aortic declamping in the left
ventricular anterior wall following cardiac arrest with polarizing (STH-POL) and
depolarizing (STH-2) cardioplegia. Mean values, bars are SE. #Significantly dif-
ferent from STH-POL at 180 min of reperfusion. Statistics as in Fig. 1. SE: stand-
ard error; RM-ANOVA: analysis of variance for repeated measurements.
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have been studied and are in use. Both intracellular solutions with
amino acids as buffer and low levels of Na+ and Ca2+, and extracellu-
lar solutions with normal levels of Na+ and Ca2+ rely on moderately
increased concentrations of potassium to obtain cardiac arrest [1].
Potassium-based depolarizing cardioplegia inactivates the fast Na+
channel in the myocyte membrane, by inducing re-equilibration of
the membrane potential to a more positive level and thereby pre-
venting the voltage-activated Na+ spike of the action potential and
the triggering of contraction [3]. This, together with myocardial
cooling, reduces energy consumption and oxygen demands during
cardiac arrest. At this re-equilibrated membrane potential, the non-
inactivating Na+ current leads to increases in intracellular Na+, with
subsequent reversal of the Na+/Ca2+-exchanger; the resultant Na+
and Ca2+ overload is potentially harmful. Increased tissue oedema in
hearts arrested with the hyperkalaemic STH-2 cardioplegia was
found compared with the normokalaemic STH-POL cardioplegia,
and this is consistent with previous findings [22]. In contrast, esmolol
inhibits the fast Na+-channels and the L-type Ca2+-channels [4]; ad-
enosine is a KATP-channel opener and magnesium is an endogenous
Ca2+-channel blocker. These pharmacological effects will reduce
the ionic heterogeneity that occurs during ischaemia and will con-
comitantly reduce high-energy phosphate utilization. Adenosine
induces hyperpolarized cardiac arrest in normokalaemic cardiople-
gic solutions, and also in a clinical setting [24]. Magnesium is a com-
ponent of STH-2 cardioplegia, exerting an anti-ischaemic protective
effect. However, the efficacy of magnesium as adjuvant to cardiople-
gic solutions has been questioned [25]. One could therefore specu-
late if esmolol and adenosine alone could be an alternative
polarizing cardioplegic solution.
Limitations
In addition to the obvious possibility of species differences, the
present study is performed in healthy young hearts without coron-
ary pathology where the conditions for myocardial protection are
optimized. In addition, the limited cross-clamp time and the total
potassium load in the present study could obscure possible advan-
tages with polarizing cardioplegic arrest. Furthermore, an increase
in both ischaemic time connected to more complex surgical proce-
dures and prolonged observation time after declamping could
more precisely clarify such differences. Also, intermittent STH-POL
cardioplegia should be compared with other routines, for instance
with solutions designed for single-shot administration.
Table 3: Cardiac and haemodynamic variables and tissue blood flow 60, 120 and 180 min after aortic declamping following 60
min of polarizing (STH-POL) or depolarizing (STH-2) cardioplegic arrest
Variable 60 min (A) 120 min (B) 180 min (C) RM-ANOVA statistics
LV-EDVi (ml/m
2)
STH-POL 60 ± 3 59 ± 4 54 ± 2 Pw = 0.26, Pg = 0.55, Pi = 0.92
STH-2 64 ± 4 60 ± 6 58 ± 4
LV-ESVi (ml/m
2)
STH-POL 23 ± 2 28 ± 4 22 ± 2 Pw = 0.54, Pg = 0.36, Pi = 0.53
STH-2 27 ± 3 29 ± 4 30 ± 7
LV-SVi (ml/m
2)
STH-POL 42 ± 2 37 ± 2 37 ± 1 Pw < 0.001, Pg = 0.22, Pi = 0.51
STH-2 42 ± 3 37 ± 4 34 ± 3
RV-EDVi (ml/m
2)
STH-POL 134 ± 5 128 ± 4 123 ± 3 Pw = 0.006, Pg = 0.55, Pi = 0.73
STH-2 142 ± 6 132 ± 4 130 ± 5
RV-EF (%)
STH-POL 30 ± 2 28 ± 1 31 ± 2 Pw = 0.162, Pg = 0.32, Pi = 0.35
STH-2 30 ± 2 26 ± 1 27 ± 2
MAP (mmHg)
STH-POL 72 ± 4 71 ± 4 74 ± 4 Pw = 0.127, Pg = 0.31, Pi = 0.046
STH-2 73 ± 3 67 ± 4 63 ± 3a,#
CVP (mmHg)
STH-POL 8.0 ± 0.7 8.1 ± 0.8 9.3 ± 0.9 Pw = 0.003, Pg = 0.57, Pi = 0.85
STH-2 8.4 ± 0.7 8.9 ± 0.8 10.1 ± 1.1
PAP (mmHg)
STH-POL 24 ± 1 24 ± 2 25 ± 1 Pw = 0.30, Pg = 0.12, Pi = 0.63
STH-2 26 ± 2 28 ± 2 28 ± 2
LV blood flow (ml/min per g)
STH-POL 1.39 ± 0.15 1.24 ± 0.10 1.36 ± 0.10 Pw = 0.16, Pg = 0.46, Pi = 0.69
STH-2 1.32 ± 0.08 1.19 ± 0.06 1.21 ± 0.09
RV blood flow (ml/min per g)
STH-POL 1.53 ± 0.21 1.27 ± 0.10 1.30 ± 0.09 Pw = 0.073, Pg = 0.58, Pi = 0.92
STH-2 1.60 ± 0.17 1.34 ± 0.08 1.42 ± 0.17
Values are mean ± SE for 10 animals in each group.
LV and RV: left and right ventricle; i: value indexed for body surface area; EDV: end-diastolic volume; ESV: end-systolic volume; SV: stroke volume; MAP: mean
arterial pressure; CVP: mean central venous pressure; PAP: mean pulmonary artery pressure; STH-POL: St Thomas’ Hospital polarizing cardioplegic solution;
STH-2: St Thomas’ Hospital cardioplegic solution No. 2; RM-ANOVA: analysis of variance for repeated measurement.
Pw, Pg and Pi: P-values for within subjects, between groups and interaction from two-way RM-ANOVA, respectively.
aSignificant difference within group means from value(s) in columns with corresponding capital letters.
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Clinical implications
On the basis of the present study, polarizing cardioplegia with
esmolol, adenosine and magnesium seems non-inferior to stand-
ard depolarizing, potassium-based repeated, oxygenated blood
cardioplegia. Clinical research protocols could be initiated, at least
in patients requiring a short-to-medium time of cardiac arrest
during heart surgery.
CONCLUSIONS
This translational large animal study demonstrates that polarizing
oxygenated blood cardioplegia with esmolol/adenosine/magnesium
offers comparable myocardial protection and improves contractility
Figure 5: (A) Mid-myocardial myocyte volume fractions, (B) mitochondrial
surface density (SVMi), surface-to-volume ratio (SVratioMi) and (C) carnitine pal-
mitoyltransferase activity in the outer (CPT-I) and inner (CPT-II) mitochondrial
membrane. Bars are mean + SE. Pg is the probability by two-sample t-tests. SE:
standard error.
Figure 4: (A) Caspase-3 activity (n = 10 + 9), (B) phosphorylated (Phospho-GRK2)
and (C) total (GRK2total) G protein-coupled receptor kinase-2) (n = 9 + 9) in myo-
cardial tissue samples obtained 180 min after reperfusion following CPB and 60
min of cardioplegic arrest with polarizing (STH-POL) and depolarizing (STH-2)
cardioplegia. Bars are mean + SE. Statistics as in Fig. 1. SE: standard error;
RM-ANOVA: analysis of variance for repeated measurements.
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compared with the standard potassium-based depolarizing blood
cardioplegia.
SUPPLEMENTARY MATERIAL
Supplementary material is available at EJCTS online.
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Online Table 1. 
Mean arterial pressure, temperature, haemoglobin, arterial blood gases and electrolytes during 
cardiopulmonary bypass in two groups of pigs with 60 min of polarising (STH-POL) or depolarising 
(STH-2) cardioplegic arrest. Values are mean ± SE, n = 10. 
Variable 1 min before 30 min  58 min  RM-ANOVA statistics 
  X-clamp X-clamp X-clamp 
                (A)     (B)     (C) 
 
MAP (mmHg) 
   STH-POL 61 ± 6  44 ± 3  62 ± 6  pw = 0.012, pg = 0.82, pi = 0.26 
   STH-2      63 ± 5  52 ± 5  56 ± 4 
Temprect (0C) 
   STH-POL 38.1 ± 0.2 34.4 ± 0.1 37.4 ± 0.3 pw < 0.001, pg = 0.14, pi = 0.59 
   STH-2            38.6 ± 0.1 34.5 ± 0.2 37.7 ± 0.3 
Hb (g/dl) 
   STH-POL 6.0 ± 0.2 6.6 ± 0.2a 7.4 ± 0.3a,b pw < 0.001, pg = 0.077, pi = 0.008 
   STH-2           5.9 ± 0.1 7.6 ± 0.3a # 8.1 ± 0.3a # 
pH 
   STH-POL 7.43 ± 0.01 7.42 ± 0.01 7.42 ± 0.01 pw = 0.73, pg = 0.73, pi = 0.70 
   STH-2           7.44 ± 0.01 7.41 ± 0.02 7.42 ± 0.02 
pO2 (kPa) 
   STH-POL 12.9 ± 1.4 19.1 ± 1.5 18.3 ± 1.4 pw = 0.002, pg = 0.96, pi = 0.26 
   STH-2            15.2 ± 1.9 17.8 ± 1.5 17.1 ± 1.1 
pCO2 (kPa) 
   STH-POL 5.4 ± 0.1 6.1 ± 0.2 6.0 ± 0.2 pw < 0.001, pg = 0.77, pi = 0.74 
   STH-2            5.4 ± 0.2 6.1 ± 0.3 5.8 ± 0.2 
HCO3- (mmol/l) 
  STH-POL 26.6 ± 0.4 28.5 ± 0.4 27.9 ± 0.4 pw < 0.001, pg = 0.90, pi = 0.20 
  STH-2            27.3 ± 0.4 28.2 ± 0.4 27.7 ± 0.6 
s-K+ (mmol/l) 
   STH-POL 4.4 ± 0.1 3.9 ± 0.1a 4.5 ± 0.1b pw < 0.001, pg = 0.019, pi < 0.001 
   STH-2            4.4 ± 0.1 4.6 ± 0.1a # 4.8 ± 0.1a # 
s-Na+ (mmol/l) 
   STH-POL 141 ± 1  142 ± 1  142 ± 1  pw = 0.20, pg = 0.78, pi = 0.64 
   STH-2            142 ± 1  142 ± 1  142 ± 1 
MAP = mean aortic pressure; Temprect = rectal temperature; s = serum levels; pw, pg, pi = p-values for 
within subjects, between groups and for interaction from two-way RM-ANOVA, respectively. a and b: 
significant difference within group means from value(s) in columns with corresponding capital letters; 
# = significantly different from STH-POL at 58 min of X-clamp. 
 
 
Online Table 2. 
Diuresis, rectal temperature, haemoglobin, arterial blood gases and serum electrolytes at Baseline and 
60, 120 and 180 min after cardioplegic arrest in two groups of pigs with 60 min of polarising (STH-
POL) or depolarising (STH-2) cardioplegic arrest. Values are mean ± SE, n = 10. 
Variable     Time after aortic declamping and reperfusion 
                  Baseline 60 min  120 min 180 min 
Diuresis (ml/kg per h) 
   STH-POL   2.5 ± 0.3 6.3 ± 1.4 3.8 ± 0.8 3.8 ± 2.0 
   STH-2   2.5 ± 0.4 4.6 ± 1.3 3.9 ± 0.6 2.2 ± 0.5  
Temprect (0C) 
   STH-POL   38.1 ± 0.2 38.1 ± 0.1 38.3 ± 0.1 38.5 ± 0.1 
   STH-2   38.5 ± 0.2 38.2 ± 0.1 38.6 ± 0.1 38.7 ± 0.1  
Hb (g/dl) 
   STH-POL   8.2 ± 0.2 7.4 ± 0.4 7.2 ± 0.4 7.5 ± 0.4 
   STH-2   8.1 ± 0.2 7.6 ± 0.3 7.0 ± 0.3 6.9 ± 0.3 
pH 
   STH-POL   7.51 ± 0.01 7.45 ± 0.01 7.47 ± 0.01 7.47 ± 0.01 
   STH-2   7.50 ± 0.3 7.43 ± 0.02 7.48 ± 0.01 7.47 ± 0.02 
pO2 (kPa) 
   STH-POL   25.8 ± 0.9 20.4 ± 2.3 21.8 ± 1.3 21.9 ± 1.3 
   STH-2   25.6 ± 0.5 19.8 ± 1.9 21.0 ± 1.8 20.9 ± 1.7  
pCO2 (kPa) 
   STH-POL   5.2 ± 0.1 5.3 ± 0.2 5.2 ± 0.1 5.2 ± 0.1 
   STH-2   5.0 ± 0.1 5.7 ± 0.2 5.0 ± 0.1 5.1 ± 0.1 
HCO3- (mmol/l) 
   STH-POL   31.2 ± 0.2 27.6 ± 0.5 28.0 ± 0.6 28.4 ± 0.6 
   STH-2   31.2 ± 0.4 27.4 ± 0.8 27.9 ± 0.6 28.1 ± 0.7  
s-K+ (mmol/l) 
   STH-POL   3.7 ± 0.1 3.9 ± 0.1 4.1 ± 0.1 4.6 ± 0.1 
   STH-2   3.7 ± 0.1 4.2 ± 0.1 4.3 ± 0.2 4.4 ± 0.1 
s-Na+ (mmol/l) 
   STH-POL   142 ± 1  143 ± 1  143 ± 1  144 ± 1 



































Representative micrographs (x15.000) from a Control heart not on CPB and cardioplegic 
arrest and from the STH-POL and the STH-2 group 180 min after aortic declamping, 
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Abstract
OBJECTIVES: This study investigated whether the novel St. Thomas’ Hospital polarizing cardioplegic solution (STH-POL) with esmolol/ad-
enosine/magnesium offers improved myocardial protection by reducing demands for high-energy phosphates during cardiac arrest com-
pared to the depolarizing St. Thomas’ Hospital cardioplegic solution No 2 (STH-2).
METHODS: Twenty anaesthetised pigs on tepid cardiopulmonary bypass were randomized to cardiac arrest for 60min with antegrade
freshly mixed, repeated, cold, oxygenated STH-POL or STH-2 blood cardioplegia every 20min. Haemodynamic variables were continu-
ously recorded. Left ventricular biopsies, snap-frozen in liquid nitrogen or fixed in glutaraldehyde, were obtained at Baseline, 58min after
cross-clamp and 20 and 180min after weaning from bypass. Adenine nucleotides were evaluated by high-performance liquid chromatog-
raphy, myocardial ultrastructure with morphometry.
RESULTS: With STH-POL myocardial creatine phosphate was increased compared to STH-2 at 58min of cross-clamp [59.9 ± 6.4 (SEM) vs
44.5 ± 7.4 nmol/mg protein; P < 0.025], and at 20min after reperfusion (61.0 ± 6.7 vs 49.0 ± 5.5 nmol/mg protein; P < 0.05), ATP levels were
increased at 20min of reperfusion with STH-POL (35.4 ± 1.1 vs 32.4 ± 1.2 nmol/mg protein; P < 0.05). Mitochondrial surface-to-volume
ratio was decreased with polarizing compared to depolarizing cardioplegia 20min after reperfusion (6.74 ± 0.14 vs 7.46 ± 0.13mm2/mm3;
P = 0.047). None of these differences were present at 180min of reperfusion. From 150min of reperfusion and onwards, cardiac index was
increased with STH-POL; 4.8 ± 0.2 compared to 4.0 ± 0.2 l/min/m2 (P = 0.011) for STH-2 at 180min.
CONCLUSIONS: Polarizing STH-POL cardioplegia improved energy status compared to standard STH-2 depolarizing blood cardioplegia
during cardioplegic arrest and early after reperfusion.
Keywords: Cardioplegia • Myocardial protection • Energy metabolism • Ultrastructure
INTRODUCTION
Repeated hyperkalaemic blood cardioplegia, considered by many
to provide optimal myocardial protection, induces depolarization
and re-equilibration of the resting cell membrane potential. This
inactivates the voltage-dependent fast Na+channels [1], prevents
initiation of the action potential and induces depolarized diastolic
arrest. However, this will cause intracellular Na+ and Ca2+ overload
by activation of the Na+/H+-exchanger and reversal of the Na+/
Ca2+ exchanger; the resulting imbalance in cytosolic ion compos-
ition activates energy utilizing compensatory mechanisms [2].
By inducing ‘polarized’ (non-depolarized) arrest the myocyte
membrane potential is maintained at or near the resting mem-
brane potential [3]. In isolated hearts, polarized cardiac arrest re-
duces myocardial oxygen consumption compared to depolarized
arrest, probably as a result of reduced activation of energy-
dependent cellular ion channels/pumps, and hence further
reduced needs for high-energy phosphates (HEP) during cardiac
arrest [4]. The normokalaemic St. Thomas’ Hospital polarizing car-
dioplegic solution (STH-POL) with esmolol/adenosine/magnesium
avoids depolarized arrest and reduces the potassium load. A re-
cent experimental study demonstrated comparable myocardial
protection and improved postoperative contractility with STH-POL
cardioplegia compared to St. Thomas’ Hospital cardioplegic
†Preliminary results were presented as an abstract at the 8th Joint Scandinavian
Conference in Cardiothoracic Surgery, Reykjavik, Iceland, 19 August 2016.
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solution No 2 (STH-2) [5]. In the present study, using the same
clinically relevant porcine model, we investigated whether cardio-
plegic arrest with STH-POL offers myocardial protection compar-
able to a standard depolarizing potassium-based cardioplegic
solution (STH-2), with the main focus on tissue levels of HEP and
myocardial ultrastructure during aortic clamping and early and
late after weaning from cardiopulmonary bypass (CPB).
METHODS
Anaesthesia and instrumentation
The experiments were conducted in accordance with the
European Communities Council Directive of 2010 (63/EU) and
approved by the Norwegian State Commission for Laboratory
Animals (Project 20135835). Twenty-two pigs (Norwegian land
race) of either gender, weighing 42 ± 3 (SD) kg were premedi-
cated with an i.m. injection of ketamine, diazepam and atropine.
Spontaneous ventilation on mask with oxygen and 3% isoflurane
(Rhodia, Bristol, UK) allowed intravenous access through two ear
veins. Loading doses followed by continuous infusions of fen-
tanyl, midazolam, pentobarbital and pancuronium secured gen-
eral anaesthesia and analgesia. This anaesthetic protocol has
previously been described and thoroughly evaluated allowing the
safe use of neuromuscular blocking agents in young pigs [5, 6].
The animals were tracheotomized, intubated and ventilated
(Julian, Dr€agerwerk, Lübeck, Germany) with nitrous oxide
(56–58%) and oxygen. Fluid substitution was Ringers acetate
(15ml/kg/h) with added KCl (20mmol/l) to maintain normal
plasma potassium levels after overnight fasting. In addition,
Ringers acetate 5 ml/kg/h was provided after weaning from CPB.
The right femoral artery and vein were cannulated for blood
sampling and infusion. An arterial blood gas analysis determined
the need for ventilator adjustments (ABL80 FLEX COOX,
Radiometer Medical ApS, Brønshøj, Denmark). A surgically in-
serted catheter measured diuresis and rectal temperature was
monitored. A midline sternotomy and pericardiotomy exposed
the heart and heparin (125 IU/kg) was given i.v. to prevent cath-
eter clotting. A continuous cardiac output catheter (CCO/EDV
177HF 75, Edwards Lifesciences Inc., Irvine, CA) was floated into
the pulmonary artery via the left internal mammary vein. Cardiac
output, right ventricular end-diastolic volume, central venous pres-
sure (CVP) and pulmonary artery pressure (PAP) (Vigilance IIVR and
TruWaveVR transducers, Edwards Lifescience Inc.) were monitored.
The proximal aorta was cannulated with a Millar microtip pressure
catheter (Millar MPC-500, Houston, TX, USA) through the left in-
ternal mammary artery. An identical catheter through the apex of
the heart monitored left ventricular pressure. The haemodynamic
parameters were recorded by a 16-channel Ponemah (ACQ-7700;
Data Sciences International, St. Paul, MN, USA).
Cardiopulmonary bypass and cardioplegia
The heart–lung machine (Stöckert SIII, Munich, Germany) was
primed with 1200ml Ringers acetate. Heparin 500 IU/kg i.v. was
given before the brachiocephalic artery (EOPA 18 Fr, Medtronic
Inc., Minneapolis, MN, USA) and right atrial appendage (MC2 28/
36 Fr, Medtronic Inc.) were cannulated and CPB established with
a flow of 90 ml/min per kg and water temperature of 32!C in the
heat exchanger. Aortic cross-clamp time was 60min and a vent
catheter (DLP 13, Medtronic Inc.) temporarily placed through the
apex for left ventricular drainage. The body temperature was
allowed to drift and CPB flow was reduced to 72 ml/min per kg
when rectal temperature reached 35!C or after 20min. After
40min of cross-clamping, rewarming was initiated with reset of
CPB-flow to 90 ml/min per kg and water temperature at 40!C.
Arterial blood gases were obtained before aortic cross-clamping
and just before declamping after 60min. Defibrillation of ven-
tricular fibrillation was the only allowed antiarrhythmic interven-
tion. After 10min of reperfusion the animals were weaned from
CPB and decannulated. The residual blood in the circuit was re-
turned and protamine sulphate 1.5mg/kg was given.
Cardioplegia was given as either the hyperkalaemic St. Thomas’
Hospital cardioplegic solution 2 (STH-2), or the normokalaemic
St. Thomas’ Hospital polarizing solution (STH-POL). Both solutions
were pre-prepared as concentrate and administered as cold
(12!C), oxygenated, blood cardioplegia, freshly mixed by a dual-
head pump and separate cooling. The cardioplegia was delivered
into the aortic root with a flow set to 7% of CPB-flow, following a
standardized protocol with an initial ‘high-dose’ (1:4 concentrate/
blood) for 3 min and 2min of ‘low-dose’ (1:8 concentrate/blood)
given at 20 and 40min after cross-clamping. The final concentra-
tions of key components in the cardioplegic solutions are pre-
sented in the Supplementary Material, Table A.
Experimental protocol
The animals were block-randomized to the STH-POL or STH-2
group (10 per group). After 10min of stabilization Baseline arter-
ial blood gases and haemodynamic variables were recorded. Two
myocardial biopsies from the anterior left ventricular wall were
obtained by using 6 and 4mm biopsy punch (Integra Miltex,
York, PA, USA). Both samples included tissue from the epi- and
midmyocardium; the 6-mm biopsy was snap-frozen in liquid ni-
trogen within 5 s and stored at -80!C for later analysis while the
4-mm biopsy was cut and fixed directly in glutaraldehyde.
During CPB the ventilator volume was reduced to 50% and with
passive drainage of the left ventricle. Additional heparin (250 IU/
kg) was given at 30min of cross-clamping. After 58min of cardio-
plegic arrest, myocardial biopsies were obtained and 2min later
the aortic clamp was removed. The animals were weaned from
CPB after 10min of myocardial reperfusion and decannulated.
Twenty and 180min after declamping myocardial biopsies were
taken similar to the Baseline situation. General haemodynamics
were recorded every 15min, from 30 to 180min after declamping.
Finally, the animal was euthanized with intracardiac injection of
high dose potassium chloride, the heart removed and samples ob-
tained for complimentary analysis.
Myocardial metabolism and ultrastructure
High energy phosphates [ATP, ADP, AMP and creatine phosphate
(CrP)], hypoxanthine and xanthine were measured by high-
performance liquid chromatography analysis as previously
described [7]. Energy charge (EC) was calculated as:
EC ¼ [ATP] + 0:5 * [ADP]
[ATP] + [ADP] + [AMP]
Myocardial volume fraction of mitochondria, myofibrils and
cytosol were quantified by point counting in 6 randomly selected
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to volume ratio and surface density were calculated by using a
Merz grid and the freeware ImageJ [8]. To evaluate inter- and
intra-observer variability, the 6 micrographs from 15 randomly
selected biopsies were recorded and analysed individually by
two observers and by one of the observers twice. For details see
Supplementary Material.
Statistical analysis
Data were analysed using SPSS v. 23 (IBM Corp., Armonk, NY,
USA) and values given as mean ± SEM or median (25% percentile;
75% percentile) unless otherwise noted. At Baseline groups were
compared by two-sample Student t-test on data with normal dis-
tribution and with Wilcoxon–Mann–Whitney test on ranks when-
ever appropriate. Tissue contents of HEPs, degradation products
and haemodynamic variables after aortic declamping were com-
pared with two-way ANOVA for repeated measurements (RM-
ANOVA) with treatment as group factor (Pg), time as within factor
(Pw) and Pi for interaction between time and group.
Morphological variables were analysed with nested RM-ANOVA.
P < 0.05 was considered statistically significant. The intraclass cor-
relation coefficient (ICC) and coefficient of variation (CV%) for
inter- and intra-observer variability were calculated for morpho-
metric data. For details see Supplementary Material.
RESULTS
Two animals were excluded. After declamping, one animal in the
STH-POL group with profound bleeding and ventricular fibrilla-
tion prior to cross-clamp developed severe left heart failure, one
animal in the STH-2 group developed severe pulmonary hyper-
tension and right heart failure. Excluded animals were replaced
by consecutive experiments. Results are given for 10 animals in
each group, except for morphometry where the biopsies from
one STH-2 animal were lost. Haemodynamic variables, left ven-
tricular function and arterial blood gases did not differ between
groups at Baseline (Fig. 1A–F and Table 1). After 58min of cardio-
plegic arrest, the level of serum potassium was significantly
increased in the STH-2 compared to the STH-POL group
(5.2 ± 0.3 vs 4.1 ± 0.1mmol/l, P < 0.001). During CPB there were
no other differences between groups regarding mean arterial
pressure, temperatures and arterial blood gases (Supplementary
Material, Table B).
Cardiac and haemodynamic variables after
weaning
Heart rate increased over time in both groups after weaning
(Fig. 1A). In both groups, cardiac index (CI) was initially increased
from Baseline but subsequently decreased to a plateau level by
90min; there were no differences between groups during this
period. At 150, 165 and 180min after declamping, CI was
increased in the STH-POL compared to the STH-2 group
(P = 0.036, P = 0.026 and P = 0.011, respectively) (Fig. 1B). Left ven-
tricular systolic pressure was unchanged and left ventricular end-
diastolic pressure decreased gradually after declamping in both
groups (Fig. 1C and D). The first derivative of the left ventricular
pressure, LV-dP/dtmax, did not change significantly over time (Fig.
1E). LV-dP/dtmin was less negative in the STH-POL group after
30min (P = 0.006) and 45min (P = 0.048) of reperfusion
compared to corresponding values in the STH-2 group (Fig. 1F).
Right ventricular indexed end-diastolic volume (RV-EDVi) and
ejection fraction (RV-EF) did not change over time (Table 2).
Indexed stroke volume (RV-SVi) decreased from 60 to 120min of
reperfusion (P < 0.001) for both groups. Central venous pressure
(CVP) gradually increased over time (Pw=0.030) in both groups.
There were no significant differences between groups regarding
mean arterial pressure and pulmonary arterial pressure.
Myocardial high-energy phosphates
At Baseline there were no significant differences between groups
for myocardial CrP, adenine nucleotides and the degradation
products hypoxanthine and xanthine (Fig. 2A–F). CrP was signifi-
cantly increased in hearts arrested with STH-POL compared to
STH-2 after 58min of cardiac arrest (59.9 ± 6.4 vs 44.5 ± 7.4 nmol/
mg protein; P < 0.025) and after 20min of reperfusion (61.0 ± 6.7
vs 49.0 ± 5.5 nmol/mg protein; P < 0.05). However, at 180min
after declamping, the CrP content did not differ between groups
(Fig. 2A). At 20min of reperfusion tissue ATP content was
increased in the STH-POL compared to the STH-2 group
(P < 0.05) (Fig. 2B). Tissue levels of ADP increased from Baseline
to 58min after cardiac arrest in both groups (P < 0.001) and
decreased to Baseline levels (P < 0.001) after 20 and 180min of
reperfusion (Fig. 2C). AMP levels increased in both groups from
Baseline to 58min of cardiac arrest (P < 0.01) and did not de-
crease after reperfusion (Fig. 2D). The level of hypoxanthine
increased significantly (P < 0.001) in the STH-POL group, and re-
mained increased at the same level at 20min after declamping
(Fig. 2E). After 180min hypoxanthine levels decreased to Baseline
levels (P < 0.001). Xanthine levels did not differ between groups
and did not change with time (Fig. 2F). There was an overall
change in energy charge (EC) over time (Pw=0.025) with no
group differences (Table 3). However, multiple contrast tests
could not confirm differences between individual time points.
The ATP/ADP ratio (pooled means, n = 20) decreased from
Baseline to 58min of cross-clamping (P < 0.001) and returned to
Baseline levels after 20 and 180min of reperfusion. The CrP/ATP
ratio was unchanged.
Mitochondrial ultrastructure
Mitochondrial surface-to-volume ratio (SVratiomit) was slightly
decreased in the STH-POL compared to the STH-2 group at
20min after reperfusion (6.74 ± 0.14 vs 7.46 ± 0.13 mm2/mm3;
P = 0.047) (Fig. 3A). None of these differences were present at
180min of reperfusion. Neither mitochondrial surface density
(SVmit) nor the myocyte volume fractions of mitochondria, myo-
fibrils and cytosol differed between groups (Fig. 3B and Table 4).
For the fractional volumes the interobserver ICC varied between
0.741 and 0.897 with a CV% between 2.48% for myofibrils and
8.14% for sarcoplasma (Table 5). For mitochondrial surface to
volume ratio the interobserver ICC was 0.790 with a CV% of
4.05%. Based on ICC calculations, both the inter- and intra-
observer variabilities for morphometric data were classified as
good to excellent, except for the intra-observer ICC for volume
fraction of sarcoplasma [9].
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DISCUSSION
A transient improvement in energy status with STH-POL cardio-
plegia was demonstrated as an increase in the myocardial tissue
content of CrP after 58min of cardioplegic arrest and at 20min
after reperfusion and weaning from CPB compared to STH-2 car-
dioplegia. Also, tissue ATP content was increased at 20min after
reperfusion (Fig. 2A and B).
One of the components of the STH-POL cardioplegia is adeno-
sine, an endogenous purine nucleoside binding to the A1
receptor. Adenosine reduces cAMP by inhibiting adenylyl cyclase
and thereby acts as a KATP-channel opener. This causes outward
K+flux and induces polarized cardiac arrest. The polarization ef-
fect is especially seen on myocardial conductive tissue such as
the atrioventricular node [10]. Esmolol is a cardio-selective beta1
adrenergic receptor blocker with rapid onset by blocking the fast
Na+ - and L-type Ca2+-channels initiating polarized arrest [11].
Clinically, esmolol seems to give protection from arrhythmias
and is protective in a vulnerable period [12]. In clinically relevant
animal studies esmolol as pre-treatment or as adjuvant to
Figure 1: Left ventricular haemodynamic variables, mean (SE) or median (25%; 75%), at Baseline and after CPB and 60min of cardiac arrest with polarizing (STH-POL;
n = 10) and depolarizing (STH-2; n =10) cardioplegia. CI: cardiac index; LVSP and LVEDP: left ventricular peak systolic- and end-diastolic pressures; dP/dtmax and dP/
dtmin:peak positive and peak negative of the first derivative of left ventricular pressure; RM-ANOVA: analysis of variance for repeated measurements; Pw, Pg and
Pi:P-values for within subjects, between groups and interaction from two-way RM-ANOVA, respectively; #: significantly different from STH-2 at corresponding time
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potassium-based oxygenated blood cardioplegia improves left
ventricular contractility after weaning from CPB [13, 14]. Both ad-
enosine (T1=2$30 s) and esmolol (T1=2$9min) have short half-lives
and the elimination does not depend on hepatic or kidney
function [15]. These two arresting agents act synergistically, re-
sulting in the desired effect at relatively low but effective concen-
trations, while minimizing potential adverse effects. Magnesium,
included in comparable concentrations both in the STH-POL and
Table 1: Baseline variables before cardiac arrest with polarizing (STH-POL) and depolarizing (STH-2) cardioplegia
Variable STH-POL STH-2 Statistics
HR (beats/min) 100 ± 6 91 ± 3 P = 0.23
LV-SPmax (mmHg) 92 ± 4 98 ± 3 P = 0.31
LV-EDP (mmHg) 7.1 ± 1.1 7.8 ± 0.7 P = 0.62
LV-dP/dtmax (mmHg/s) 1304 (1066; 1611) 1133 (1084; 1645) P = 0.85
LV-dP/dtmin (mmHg/s) -1638 (-1864; -1568) -1763 (-1871; -1732) P = 0.12
CI (L/min per m2) 3.8 ± 0.1 3.7 ± 0.2 P = 0.85
s (ms) 31.4 ± 1.1 31.9 ± 1.2 P = 0.76
RV-EDVi (ml/m
2) 132 ± 5 132 ± 5 P = 0.97
RV-EF (%) 32 ± 2 34 ± 2 P = 0.44
MAP (mmHg) 79 ± 4 88 ± 3 P = 0.092
CVPmean (mmHg) 7.3 ± 0.7 6.7 ± 0.7 P = 0.51
PAPmean (mmHg) 17.8 ± 0.9 17.2 ± 0.8 P = 0.61
Arterial blood gases
pH 7.50 ± 0.01 7.50 ± 0.01 P = 0.94
pCO2 (kPa) 5.42 ± 0.08 5.28 ± 0.08 P = 0.23
HCO3 - (mmol/l) 31.1 ± 0.5 30.1 ± 0.3 P = 0.10
BE (mmol/l) 7.3 ± 0.5 6.4 ± 0.3 P = 0.15
pO2 (kPa) 27.0 ± 0.3 27.4 ± 0.3 P = 0.41
Hb (g/dl) 7.7 ± 0.2 8.2 ± 0.5 P = 0.41
s-Na+ (mmol/l) 140 ± 1 141 ± 1 P = 0.22
s-K+ (mmol/l) 3.5 ± 0.1 3.6 ± 0.1 P = 0.74
s-Cl- (mmol/l) 102 (102; 103) 103 (101; 103) P = 0.76
Values are mean± SEM or median (25-percentile; 75-percentile), n= 10.
LV and RV: left and right ventricle; HR: heart rate; SPmax and EDP: peak systolic and end-diastolic pressure; dP/dtmax and dP/dtmin: peak positive and peak nega-
tive of the first derivative of left ventricular pressure; CI: cardiac index; EF: ejection fraction; EDVi: end-diastolic volume indexed for body surface area; MAP:
mean arterial pressure; CVPmean: mean central venous pressure; PAPmean: mean pulmonary artery pressure; P: P-values from two-sample t-tests or Mann–
Whitney Rank Sum Tests.
Table 2: Cardiac and haemodynamic variables 60, 120 and 180min after aortic declamping following 60min of polarizing (STH-
POL) or depolarizing (STH-2) cardioplegic arrest
Variable 60min 120min 180min RM-ANOVA statistics
RV-EDVi (ml/m
2)
STH-POL 116 ± 5 110 ± 4 105 ± 7 Pw = 0.24, Pg = 0.082, Pi = 0.83
STH-2* 128 ± 5 123 ± 7 121 ± 11
RV-SVi (ml/m
2)
STH-POL 37 ± 2 32 ± 2 34 ± 1 Pw < 0.001, Pg = 0.46, Pi = 0.10
STH-2* 41 ± 2 35 ± 2 32 ± 2
RV-EF (%)
STH-POL 32 ± 2 29 ± 2 34 ± 2 Pw = 0.12, Pg = 0.32, Pi = 0.085
STH-2* 33 ± 2 29 ± 2 27 ± 2
MAP (mmHg)
STH-POL 67 ± 5 69 ± 8 63 ± 5 Pw = 0.49, Pg = 0.34, Pi = 0.42
STH-2 76 ± 3 69 ± 3 71 ± 4
CVPmean (mmHg)
STH-POL 9.1 ± 0.6 9.8 ± 0.9 10.0 ± 0.8 Pw = 0.030, Pg = 0.52, Pi = 0.56
STH-2 8.4 ± 0.8 8.6 ± 1.1 9.7 ± 1.0
PAPmean (mmHg)
STH-POL 25 ± 2 26 ± 2 25 ± 2 Pw = 0.25, Pg = 0.50, Pi = 0.74
STH-2 23 ± 2 25 ± 2 24 ± 2
Values are mean ± SEM for 10 animals in each group (*n = 9).
RV: right ventricle; i: value indexed for body surface area; EDV: end-diastolic volume; SV: stroke volume; EF: ejection fraction; MAP: mean arterial pressure;
CVPmean: mean central venous pressure; PAPmean: mean pulmonary artery pressure. Pw, Pg and Pi: P-values for within subjects, between groups and interaction
from two-way RM-ANOVA, respectively.
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the STH-2 cardioplegia used in the present study supresses intra-
cellular Ca2+overload during cardioplegia [16].
Mitochondrial creatine kinase present in the mitochondrial
intermembrane space regenerates CrP from creatine imported
from the cytosol and mitochondrial ADP. In the cytosol CrP
serves as an energy reservoir for the rapid buffering and regener-
ation of ATP in situ, as well as for intracellular energy transport
by the phosphocreatine shuttle or circuit [17, 18]. Our finding in-
dicates a decrease in consumption of CrP during the 60min of
cardioplegic arrest and early reperfusion in the STH-POL group
(Fig. 2A). When reperfusion and contraction is re-established, the
differences between groups fade with time.
Since contraction is ceased during cardioplegic arrest in both
groups, the difference in CrP consumption is probably related to
reduced energy consumption with polarizing cardioplegia for
maintaining intracellular ion balance. For STH-2 cardioplegia
intracellular Na+and Ca2+overload occurs as a result of extracel-
lular hyperkalaemia. The energy dependent ion channel pumps
in the cellular membrane, Na+/K+-ATPase, Ca2+ channels and the
sarcoplasmic Ca2+ channel are active in correcting the imbalance
Figure 2: Myocardial tissue levels of creatine phosphate, high energy phosphates and degradation products at Baseline, after 58min of cardiac arrest with polarizing
(STH-POL) and depolarizing (STH-2) cardioplegia, and 20 and 180min after aortic declamping and reperfusion, n = 10 in both groups. CrP: creatine phosphate; ATP,
ADP and AMP: adenosine tri-, di- and monophosphate. Pw, Pg and Pi: P-values for within subjects, between groups and interaction from two-way RM-ANOVA, re-
spectively; *: significantly different from the previous value in the STH-POL group; #: significantly different compared to STH-2 at the corresponding time after
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in cytosolic ion composition. Since the Na+and Ca2+overload is
not prominent with polarizing cardiac arrest, these ion pumps
are less active during the phase of cardioplegic arrest. As a conse-
quence the requirement for CrP to rephosphorylate ADP to
maintain ATP levels is less pronounced (Fig. 2A). In addition, CrP
also stabilizes the membrane phospholipid bilayer by binding to
the polar heads and decreasing membrane fluidity. Stabilizing
the membrane attenuates some of the damage caused by transi-
ent ischaemia and hypoxia and helps to prevent cytoplasmic
leakage [1, 4, 17].
The consumption of ATP resulted in an increase in both tissue
ADP and AMP after 58min of cardioplegic arrest in both groups.
The degradation product hypoxanthine is increased both during
arrest and at 20min after declamping and reperfusion in the
STH-POL compared to the STH-2 group. The surplus myocardial
hypoxanthine in the STH-POL group is washed out with time
during reperfusion and not oxidized to xanthine due to minimal
levels of xanthine oxidase in the pig heart [19].
The decrease in surface-to-volume ratio of mitochondria at
20min after reperfusion and declamping with STH-POL cardio-
plegia, indicates a temporary mitochondrial swelling (Fig. 3A).
Mitochondrial swelling can be observed as early as 10min after
regional myocardial ischaemia [20]. Judged from the tissue levels
of HEP, there were no signs of a more severe ischaemia in the
STH-POL group than the STH-2 group. We speculate that this
could be a result of transient differences in intracellular ionic
composition and osmolality. Cytoplasmic volume fractions of cel-
lular components did not differ (Table 4).
Transient differences were observed for energy metabolism and
morphology at the end of the ischaemic period and at 20min after
declamping and reperfusion. Cardiac index was increased in the
STH-POL compared to the STH-2 group from 150min of reperfu-
sion and onwards (Fig. 1B). This improved function could be inter-
preted as a reduction of the ischaemia/reperfusion injury, reduced
myocardial stunning or alleviated adrenergic desensitization with
STH-POL compared to STH-2 cardioplegia. In the present study
myocardial injury was not evaluated. However, with a similar
protocol in a recent study showed that STH-POL cardioplegia did
not affect the release of troponin-T or myocardial caspase-3 activ-
ity as a sign of apoptosis [5]. Whether the transient differences in
energy metabolism indicate a reduction of reversible myocardial
Table 3: Energy status in myocardial tissue at Baseline, after 58min of cardioplegic arrest with STH-POL or STH-2 cardioplegia; and
20 and 180min after declamping and weaning from CPB
Baseline 58min 20min 180min RM-ANOVA
Cross-clamp reperfusion reperfusion
Energy charge
STH-POL 0.89 ± 0.01 0.88 ± 0.01 0.90 ± 0.01 0.89 ± 0.01 Pw = 0.025, Pg = 0.75, Pi = 0.32
STH-2 0.90 ± 0.01 0.87 ± 0.01 0.88 ± 0.01 0.90 ± 0.01
ATP/ADP
STH-POL 5.10 ± 0.29 4.66 ± 0.25 5.25 ± 0.32 5.11 ± 0.30 Pw = 0.009, Pg = 0.84, Pi = 0.17
STH-2 5.73 ± 0.35 4.48 ± 0.37 4.82 ± 0.34 5.35 ± 0.27
CrP/ATP
STH-POL 1.57 ± 0.11 1.68 ± 0.16 1.69 ± 0.16 1.70 ± 0.15 Pw = 0.28, Pg = 0.36, Pi = 0.16
STH-2 1.65 ± 0.15 1.26 ± 0.20 1.48 ± 0.13 1.60 ± 0.12
Mean ± SEM, n = 10.
Energy charge (EC) calculated as: EC = (ATP + 0.5 ADP)/(AMP +ADP +ATP).
ATP and ADP: adenosine tri- and diphosphate; CrP: creatine phosphate. Pw, Pg and Pi: P-values for within subjects, between groups and interaction from two-
way RM-ANOVA, respectively.
Figure 3:Myocyte mitochondrial surface to volume ratio (Svratiomit) (A) and surface
density (SVmit) (B) in 10 animals in the STH-POL group and 9 animals in the STH-2
group. Bars are mean+SEM. Pw, Pg and Pi:P-values for within subjects, between
groups and interaction from two-way nested ANOVA, respectively; #: significantly
different from STH-2 at 20min after declamping. One micrograph from each group
with morphometric readings close to mean values at 20min after declamping.
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injury appearing as increased cardiac index after 150min, cannot
be answered by this study.
Limitations
The study is performed in young pigs with healthy hearts. Both
the ischaemic time of 60min and the 180min of observation
after declamping and weaning from CPB are relatively short.
With regard to the development of myocardial stunning, the ob-
servation after weaning may have been extended. On the other
hand, the stability of the experimental protocol is also of import-
ance. The results in the present study could be directly compared
with a recent and similar study focusing on left ventricular func-
tion [5]. The serial tissue biopsies obtained demanded an infre-
quent need for a haemostatic myocardial suture. For this reason,
troponin-T was not evaluated in this study.
CONCLUSION AND IMPLICATIONS
These results demonstrate an improved energy status with polar-
izing oxygenated blood cardioplegia with esmolol/adenosine/
magnesium (STH-POL) compared to the standard potassium-
based depolarizing blood cardioplegia (STH-2) during 60min of
cardioplegic arrest and at early reperfusion. Myocardial function
was improved from 150min after reperfusion and onwards.
Comparable results should be obtained in clinical trials before
implementation into a new clinical routine.
SUPPLEMENTARY MATERIAL
Supplementary material is available at EJCTS online.
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Online Table A. 
Final molar concentrations in oxygenated blood cardioplegia. 
     STH-POL    STH-2 
    High-dose Low-dose       High-dose      Low-dose 
       3 min               2 min                          3 min              2 min 
Esmolol (mM)   1.35  0.68     -    - 
Adenosine (mM)  0.50   0.25     -    - 
Mg2+ (mM)   20         10   16    9 
K+ (mM)   4.3  4.3   22  14 
Cl- (mM)   106  106   134  120 
Procaine-HCl (mM)   0.8  0.4    0.8  0.4 
STH-POL = St.Thomas´ Hospital polarizing cardioplegic solution. 
STH-2 = St.Thomas´ Hospital cardioplegic solution No 2. 
 
 
Analysis of myocardial metabolism 
Frozen tissue samples averaging 65 mg, were homogenized with a micro-dismembranator and 
deproteinized with 500µL of 0.4 mol/L perchloric acid. After centrifugation (12000g) 200 µL of the 
acid extract was neutralized with 20-25 µL of 2 mol/L potassium carbonate (4°C). The supernatant 
(20µL injection volume) obtained after centrifugation was used for high-performance liquid 
chromatography (HPLC) analysis. The pellets of the acid extract were dissolved in 1 mL of 0.1 mol/L 
sodium hydroxide and further diluted 1:10 with physiologic saline for protein determination (BCA 
Protein Assay, Pierce). High energy phosphates (ATP, ADP, AMP and creatine phosphate), 
hypoxanthine and xanthine were measured by HPLC. Separation was performed on a Hypersil ODS 
column (5µm, 250 mm x 4 mm I.D.) using a L-2200 autosampler, two L-2130 HTA pumps and a L-
2450 diode array detector (all: VWR Hitachi, Radnor, PA). Detector signals (absorbance at 214 nm 
and 254 nm) were recorded and the program EZchrom Elite (VWR Hitachi) was used for data 
acquisition and analysis. 
Analysis of ultrastructure 
Myocardial biopsies were fixed overnight in 0.1 mol/L Na-cacodylate buffer with 2.5% 
glutaraldehyde, washed, post-fixated with 1% OsO4, dehydrated and stored in 70% ethanol, sectioned 
and stained with uranyl acetate. Sections were visualized by transmission electron microscope (JEM-
1230, Jeol, Tokyo, Japan) and images acquired using a 1 MP gatan camera. The scanning electron 
microscopy images were acquired with microscope (JSM-7400F, Jeol). Myocardial volume fraction of 
mitochondria, myofibrils and cytosol were quantified by point counting with a grid (9 x 9 points, 
random offset) in 6 randomly selected micrographs (x 15.000) from each biopsy, mitochondrial 
surface to volume ratio and surface density were calculated by counting mitochondrial points and 
membrane crossings using a Merz grid (random offset, random phase) and the freeware ImageJ.  
 
The results are based on a total of 456 micrographs and 36936 points (crosses for illustration) counted 
to calculate of volume fractions (left). For mitochondrial surface-to-volume ratio and surface density 
calculations, a total of 34629 points within the mitochondria and 44310 line crossings of the 
mitochondrial outer membrane were counted (right). For the Merz grid mitochondria crossing beyond 
the lower horizontal and the right vertical edges (red) of the micrographs were not included. 
 
Statistical analysis 
At Baseline groups were compared by two-sample Student t-test on data with normal distribution and 
with Wilcoxon-Mann-Whitney test on ranks if the Kolmogorov-Smirnov test or the Levene equal 
variance tests were significant. Variables describing tissue contents of HEPs, degradation products and 
haemodynamic variables after aortic declamping were compared with two-way ANOVA for repeated 
measurements (RM-ANOVA) with time as within factor (Pw) and cardioplegia with STH-POL or 
STH-2 as grouping factor (Pg) and post hoc Bonferroni contrasts. If Mauchly´s test of sphericity was 
significant (P < 0.05), the Greenhouse-Geisser adjustment of degrees of freedom was used for the 
evaluation of main effects. If a significant interaction (Pi < 0.10) was found, new ANOVA`s for 
simple main effect were performed with adjustment of degrees of freedom. Cell means were finally 
compared with Neumann-Keuls multiple contrast tests when justified by the preceding ANOVA. The 
morphological variables were analysed with a nested RM-ANOVA with 6 micrographs from each 
biopsy and 4 different biopsies (time) from each animal. P < 0.05 was considered statistically 
significant. The Intraclass correlation coefficient (ICC) and Coefficient of variation (CV%) for inter- 





Online Table B. 
Mean arterial pressure, temperature, haemoglobin, arterial blood gases and electrolytes during 
cardiopulmonary bypass in two groups of pigs with 60 min of polarizing (STH-POL) or depolarizing 
(STH-2) cardioplegic arrest. Values are mean ± SEM, n = 10. 
 
Variable 1 min before 30 min  58 min  RM-ANOVA statistics 
  X-clamp X-clamp X-clamp 
             (A)    (B)     (C) 
MAP (mmHg) 
   STH-POL 55 ± 6  45 ± 5  41 ± 4  Pw = 0.39, Pg = 0.64, Pi = 0.14 
   STH-2      48 ± 6  47 ± 3  52 ± 3 
Temprect (0C) 
   STH-POL 38.2 ± 0.2 34.5 ± 0.2 37.4 ± 0.3 Pw < 0.001, Pg = 0.68, Pi = 0.62 
   STH-2            38.5 ± 0.2 34.4 ± 0.1 37.4 ± 0.2 
Arterial blood gases (n = 9 + 9)    
Hb (g/dL) 
   STH-POL 6.0 ± 0.3   7.1 ± 0.4  Pw < 0.001, Pg = 0.29, Pi = 0.32 
   STH-2           6.1 ± 0.3   7.9 ± 0.4  
pH 
   STH-POL 7.45 ± 0.01   7.41 ± 0.01 Pw = 0.024, Pg = 0.23, Pi = 0.19 
   STH-2           7.42 ± 0.01               7.41 ± 0.01         
pO2 (kPa) 
   STH-POL 16.5 ± 2.0   18.0 ± 2.0  Pw = 0.19, Pg = 0.29, Pi = 0.49 
   STH-2            13.2 ± 1.6               18.0 ± 1.9  
pCO2 (kPa) 
   STH-POL 5.6 ± 0.1   6.5 ± 0.2 Pw = 0.003, Pg = 0.76, Pi = 0.06 
   STH-2            6.0 ± 0.3               6.2 ± 0.2   
HCO3- (mmol/L) 
  STH-POL 28.6 ± 0.7   30.1 ± 0.5 Pw = 0.037, Pg = 0.43, Pi = 0.21 
  STH-2            28.5 ± 0.6   28.9 ± 0.7  
s-K+ (mmol/L) 
   STH-POL 4.0 ± 0.1   4.1 ± 0.1 Pw = 0.005, Pg = 0.010, Pi = 0.013 
   STH-2            4.2 ± 0.2   5.2 ± 0.3a #  
s-Na+ (mmol/L) 
   STH-POL 139 ± 1    139 ± 1  Pw = 0.80, Pg = 0.85, Pi = 0.94 
   STH-2            139 ± 1    139 ± 1 
MAP = mean aortic pressure; Temprect = rectal temperature; s = serum levels; Pw, Pg, Pi = p-values for 
within subjects, between groups and for interaction from two-way RM-ANOVA, respectively; a = 
significant different within the same group mean from value in columns with corresponding capital 
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Depolarized cardioplegic arrest with repeated adminis-
tration of hyperkalaemic solutions has been used for 
decades in cardiothoracic surgery.1 Hyperkalaemic crys-
talloid solutions with intracellular (low sodium) or extra-
cellular (high sodium) composition administered once 
are also established routines in clinical practice.2,3 The 
most widely used cardioplegia worldwide is hyperkalae-
mic solutions given intermittently as cold crystalloid or 
oxygenated blood cardioplegia.4,5 Various normokalae-
mic, substrate-enriched cardioplegic solutions have been 
evaluated after continuous, intermittent or single-dose 
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Abstract
Introduction: This experimental study compares myocardial function after prolonged arrest by St. Thomas’ Hospital 
polarizing cardioplegic solution (esmolol, adenosine, Mg2+) with depolarizing (hyperkalaemic) St. Thomas’ Hospital No 2, 
both administered as cold oxygenated blood cardioplegia.
Methods: Twenty anaesthetized pigs on tepid (34°C) cardiopulmonary bypass (CPB) were randomised to cardioplegic 
arrest for 120 min with antegrade, repeated, cold, oxygenated, polarizing (STH-POL) or depolarizing (STH-2) blood 
cardioplegia every 20 min. Cardiac function was evaluated at Baseline and 60, 150 and 240 min after weaning from CPB, 
using a pressure-conductance catheter and epicardial echocardiography. Regional tissue blood flow, cleaved caspase-3 
activity and levels of malondialdehyde were evaluated in myocardial tissue samples.
Results: Preload recruitable stroke work (PRSW) was increased after polarizing compared to depolarizing cardioplegia 
150 min after declamping (73.0±3.2 vs. 64.3±2.4 mmHg, p=0.047). Myocardial tissue blood flow rate was high in both 
groups compared to the Baseline levels and decreased significantly in the STH-POL group only, from 60 min to 150 min 
after declamping (p<0.005). Blood flow was significantly reduced in the STH-POL compared to the STH-2 group 240 min 
after declamping (p<0.05). Left ventricular mechanical efficiency, the ratio between total pressure-volume area and blood 
flow rate, gradually decreased after STH-2 cardioplegia and was significantly reduced compared to STH-POL cardioplegia 
after 150 and 240 min (p<0.05 for both).
Conclusion: Myocardial protection for two hours of polarizing cardioplegic arrest with STH-POL in oxygenated blood is 
non-inferior compared to STH-2 blood cardioplegia. STH-POL cardioplegia alleviates the mismatch between myocardial 
function and perfusion after weaning from CPB
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administration. This alternative concept, polarized arrest, 
has several potential advantages, proven in both experi-
mental and clinical studies.6–9 Still, the use of polarized 
cardioplegic arrest is not widely established clinically.
In a porcine study, the normokalaemic St. Thomas’ 
Hospital polarizing cardioplegic solution (STH-POL), 
formulated with a mixture of the short-acting β-
adrenergic blocker esmolol, adenosine and Mg2+, 
improves myocardial contractility after 60 min of car-
dioplegic arrest compared to the standard depolarizing 
St. Thomas’ Hospital cardioplegic solution No 2 (STH-
2).10 Esmolol, adenosine and Mg2+ each target ion chan-
nels in the myocyte cellular membrane, thus, preventing 
rapid depolarization and triggering of the action poten-
tial.11 Furthermore, STH-POL blood cardioplegia 
improves myocardial energy status compared to STH-2 
blood cardioplegia just before and early after aortic dec-
lamping following 60 min of cardioplegic arrest.12 The 
aim of the present study was to compare STH-POL and 
STH-2 oxygenated blood cardioplegia in an experimen-
tal setting with prolonged (120 min) myocyte mem-
brane polarization or depolarization, with clear 
differences in total potassium load. In this clinically rel-
evant animal study, left ventricular function was evalu-
ated and compared up to 4 hours after 120 min of 
cardioplegic arrest. We hypothesize that the experimen-
tal STH-POL cardioplegic solution is non-inferior com-
pared to STH-2 with respect to myocardial function in 
the early hours after aortic declamping.
Methods
The experiments were conducted in accordance with 
the European Communities Council Directive of 2010 
(63/EU) and approved by the Norwegian State 
Commission for Laboratory Animals (Project 
20135835). Twenty-eight anaesthetized young pigs 
(Norwegian Landrace) of either gender, weighing 42 ± 3 
(SD) kg were used. The protocol for premedication and 
anaesthesia has been evaluated (for details see 
Supplementary Material).13 Prophylactic antibiotic 
therapy with cefalotin 1.0 g IV followed by 0.5 g during 
CPB and 1.0 g after weaning was administered. Fluid 
substitution, Ringer’s acetate 15 mL/kg/h with 20 
mmol/L KCl added, was given throughout the experi-
ment. Additional Ringer’s acetate 5 mL/kg/h was admin-
istered after weaning from CPB.
Instrumentation and evaluation
The right femoral artery and vein were cannulated for blood 
sampling and infusion. An early arterial blood gas analysis 
determined the need for ventilator adjustments. Rectal 
temperature was monitored and an open suprapubic 
cystotomy with insertion of a catheter measured diuresis. 
After midline sternotomy and pericardiotomy, heparin (125 
IU/kg) was given IV to prevent catheter clotting. A continu-
ous cardiac output catheter (CCO/EDV 177HF 75, Edwards 
Lifesciences Inc., Irvine, CA, USA), advanced from the left 
internal mammary vein into the pulmonary artery, moni-
tored cardiac output, right ventricular end-diastolic volume 
(EDV), central venous pressure (CVP) and pulmonary 
artery pressure (PAP) (Vigilance II® and TruWave® trans-
ducers, Edwards Lifescience Inc.). A microtip pressure cath-
eter (Millar MPC-500, Houston, TX, USA) was inserted 
into the proximal aorta through the left internal mammary 
artery. The haemodynamic parameters were digitised and 
later analysed (Ponemah ACQ-7700 and Ponemah 
Physiology Platform v. 5.2, Data Sciences International, St. 
Paul, MN, USA). A dual-field pressure-conductance cathe-
ter (CA71083-PL, CDLeycom, Hengelo, the Netherlands) 
connected to a Sigma-M signal conditioner (CDLeycom) 
was inserted through the apex and into the left ventricle 
(LV). The distal part was positioned above the aortic valve, 
verified by epicardial echocardiography (Vivid E9, GE 
Vingmed Ultrasound, Horten, Norway). An infant feeding 
tube inserted into the left atrium was used for microsphere 
injections and a tourniquet placed around the inferior vena 
cava allowed brief intermittent dynamic preload reductions.
Baseline variables were obtained: arterial blood 
gases (OPTI CCA-TS2, OPTI Medical Systems, 
Atlanta, GA), serum troponin-T (Troponin-T hs, 
Roche Diagnostics GmbH, Mannheim, Germany), 
haemodynamic variables and the first injection of 15 
µm fluorescent microspheres (Dye-Trak “F”; Triton 
Technology Inc., San Diego, CA, USA). After a short 
period of pre-oxygenation and respirator shut-off in 
the end expirium, LV pressure-volume loops were 
registered before and during a brief period of inferior 
vena cava occlusion. During a bolus of 5 mL hyper-
tonic saline (10%) injected into the pulmonary artery, 
pressure-volume loops were recorded three times for 
the estimation of parallel conductance.14,15 
Echocardiographic recordings were obtained for eval-
uation of strain and strain rate during brief periods of 
respiratory shut-off. Pulsed-wave Doppler signals in 
the aortic outflow tract, speckle tracking echocardiog-
raphy (STE) in the 4-chamber and the short-axis views 
and tissue Doppler imaging (TDI) of the anterior left 
ventricular wall in short-axis view were recorded (for 
details see Supplementary Material).
Experimental protocol
The animals were block-randomised to either the STH-
POL or the STH-2 group (10 per group). The heart-lung 
machine was primed with 1200 mL Ringer’s acetate. 
Systemic heparinization (500 IU/kg) was followed by can-
nulation of the brachiocephalic artery (EOPA 18 Fr, 
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Medtronic Inc., Minneapolis, MN, USA) and the right 
atrial appendage (MC2 28/36 Fr, Medtronic Inc.). 
Cardiopulmonary bypass (CPB) was established with a 
flow of 90 mL/min/kg and a water temperature of 32°C in 
the heat exchanger. After aortic cross-clamping, cardiople-
gia was induced, either with normokalaemic STH-POL or 
hyperkalaemic STH-2 cardioplegia. Both solutions were 
pre-prepared as concentrate, modified with procaine and 
administered as cold (12°C), oxygenated, blood cardiople-
gia, freshly mixed by a dual-head pump with separate cool-
ing. The cardioplegia was given into the aortic root, with 
the flow set to 7% of CPB flow, following a standardised 
protocol with an initial ‘high-dose’ for 3 min and 2 min of 
‘low-dose’ at 20, 40, 60, 80 and 100 min after cross-clamp-
ing. The final concentrations of key components in the car-
dioplegic solutions are presented in Table 1. The aortic 
cross-clamp time was 120 min. A left heart vent catheter 
(DLP 13, Medtronic Inc.), temporarily replacing the pres-
sure-conductance catheter, was placed through the apex 
and allowed passive drainage of the heart during the arrest. 
The body temperature drifted towards 34°C and CPB flow 
was reduced to 72 mL/min/kg when the rectal temperature 
reached 35°C or after 20 min. After 100 min of cross-
clamping, systemic rewarming was initiated, with CPB 
flow reset to 90 mL/min/kg and the water temperature at 
40°C. Arterial blood gases were obtained before cross-
clamping, after 60 min and prior to declamping after 120 
min. During CPB, the ventilator volume was reduced to 
50%. Additional heparin (250 IU/kg) was given after 60 
min of cross-clamping. Defibrillation was the only allowed 
anti-arrhythmic intervention if ventricular fibrillation 
occurred at declamping. After 10 min of reperfusion, the 
animals were weaned from CPB and the residual blood in 
the circuit infused followed by decannulation. Protamine 
sulphate 2 mg/kg was given for heparin reversal.
After weaning from CPB, general haemodynamics 
were continuously recorded for 240 min. As for Baseline, 
measurements of LV pressures, volumes, systolic and 
diastolic function, regional tissue blood flow and echo-
cardiographic recordings were repeated at 60, 150 and 
240 min after reperfusion. Finally, the animal was euth-
anized with an intracardiac injection of high-dose 
potassium chloride, the heart was explanted and sam-
ples were obtained for regional tissue blood flow meas-
urements, tissue water content, caspase-3 activity and 
levels of malondialdehyde (MDA).
Global and regional left ventricular function
Associated data files obtained by the pressure-conduc-
tance catheter (1 for evaluation of function, 3 for paral-
lel conductance) were coded and analysed as 80 
independent entities with custom-made software. The 
mean of 5-8 cardiac cycles during the stable situations 
and load-independent variables obtained during 
dynamic preload reductions were calculated. Absolute 
volumes were estimated by correcting for parallel con-
ductance and cardiac output. Volumes were indexed by 
body surface area calculated as BSA (m2) = (BW2/3 x 
k)/100, where BW is body weight in kg and k for pigs is 
9 m2/kg-2/3.16 The LV mechanical efficiency (Joules/
mL/g) was calculated as a ratio between the total pres-
sure-volume area (PVA) and the blood flow rate by the 
formula; Mechanical efficiency = (PE+SW) x HR/BFR, 
where PE and SW are pressure-volume areas for the LV 
potential energy and stroke work in Joules, HR is heart 
rate and BFR is LV blood flow rate per gramme of tissue.
Regional myocardial strain and strain rate were 
recorded with STE and TDI. Peak systolic strain in the 
circumferential, radial and longitudinal direction and 
radial peak ejection strain rate were measured with 
appropriate software (EchoPAC BT12, GE Vingmed 
Ultrasound).
Myocardial tissue samples and analyses
Multiple tissue samples were obtained from the LV 
endo-, mid- and epicardium and the right ventricle 
(RV). Myocardium, snap-frozen and stored in liquid 
nitrogen, was analysed for apoptosis by caspase-3 










Esmolol (mM) 1.35 0.68 − −
Adenosine (mM) 0.50 0.25 − −
Mg2+ (mM) 20 10 16 9
K+ (mM) 4.3 4.3 22 14
Cl- (mM) 106 106 134 120
Procaine-HCl (mM) 0.8 0.4 0.8 0.4
STH-POL: Modified St.Thomas’ Hospital polarizing cardioplegic solution; STH-2: Modified St.Thomas’ Hospital cardioplegic solution No 2. 
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activity (K105-400, BioVision Inc., Milpitas, CA, USA) 
and for oxidative stress by MDA (K739-100, BioVision 
Inc.). Samples were homogenised, lysed and analysed 
according to the manufacturer’s instructions. Samples 
from the left and right ventricles and reference blood 
were weighed, hydrolysed, microspheres isolated, 
colours dissolved and quantified by fluorospectropho-
tometry. Blood flow rate was calculated as earlier 
described.17 Tissue water content was calculated as a 
fraction of the wet weight after drying samples for 
three weeks at 60°C.
Statistical analysis
Data analyses were performed by SPSS v. 23 (IBM 
Corp., Armonk, NY) and the values given as 
mean±SEM or median (25% percentile; 75% percen-
tile) unless otherwise noted. Groups were compared 
at Baseline by two-sample Student t-test and 
Wilcoxon-Mann-Whitney test on ranks, whenever 
appropriate. Haemodynamic variables during and 
after CPB were compared with two-way analysis of 
variance for repeated measures (RM-ANOVA). For 
details see Supplementary Material.
Results
Characteristics at Baseline and during CPB
Eight animals were excluded due to reasons other 
than technical failure during surgery or instrumenta-
tion. Of these, seven animals, two in the STH-POL 
and five in the STH-2 group, developed severe pulmo-
nary hypertension and right heart failure soon after 
declamping and weaning from CPB. The concomitant 
reduction of LV filling and systemic hypotension 
ended in myocardial ischemia and LV failure. One 
animal in the STH-POL group developed severe 
tachyarrhythmia at reperfusion, making further eval-
uation futile. Excluded animals were replaced by the 
subsequent experiment and results are given for 10 
animals in each group.
At Baseline, the STH-POL and STH-2 groups were 
similar regarding variables describing general haemo-
dynamics, left ventricular and myocardial function, 
tissue blood flow rate, temperature, blood gases and 
serum troponin-T levels (Supplement Table A, Figures 
2-4). Mean arterial pressure (MAP) was significantly 
lower in the STH-POL at 60, 80 and 100 min of car-
dioplegic arrest compared to the STH-2 group (Figure 
1). Serum potassium did not differ before cross-
clamping while gradually increasing over time in both 
groups, but was more pronounced with STH-2 cardio-
plegia. At declamping, the serum potassium averaged 
4.4±0.1 mmol/L in the STH-POL vs. 5.5±0.2 mmol/L 
in the STH-2 group (p < 0.001). Arterial blood gases, 
haemoglobin and other electrolytes did not differ 
between the groups during cross-clamping 
(Supplement Table B). Electrical cardioversion of ven-
tricular fibrillation at declamping was needed in 2 out 
of 10 animals in the STH-POL vs. 8 out of 10 in the 
STH-2 group (p=0.025).
Haemodynamic and cardiac variables after CPB
The heart rate (HR) gradually increased in both 
groups over time while the left ventricular systolic 
pressure (LVSP) decreased after weaning from CPB 
(Figure 2). The left ventricular end-diastolic pressure 
(LVEDP) was unchanged. The peak positive deriva-
tive of LV pressure, dP/dtmax, decreased from 90 min 
and onwards, while peak negative dP/dtmin increased. 
Cardiac index (CI) decreased gradually in the first 90 
min after declamping, levelled out around 175 min 
and then stabilised at levels comparable to the 
Baseline in both groups. The slope of the LV end-sys-
tolic pressure-volume relation (ESPVRslope) increased 
in both groups during reperfusion (Figure 3). At 240 
min after declamping, there was a borderline differ-
ence between the groups (p=0.088). PRSW was sig-
nificantly increased in the STH-POL compared to the 
Figure 1. Mean arterial pressure (MAP), temperature and 
serum potassium (mean±SEM) during 120 min of cardioplegic 
arrest with polarizing (STH-POL; n=10) and depolarizing (STH-
2; n=10) cardioplegia. #: p<0.05 vs. STH-2 at the corresponding 
point in time.
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STH-2 group 150 min after declamping (73.0±3.2 vs. 
64.3±2.4 mmHg, p=0.047), but did not differ after 
240 min. The LV isovolumic relaxation time constant 
τ and the logarithmic end-diastolic pressure-volume 
relation β did not differ over time or between groups. 
Both peak systolic strain in the longitudinal direction 
(STE) and radial peak ejection strain rate (TDI) 
decreased over time in both groups (Supplement 
Figure A and B).
The LV end-diastolic volume (LVEDV), stroke vol-
ume and stroke work decreased in both groups from 
60 min to 150 min after aortic declamping and reper-
fusion, paralleled by a borderline significant (pw=0.052) 
decrease in the RV end-diastolic volume (Supplement 
Table C).
Myocardial blood flow and mechanical 
efficiency
Regional tissue blood flow rate in the RV wall did not 
differ between the groups after declamping, decreased 
from 60 min to 150 min after declamping (p = 0.001) 
and did not change further (Supplement Table C). LV 
tissue blood flow rate was high in both groups com-
pared to levels seen at Baseline (Figure 4). Blood flow 
decreased significantly in the STH-POL group only 
(p<0.005) from 60 min to 150 min after declamping 
and was essentially unchanged in the STH-2 group. At 
240 min after declamping, LV blood flow was signifi-
cantly reduced in the STH-POL compared to the 
STH-2 group (p<0.05). The ratio between LV mechan-
ical energy gain and blood flow rate was reduced by 
approximately 50% 60 min after aortic declamping 
compared to Baseline (Figure 4). Left ventricular 
mechanical efficiency gradually decreased in the 
STH-2 group only and was significantly lower than in 
the STH-POL group after 150 and 240 min.
Myocardial oxidative stress, apoptosis and 
ischemic injury
Apoptotic activation evaluated by caspase-3 activity was 
more pronounced in the RV and subepicardial LV tissue 
compared to the myocardium in the mid- and subendo-
cardial left ventricle, but with no differences between the 
treatment groups (Figure 5). Oxidative stress evaluated 
by MDA did not differ between different regions of the 
left and the right ventricle. Serum troponin-T levels 
accumulated over time from 60 to 240 min after declamp-
ing, but did not differ between groups (Supplement Table 
C). The levels of serum potassium were increased 
throughout the reperfusion period in the STH-2 com-
pared to the STH-POL group (Supplement Table D).
Discussion
This porcine study indicates better myocardial contrac-
tile efficiency, demonstrated as a reduced mismatch 
between myocardial function and flow after weaning 
from CPB following 120 min of cardioplegic arrest with 
St.Thomas’ Hospital polarizing solution compared to 
standard blood cardioplegia. The pressure-volume loop 
area of the LV potential energy and mechanical perfor-
mance strongly correlates with myocardial oxygen con-
sumption and, hence, with myocardial blood flow 
rate.18–21 In the present study, both cardioplegic proto-
cols demonstrate a mismatch between performance and 
myocardial blood flow rate compared to Baseline after 
120 min of cardiac arrest (Figure 4). However, cardiac 
function did not differ between the groups evaluated by 
Figure 2. Haemodynamic variables, mean (SEM) or median 
(25%; 75%), at Baseline and every 15 min of reperfusion after 
CPB and 120 min of cardiac arrest with polarizing (STH-POL; 
n=10) and depolarizing (STH-2; n=10) cardioplegia. LVSP 
and LVEDP: left ventricular peak systolic- and end-diastolic 
pressures; dP/dtmax and dP/dtmin: peak positive and peak 
negative of the first derivate of the left ventricular pressure; 
RM-ANOVA: analysis of variance for repeated measurements; 
pw, pg and pi: p-values for within subjects, between groups and 
interaction from two-way RM-ANOVA, respectively.
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variables like CI and ejection fraction after reperfusion 
and weaning (Figure 2, Supplement Table C). Myocardial 
blood flow rate was reduced in the STH-POL compared 
to the STH-2 group at 240 min after declamping. This 
could be interpreted as a reduction of myocardial stun-
ning following polarizing compared to depolarizing car-
dioplegia.22,23 Depolarizing cardioplegia exposes the 
myocardium to high levels of potassium during cardio-
plegic arrest. Several studies have demonstrated that 
hyperkalaemic cardiac arrest contributes to myocardial 
stunning.6,24,25
In a previous study, creatine phosphate and adeno-
sine triphosphate (ATP) levels were temporary increased 
just before and 20 min after declamping following 60 
min of cardioplegic arrest with STH-POL compared to 
STH-2 cardioplegia.12 Creatine phosphate exerts both 
anti-oxidant and anti-apoptotic effects.26 One could 
speculate if these factors might contribute to the 
improved mechanical efficiency (Figure 4) also seen 
after 120 min of cardioplegic arrest.
Myocardial blood flow rate is influenced by factors 
such as preload, afterload, heart rate and resistance in 
myocardial vessels.27 Neither LVEDP, LVEDV, HR nor 
MAP differed between the groups after weaning from 
CPB (Figure 2, Supplement Table C). Both adenosine 
and esmolol are short-acting and probably do not influ-
ence myocardial vascular resistance after reperfusion 
and weaning.11,28,29 In the STH-2 group, hyperkalaemia 
was present at 60, 150 and 240 min after declamping 
compared to the STH-POL group (Supplement Table 
D). Hyperkalaemic cardioplegic solutions may induce 
vasoconstriction by direct depolarization of vascular 
smooth muscle or the underlying endothelium in coro-
nary arteries.30,31 Conversely, hyperkalaemia does not 
directly reduce myocardial vascular resistance following 
dilatation and, hence, relative hyperaemia.32
In the STH-POL group, two of 10 animals required 
defibrillation for ventricular fibrillation after declamp-
ing compared to eight out of 10 in the STH-2 group, 
probably related to increased potassium levels in the 
Figure 3. Left ventricle functional variables mean (SEM) or median (25%; 75%) at Baseline and 60, 150 and 240 min after CPB 
and aortic declamping following 120 min of cardiac arrest with polarizing (STH-POL) and depolarizing (STH-2) cardioplegia, 
n=10 in both groups. Statistics as in Figure 2. ESPVRslope: slope of the end-systolic pressure volume relationship; PRSW: slope of 
preload recruitable stroke work; Tau (τ): isovolumic relaxation constant; Beta (β): the logarithmic end-diastolic pressure-volume 
relationship. #: significantly different from STH-POL at 150 min of reperfusion.
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latter (Figure 1). Evidence of increased myocardial 
damage and apoptotic activity in the STH-2 group 
compared to the STH-POL group was not found in the 
present study, based on activated caspase-3 or s-tro-
ponin-T release (Figure 5, Supplement Table C). There 
is no evidence of myocardial damage caused by elective 
external cardioversion in patients, evaluated by the 
release of s-troponin-T.33,34
Myocardial levels of xanthine oxidase are found to be 
low in both pigs and in humans.35 Temporary high levels 
of hypoxanthine are to be expected in the STH-POL 
group due to degradation of the adenosine compo-
nent.12 However, no difference in tissue levels of MDA 
was found, demonstrating that degradation of hypoxan-
thine to uric acid by xanthine oxidase did not cause an 
extra myocardial oxidative stress in the present study.36
Contractility, evaluated as PRSW, was increased 150 
min after declamping with STH-POL cardioplegia, but 
did not differ from the STH-2 group after 240 min 
(Figure 3). In a previous study comparing STH-POL 
and STH-2 cardioplegia, LV contractility and myocar-
dial strain rate were better maintained 180 min after 
weaning following 60 min of cardioplegic arrest.10 With 
an ischemic period of 120 min of cardioplegic arrest in 
this present study, group differences with regard to con-
tractility faded after 240 min.
Limitations
The present study was performed in young, porcine 
hearts without clinically relevant pathology. Both the 
ischemic time and the observation period after declamp-
ing were limited. In our experience, 120 min of cardio-
plegic arrest following weaning from CPB and 240 min 
of reperfusion is close to the limit of what is feasible and 
reproducible for a translational animal study design in 
pigs. The replacement of three vs. five animals in the 
STH-POL and the STH-2 groups could introduce a 
selection bias. However, irrespective of cardioplegic 
solution, the frequency of arrhythmias and pulmonary 
hypertension after myocardial ischaemia/reperfusion 
and CPB is high in this model. For the purpose of stan-
dardisation, treatment interventions in this protocol 
were limited, which is reflected in a high mortality rate.
Figure 4. Left ventricular (LV) pressure-volume area (PVA), myocardial blood flow rate and mechanical efficiency at Baseline and 
60, 150 and 240 min after CPB and aortic declamping following 120 min of cardioplegic arrest, n=10 in both groups. Statistics as in 
Figure 2. *: significantly different from 60 to 150 or 240 min of reperfusion within group; #: significantly different between groups at 
corresponding point of time.
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Clinical implications
Results from the present study demonstrate polarizing 
cardioplegia with esmolol, adenosine and magnesium to 
be non-inferior to standard depolarizing, potassium-
based, repeated, oxygenated, blood cardioplegia. 
Clinical trials determining safety should be conducted 
before implementation into a new clinical routine. In 
theory, the use of STH-POL could be beneficial, espe-
cially in patients with preoperative left ventricular dys-
function and/or in patients requiring a long period of 
cardioplegic arrest.
Conclusion
Two hours of cardioplegic arrest with St.Thomas’ 
Hospital polarizing solution in oxygenated blood allevi-
ates mismatch between myocardial function and perfu-
sion after weaning from CPB compared to St.Thomas’ 
Hospital No 2 blood cardioplegia.
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Animals and anaesthesia 
The pigs, weighing 42 ± 3 (SD) kg, were premedicated with an intramuscular injection of a mixture of 
ketamine (20 mg/kg), diazepam (10 mg) and atropine (1 mg) followed by a short period of 
spontaneous mask ventilation with oxygen and 3% isoflurane (Rhodia, Bristol, UK), allowing 
cannulation of two ear veins. Loading doses of fentanyl (0.02 mg/kg), midazolam (0.3 mg/kg), 
pancuronium (0.063 mg/kg) and pentobarbital (15 mg/kg) were given IV, followed by continuous 
infusion of fentanyl (0.02 mg/kg/h), midazolam (0.3 mg/kg/h), pancuronium (0.2 mg/kg/h) and 
pentobarbital (4 mg/kg/h). The animals were tracheotomised and ventilated (Julian, Drägerwerk, 
Lübeck, Germany) with a mixture of nitrous oxide (56-58%) and oxygen. Tidal volume was set to 11 
mL/kg and the frequency adjusted, aiming at an end-tidal pCO2 ranging from 5.0 to 5.6 kPa. This 
anaesthetic protocol has been thoroughly evaluated previously, allowing the use of a neuromuscular 
blocking agent in young pigs.A  
 
Epicardial echocardiography  
The echocardiographic recordings were performed with a Vivid E9 scanner and a 6S cardiac probe 
(GE Vingmed Ultrasound, Horten, Norway). The respirator was disconnected during recordings. A 
soft silicon pad (4×4×3 cm) served as an offset between the epicardium and the sector probe.B B-mode 
cine-loops of the short-axis view at the equator were recorded and used for speckle tracking analysis 
(STE) of radial and circumferential strain. In the same view a high frame-rate recording focusing on 
the anterior left ventricular wall was obtained with Tissue Doppler Imaging (TDI) for strain and strain 
rate measurements. From the apical view pulsed-wave Doppler velocity recordings from the aortic 
valve were obtained for timing purposes. Still in the long-axis view, 4-chamber B-mode cine-loops of 
the left ventricle were obtained for STE analysis of longitudinal strain. All analyses were performed 
off-line using EchoPac BT12 (GE Vingmed Ultrasound). End-diastole was defined as the beginning of 
the first deflection of the QRS complex on electrocardiogram, whereas the end-systole was defined as 
the time of aortic valve closure on corresponding pulsed-wave Doppler spectral recordings. For TDI 
analysis, strain length (SL) was set to 6 mm and the region of interest (ROI) to 6x6 mm. The ROI was 
placed within a distance of ½SL from the epicardium and ½SL from the endocardium. Regional STE-
strain in the circumferential and radial direction was recorded in the Antero-Septal segment, 
longitudinal strain in the Mid-Septal segment. Both radial peak systolic strain and peak ejection strain 
rate in the anterior left ventricular wall were obtained from the TDI recordings.  
 
Statistical analysis 
Data analyses were performed by SPSS v. 23 (IBM Corp., Armonk, NY, USA) and values given as 
mean ± SEM or median (25% percentile; 75 % percentile) unless otherwise noted. The Baseline 
variables were compared by two-sample Student t-test and Wilcoxon-Mann-Whitney test on ranks, 
whenever appropriate. Hemodynamic variables during CPB and after aortic declamping were 
compared with two-way analysis of variance for repeated measures (RM-ANOVA) with STH-POL or 
STH-2 as group factor (pg) and time as within factor (pw) with post hoc Bonferroni contrasts when 
appropriate.C The Greenhouse-Geisser adjustment of degrees of freedom was used for the evaluation 
of main effects when Mauchly´s test of sphericity was significant (p < 0.05). If a significant interaction 
(pi < 0.10) was found, new ANOVAs for simple main effect were performed with adjustment of 
degrees of freedom. Cell means were finally compared with Neumann-Keuls multiple contrast tests 
when justified by the preceding ANOVA. The Intraclass Correlation Coefficient (ICC) for 20 
randomly selected TDI recordings was calculated. 
A:  














Supplement Table A.  
Baseline variables before cardioplegic arrest in two groups of pigs randomized to 120 min of 
polarizing (STH-POL) or depolarizing (STH-2) cardioplegic arrest. 
Variable STH-POL  STH-2  p-statistics 
 
LV-EDVi (mL/m2) 77 ± 3 82 ± 4 0.38 
LV-ESVi (mL/m2) 35 ± 1 37 ± 3 0.42 
LV-SVi (mL/m2) 43 ± 2 45 ± 1 0.58 
LV-EF (%) 55 ± 1 55 ± 2 0.91 
LV-SWi (mmHg*mL/m2) 4230 ± 361 4389 ± 385 0.77 
LV-flow-Epi   (mL/min/g) 0.83 ± 0.05 0.86 ± 0.04 0.67 
LV-flow-Mid  (mL/min/g) 0.96 ± 0.5 0.98 ± 0.05 0.73 
LV-flow-Endo (mL/min/g) 1.00 ± 0.06 1.03 ± 0.05 0.70 
RV-EDVi (mL/m2) 130 (119; 165) 125 (110; 149) 0.21 
RV-EF (%) 25 (22; 26) 27 (24; 33) 0.20 
RV-flow (mL/min/g) 0.62 ± 0.05 0.67 ± 0.05 0.53 
AOPmean (mmHg) 98 ± 6 97 ± 4 0.90 
CVPmean (mmHg) 7.0 ± 0.7 7.2 ± 0.7 0.89 
PAPmean (mmHg) 17.8 (15.4; 19.5) 18.8 (16.1; 21.2) 0.39 
pH  7.49 (7.45; 7.52) 7.51 (7.49; 7.53) 0.43 
pCO2 (kPa) 5.2 (4.5; 5.4) 5.3 (5.0; 5.4) 0.60 
pO2 (kPa)  25.2 ± 0.6 26.1 ± 0.4 0.19 
BE (mmol/L) 6.6 (0.3; 8.0) 7.3 (5.5; 9.1) 0.33 
HCO3- (mmol/L) 30.2 (23.8; 31.6) 30.8 (28.9; 32.7) 0.33 
Hb (g/dL)  8.8 ± 0.2 8.9 ± 0.1 0.60 
Hct (%)  26.5 ± 0.5 26.9 ± 0.3 0.56 
s-Na+ (mmol/L)  139 (138; 140) 140 (139; 140) 0.45 
s-K+ (mmol/L) 3.9 (3.8; 4.1) 3.9 (3.8; 4.2)  0.82 
s-Cl- (mmol/L)  102 ± 1 102 ± 1 0.62 
s-troponin-T (ng/L) 46 (39; 61) 60 (40; 110) 0.43 
Temperaturerectal (0C) 38.4 ± 0.2 38.4 ± 0.2 0.85 
Diuresis (mL/kg/h) 2.3 (1.6; 3.6)  2.7 (1.7; 3.9) 0.68 
    
 
 
Values are mean ± SEM or median (25-percentile; 75-percentile), n = 10. 
LV and RV = left and right ventricle; i = value indexed for body surface area; ESV and EDV = end-
systolic and end-diastolic volume; SV = stroke volume; EF = ejection fraction; SW = stroke work; 
Epi-, Mid- and Endo- = subepi-, midmyo- and subendocardium. AOP, CVP and PAP = aortic, central 




Supplemental Table B.  
Arterial blood gases, haemoglobin and electrolytes during cardiopulmonary bypass in two groups of 
pigs with 120 min of polarizing (STH-POL) or depolarizing (STH-2) cardioplegic arrest.  
Variable 1 min before 60 min  118 min RM-ANOVA statistics 
  X-clamp X-clamp X-clamp 
      (A)      (B)      (C) 
    
pH 
   STH-POL 7.42 ± 0.01 7.39 ± 0.01 7.39 ± 0.02 pw < 0.001, pg = 0.19, pi = 0.042 
   STH-2           7.42 ± 0.01 7.35 ± 0.01a,# 7.38 ± 0.01a,b         
pO2 (kPa) 
   STH-POL 15.7 ± 1.5 27.7 ± 2.1 17.3 ± 1.1  pw < 0.001, pg = 0.42, pi = 0.68 
   STH-2            14.0 ± 1.0 25.5 ± 2.0 17.6 ± 1.7  
pCO2 (kPa) 
   STH-POL 5.5 ± 0.2 6.3 ± 0.2a 6.4 ± 0.3a pw < 0.001, pg = 0.52, pi = 0.082 
   STH-2            5.7 ± 0.2 6.9 ± 0.3a,#        6.1 ± 0.2a,b   
HCO3- (mmol/L) 
  STH-POL 26.7 ± 0.8 28.1 ± 0.8 27.6 ± 1.0 pw = 0.13, pg = 0.81, pi = 0.40 
  STH-2            27.1 ± 0.9 27.8 ± 1.0 26.6 ± 1.2 
BE (mmol/L) 
   STH-POL 2.1 ± 0.8 3.0 ± 0.8 2.4 ± 1.1 pw = 0.29, pg = 0.65, pi = 0.24 
   STH-2            2.5 ± 0.8 2.1 ± 0.8            1.3 ± 1.1 
Hb (g/dL) 
   STH-POL 6.5 ± 0.2 7.6 ± 0.2 7.7 ± 0.3  pw < 0.001, pg = 0.078, pi = 0.27 
   STH-2           6.6 ± 0.2 8.4 ± 0.3 8.5 ± 0.3  
s-Na+ (mmol/L) 
   STH-POL 138 ± 1  139 ± 1  139 ± 1  pw = 0.59, pg = 0.72, pi = 0.17 
   STH-2            139 ± 1  139 ± 1  138 ± 1 
s-Cl- (mmol/L) 
   STH-POL 103 ± 1  103 ± 1  104 ± 1a,b pw < 0.001, pg = 0.13, pi = 0.098 
   STH-2            103 ± 1  105 ± 1a,# 105 ± 1a,b 
 
Values are mean ± SEM, n = 10. 
s = serum levels; pw, pg, pi = p-values for within subjects, between groups and for interaction from 
two-way RM-ANOVA, respectively; a and b = significantly different within the same group mean from 
value(s) in columns with corresponding capital letter; # = significantly different from STH-POL at 60 




Supplement Table C.                                          
Cardiac and haemodynamic variables, tissue blood flow and serum troponins 60, 150 and 240 min 
after aortic declamping following 120 min of polarizing (STH-POL) or depolarizing (STH-2) 
cardioplegic arrest.  










    
 STH-POL 24 ± 4  22 ± 2 22 ± 1 pw = 0.81, pg =0.76, pi = 0.75 
 STH-2 23 ± 3 23 ± 3 24 ± 4  
LV-EDVi  (mL/m2)     
 STH-POL 63 ± 5 54 ± 5 55 ± 2 pw = 0.046, pg = 0.99, pi = 0.79 
 STH-2 61 ± 5 54 ± 3 57 ± 5  
LV-SVi  (mL/m2)     
 STH-POL 39 ± 3 32 ± 2 34 ± 2 pw < 0.001, pg = 0.75, pi = 0.89 
 STH-2 37 ± 3 32 ± 1 33 ± 2  
LV-EF (%)     
 STH-POL 62 ± 3 60 ± 2 61 ± 2 pw = 0.52, pg =0.72, pi = 0.93 
 STH-2 62 ± 2 60 ± 3 59 ± 4  
SWi (mmHg*mL/m2)     
 STH-POL 3046 ± 278 2520 ± 273 2468 ± 255 pw < 0.001, pg = 0.58, pi = 0.84 
 STH-2 2983 ± 290 2297 ± 142 2252 ± 201  
RV-EDVi (mL/m2)      
 STH-POL 150  ± 7 136 ± 5 134  ± 5 pw = 0.052, pg =0.71, pi = 0.25 
 STH-2 139  ± 11 138 ± 9 134  ± 6  
RV-EF (%)      
 STH-POL 29  ± 2 27 ± 1 29  ± 2 pw = 0.35, pg =0.69, pi = 0.94 
 STH-2 28  ± 2 26 ± 2 29  ± 2  
RV blood flow rate (mL/min/g)     
 STH-POL 1.65 ± 0.19 1.18 ± 0.09 1.23 ± 0.12 pw = 0.006, pg =0.089, pi = 0.76 
 STH-2 1.96 ± 0.23 1.46 ± 0.12 1.69 ± 0.23  
MAP (mmHg)     
 STH-POL 75 ± 8 59 ± 4 60 ± 4 pw < 0.001, pg =0.68, pi = 0.66 
 STH-2 75 ± 5 64 ± 4 63 ± 4  
CVPmean (mmHg)     
 STH-POL   8.6 ± 0.7   9.4 ± 0.6 10.6 ± 0.7 pw = 0.054, pg =0.093, pi = 0.39 
 STH-2 10.9 ± 1.2 11.5 ± 1.0 11.6 ± 0.8  
PAPmean (mmHg)     
 STH-POL 26 ± 2 25 ± 2 25 ± 1 pw = 0.027, pg =0.19, pi = 0.18 
 STH-2 31 ± 3 29 ± 2 27 ± 2  
s-troponin-T (ng/L)      
 STH-POL 519  ± 98 527 ± 76 802  ± 114 pw < 0.001, pg =0.35, pi = 0.33 
 STH-2 743  ± 155 707 ± 140 907  ± 169  
     
Values are mean ± SEM for 10 animals in each group. 
LV and RV = left and right ventricle; i = value indexed for body surface area; ESV and EDV = end-
systolic and end-diastolic volume; SV = stroke volume; EF = ejection fraction; SW = stroke work; 
MAP, CVP and PAP = mean arterial-, central venous- and pulmonary artery pressure; s- = serum. pw, 
pg and pi = p-values for within subjects, between groups and interaction from two-way RM-ANOVA, 
respectively.   
 
Supplement Table D.  
Arterial blood gases, haemoglobin, electrolytes, temperature and diuresis in pigs 60, 150 and 240 min 
after weaning from 120 min of polarizing (STH-POL) or depolarizing (STH-2) cardioplegic arrest.  
Variable  60 min        150 min      240 min      RM-ANOVA statistics 
     
pH     
 STH-POL 7.42 ± 0.01 7.43 ± 0.01 7.43 ± 0.02 pw = 0.005, pg =0.74, pi = 0.056 
 STH-2 7.41 ± 0.02 7.44 ± 0.02 7.45 ± 0.01a  
pCO2 (kPa)     
 STH-POL 5.4 ± 0.2 5.4 ± 0.2 5.4  ± 0.3 pw = 0.19, pg =0.58, pi = 0.14 
 STH-2 5.8 ± 0.2 5.5 ± 0.2 5.4  ± 0.2  
pO2 (kPa)     
 STH-POL 17.0 ± 2.1 19.8 ± 1.3 20.9  ± 2.1 pw < 0.001, pg =0.89, pi = 0.73 
 STH-2 16.0 ± 2.0 19.4 ± 1.7 21.3  ± 1.2  
HCO3- (mmol/L)      
 STH-POL 25.9  ± 1.3 26.2 ± 1.5 26.6  ± 1.5 pw = 0.24, pg =0.57, pi = 0.84 
 STH-2 27.0  ± 1.3 27.6 ± 1.5 27.6  ± 1.4  
BE (mmol/L)      
 STH-POL 1.5  ± 1.3 1.8 ± 1.5 2.1  ± 1.5 pw = 0.036, pg =0.56, pi = 0.54 
 STH-2 2.2  ± 1.4 3.4 ± 1.5 3.3  ± 1.4  
Hb (g/dL)      
 STH-POL 9.0  ± 0,3 8.5 ± 0.2 7.8  ± 0.2 pw < 0.001, pg =0.098, pi = 0.53 
 STH-2 8.4  ± 0.2 7.8 ± 0.3 7.4  ± 0.2  
Hct (%)      
 STH-POL 27.1  ± 0.8 25.7 ± 0.7 23.5 ± 0.7 pw < 0.001, pg =0.11, pi = 0.53 
 STH-2 25.3  ± 0.8 23.7 ± 0.9 22.4 ± 0.7  
s-Na+ (mmol/L)      
 STH-POL 141  ± 1 142 ± 1 142  ± 1 pw = 0.67, pg =0.001, pi = 0.47 
 STH-2 139  ± 1 138 ± 1 138  ± 1  
s-K+ (mmol/L)      
 STH-POL 4.5  ± 0,1 4.8 ± 0.1 5.0  ± 0.1 pw < 0.001, pg =0.013, pi = 0.45 
 STH-2 5.1  ± 0.2 5.6 ± 0.3 5.5  ± 0.3  
s-Cl-  (mmol/L)      
 STH-POL 104  ± 1 105 ± 1a 105  ± 1a pw = 0.17, pg =0.14, pi = 0.006 
 STH-2 104  ± 1 103 ± 1 104  ± 1  
Temprect (0C)     
 STH-POL 37.7 ± 0.1 37.8 ± 0.2 37.8 ± 0.2 pw = 0.026, pg =0.98, pi = 0.097 
 STH-2 37.4 ± 0.2 37.8 ± 0.2a 38.0 ± 0.2a  
Diuresis (mL/kg/h)     
 STH-POL 12.5 ± 2.8 5.9 ± 1.2 3.4 ± 0.8 pw < 0.001, pg =0.37, pi = 0.56 
 STH-2 9.8   ± 1.5 4.1 ± 0.8 3.3 ± 0.4  
Values are mean ± SEM, n = 10.  
s- = serum; Temprect = rectal temperature. pw, pg, pi = p-values for within subjects, between groups and 
for interaction from two-way RM-ANOVA, respectively. a denotes significantly different from 60 
min.  
Supplement Figure A 



































Values are mean ± SEM for 10 experiments in each group. 
Regional strain by Speckle Tracking Echocardiography in the circumferential (STECirc) and radial 
(STERad) directions from the short-axis view in the antero-septal (AntSept) segment, and in the 
Longitudinal direction (STELong) from the four-chamber view in the mid-septal (MidSept) segment. 
STH-POL and STH-2 = polarizing and depolarizing cardioplegia. RM-ANOVA = analysis of 
variance for repeated measurements; pw, pg, pi = p-values for within subjects, between groups and for 
interaction from two-way RM-ANOVA, respectively.  
 
Frame rates for the STE recordings were 74 ± 5 (SD) (range 63 – 88) frames/s, in the short-axis view  





































 pg = 0.65






































 pg = 0.20
 pi  = 0.23
 



































 pg = 0.86
 pi  = 0.79
 
Supplement Figure B 

































Values are mean ± SEM for 10 experiments in each group. 
Radial peak systolic strain and peak ejection strain rate in the left ventricular anterior wall by Tissue 
Doppler Imaging from the short-axis view. STH-POL and STH-2 = polarizing and depolarizing 
cardioplegia. RM-ANOVA = analysis of variance for repeated measurements; pw, pg, pi = p-values for 
within subjects, between groups and for interaction from two-way RM-ANOVA, respectively. 
 
Frame rate for the TDI recordings were 619 ± 67 (SD) (range 327 - 749) frames/s. 
 
Two independent observers analysed 20 randomly selected TDI recordings. The Intraclass Correlation 
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